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'What we learn with pleasure we never forget' 
Albert Mercier 
 
'Recurrent aphthous stomatitis may be considered a condition that is the most tantalizing for the 
researcher, the most painful for the patient, and the most frustrating for the clinician' 
Nihill Henry Somers, 1971 
 
 
 
 
 
 
 
 
 
 
To my family 
 
To those unfortunate enough to suffer from recurrent aphthous stomatitis
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ABSTRACT 
 
Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal lesions. The aetiology is unknown 
and currently there is no consensus regarding suitable treatment regimens. RAS is recognised as a multi-factorial 
condition in which both endogenous and exogenous factors contribute to the recurrent oral ulcerations 
characteristic of this oral mucosal disease. 
 
The overall aim of this thesis was to study the aetiological factors associated with RAS. Previously, it has been 
suggested that genetic factors, a microbiological component, and the abrogation of tolerance to specific food 
antigens are of importance in RAS. Hence, two clinical studies were conducted to explore the roles in RAS of 
host genetics and the composition of the oral microbiota. To reveal the actions of food components as exogenous 
triggering factors for RAS, it is necessary to understand the immunoregulatory networks involved in the 
induction of tolerance in the oral cavity. Extensive pre-clinical studies of these mechanisms are required before 
translating the acquired knowledge to the clinical setting. Therefore, two pre-clinical studies in mice were 
performed to explore the roles of the oral cavity and associated lymphoid tissues in comparison to those of the 
mesenteric lymph nodes (MLN), which are known to be of importance for oral tolerance induction.  
 
The specific aims of the clinical studies were to: (i) identify patterns of association and segregation regarding 
genetic variants passed down to the offspring within families with RAS and to identify the genes and signalling 
pathways that determine the risk of developing this condition; and (ii) compare the oral microbiota profiles of 
patients with RAS and healthy control subjects, so as to define microbiotal changes in relation to disease 
activity. The specific aims of the pre-clinical studies were to: (i) identify differences between the murine APC 
and T-cell populations of the oral-associated lymphoid tissues [i.e., the nose-associated lymphoid tissues 
(NALT) and the cervical lymph nodes (CLN)] and the MLN; and (ii) determine whether the passage of an 
antigen through the oral cavity contributes to the overall immunological response and the degree of tolerance 
induced, as compared to gastric administration of the same antigen.  
 
Buccal swabs were obtained from non-ulcerative areas of the mouths of patients with RAS (N=60) and healthy 
age- and gender-matched controls (N=60), with some of the patients (N=42) presenting with lesions upon 
sampling. Additional swabs from members of 16 families with RAS (N=91) were also included. The human 
DNA was analysed in a Genome-wide association study (GWAS), using a CoreExome array, and the bacterial 
DNA was analysed by Terminal-restriction fragment length polymorphism (T-RFLP). Flow cytometry and in 
vitro proliferation were used to analyse the APC and T-cell subsets at the different sites in the BALB/c mice. To 
compare oral and gastric administration of the antigen (ovalbumin, OVA), a DO11.10 TCR transfer model and 
an oral tolerance model, using BALB/c mice, were applied. 
 
No pattern of association or segregation for genetic variants being passed down to the offspring within these 
families was detected. The most significant pathways implicated in RAS were the Ras signalling pathway, the 
PI3K-Akt signalling pathway, pathways in cancer, circadian entrainment, and the Rap 1 signalling pathway. The 
oral microbiota profiles differed between patients and controls, especially regarding the profiles of patients who 
presented with lesions during sampling, which clustered furthest from the profiles of the controls. The NALT 
contained a higher proportion of APCs and a lower proportion of T cells than the CLN and MLN. The APCs of 
the NALT displayed few signs of activation, instead showing high-level expression of markers associated with 
effector and tolerogenic functions. Furthermore, the T cells in the NALT more often showed a memory/effector 
phenotype, whereas those in the CLN and MLN had a naïve phenotype. In general, the cells of the NALT did not 
proliferate upon in vitro stimulation with concanavalin A, in contrast to the cells from the CLN and MLN. A 
similar activation pattern and degree of tolerance induction emerged when the two administration routes were 
compared.  
 
In summary, understanding the genetic basis of RAS may allow the identification of individuals who are at risk 
of acquiring this condition. Changes to the oral microbiota may trigger the development of lesions or vice versa. 
The NALT displayed effector and tolerogenic functions as opposed to the other sites that demonstrated a strong 
capacity for primary immune activation. The contribution of the mucosal immune system, besides the intestine, 
for induction of oral tolerance remains to be further investigated. Suitable and efficient treatment strategies for 
RAS can be developed only when the aetiology of this condition is fully understood. 
 
Keywords: Aphthous stomatitis, oral mucosa, oral medicine, genome-wide association study, genetic linkage, 
association, genetic polymorphism, microbiota, restriction fragment length polymorphism, antigen-presenting 
cell, T-lymphocyte, lymph node, flow cytometry 
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SAMMANFATTNING PÅ SVENSKA 
 
Recidiverande aftös stomatit (RAS) anses vara en av de vanligast förekommande orala slemhinneförändringarna 
i världen idag. Trots att tillståndet är så utbrett saknas kunskap om orsakerna bakom och det finns idag inte heller 
någon formell konsensus kring de behandlingsalternativ som ska erbjudas de drabbade patienterna. RAS är 
förmodligen ett multifaktoriellt tillstånd där ett flertal både yttre miljöfaktorer och inre kroppsegna faktorer 
samverkar för att skapa de återkommande sårbildningar i den orala slemhinnan som så tydligt kännetecknar detta 
tillstånd. 
 
Det huvudsakliga syftet med avhandlingen har varit att förstå mer kring orsakerna bakom RAS. Tidigare har det 
i litteraturen framhållits en möjlig ärftlighet bakom detta tillstånd, betydelsen av bakteriefloran i munhålan och 
att specifika födoämnen kan vara av vikt för att utlösa sår genom att det uppstår en bristande toleransutveckling 
mot vissa födoämnen. Avhandlingen består av två kliniska studier där betydelsen av ärftliga faktorer och 
bakteriefloran i munhålan undersökts. Dessutom har två prekliniska studier på möss genomförts med fokus på 
toleransutveckling och munhålans betydelse för denna mekanism. Tidigare har tarmens betydelse för 
toleransutveckling stått i centrum och munhålan har kommit i skymundan trots att den är en del av mag-
tarmkanalen. Eftersom kunskaperna om munhålans och de tillhörande lymfkörtlarnas betydelse är bristande 
krävs fler prekliniska studier innan det är möjligt att vidare undersöka dessa mekanismer hos människa. 
 
De huvudsakliga frågeställningarna för de kliniska studierna har varit att (i) ta reda på om det finns några 
skillnader i hur olika gener nedärvs från föräldrar till barn i familjer där RAS förekommer och att identifiera 
vilka gener och signalvägar som kan vara av betydelse för att utveckla det här tillståndet och (ii) ta reda på om 
bakterieprofilen i munhålan skiljer sig åt mellan patienter med RAS och friska kontrollindivider och även att 
undersöka om det uppstår skillnader hos patienter med RAS då de har sår jämfört med då de inte har sår, dvs. om 
vissa bakterier är kopplade till sjukdomsaktiviteten. De huvudsakliga frågeställningarna för de prekliniska 
studierna har varit att (i) undersöka möjliga skillnader i förekomsten och typen av immunceller i lymfvävnaderna 
i anslutning till munhålan (näs-associerad lymfoid vävnad, NALT och cervikala lymfnoder, CLN) jämfört med 
lymfvävnaden i anslutning till magen (mesenteriska lymfnoder, MLN) och (ii) ta reda på om det spelar någon 
roll för det immunologiska svaret och graden av toleransutveckling om ett födoämne tillförs mag-tarmkanalen 
genom att först passera munhålan och sedan magen eller om födoämnet tillförs magen direkt utan att först 
passera munhålan. 
 
För de kliniska studierna samlades slemhinnestryk från kinden in, från patienter med RAS (N=60), och från 
kontrollindivider av samma ålder och kön (N=60). I patientgruppen uppvisade 42 individer sår vid 
provtagningstillfället men inte i anslutning till provtagningsområdet utan någon annanstans i munhålan. 
Slemhinnestryk från kinden togs också från 16 familjer där RAS förekom (N=91). Resultaten av de kliniska 
studierna visade att det inte verkar finnas några skillnader i hur gener nedärvs som är av betydelse för 
utvecklandet av det här tillståndet. RAS förefaller inte heller vara en monogen sjukdom dvs. orsakas av en enda 
gen utan är ett resultat av åtskilliga gener som samverkar. Ett flertal gener och signalvägar kunde också hittas 
som verkar vara av betydelse för att utveckla RAS. Gällande bakterieprofilen i munhålan så skiljde den sig åt 
mellan patienter med RAS och friska kontrollindivider. Skillnaderna var som störst då patienterna hade sår 
jämfört med när de inte hade sår.  
 
För de prekliniska studierna samlades lymfoida vävnader in från de olika lokalerna från en experimentellt avlad 
stam av den vanliga husmusen (BALB/c mus) för att undersöka immuncellernas egenskaper och funktion. 
Vidare jämfördes det immunologiska svaret och graden av toleransutveckling genom att mata ett 
födoämnesprotein oralt jämfört med att föra ner det direkt i magen. För de här experimenten användes en 
genmodifierad musstam (DO11.10 TCR möss) samt BALB/c möss. Resultaten av de prekliniska studierna 
visade att det fanns skillnader i förekomst och funktion av immunceller och att skillnaderna var som störst för 
NALT jämfört med de andra lymfvävnaderna. Inga betydande skillnader kunde noteras i det immunologiska 
svaret eller i graden av toleransutveckling när de två olika sätten att tillföra ett födoämne jämfördes. Munhålans 
betydelse för utvecklandet av tolerans är därför fortfarande oklar. 
 
Sammanfattningsvis är det av yttersta vikt att förstå mer kring orsakerna bakom RAS genom att studera de olika 
faktorerna var för sig men också att undersöka hur de samverkar för att kunna hitta lämpliga 
behandlingsstrategier och att kunna identifiera de patienter som riskerar att utveckla detta tillstånd. 
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PREFACE 
 
This thesis is based on the following studies, which are referred to in the text by their Roman 
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III. Bankvall M, Jontell M, Wold A, Östman S. Tissue-specific differences in immune 
cell subsets located in the oral-associated lymphoid tissues. In manuscript 
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associated lymphoid tissues during oral versus gastric antigen administration. 
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DEFINITIONS IN BRIEF 
 
Thesis Frame 
 
Aetiology The origin of a disease involving the agents that trigger the 
disease.  
 
Histopathology Microscopic examination of a tissue to study the manifestations 
of a disease. 
 
Immunopathogenesis The development of a disease, emphasising the chain of events 
and focusing on the immunological mechanism/mechanisms 
that leads to the diseased state. 
 
Major RAS (mRAS) Lesions of RAS with a diameter >10 mm. 
 
Minor RAS (miRAS) Lesions of RAS with a diameter <10 mm. 
 
Pathogenesis The development of a disease, emphasising the chain of events 
and focusing on the biological mechanism/mechanisms that 
leads to the diseased state. 
 
 
Paper I 
 
Association analysis This type of analysis involves comparing the frequency of a 
particular genetic variant between cases and controls, where the 
controls can be selected from a random population or from the 
same family as the case, to determine whether the variant is 
inherited more often in those who are affected in a population 
than in those who are not affected.  
 
Call-rate The proportion of genotypes of an SNP with non-missing data. 
 
Candidate gene study A hypothesis-based study design in which particular genes that 
are putatively involved in a particular disease are studied, either 
due to their location in a region of linkage or based on evidence 
that they might be involved in the particular disease being 
studied. 
 
Dominant Genes that influence the phenotype both in the homozygous and 
the heterozygous state. 
 
Extended family A family unit that extends beyond the nuclear family to include 
other relatives, such as aunts, uncles, and grandparents. 
 
Definitions in brief   
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Genetic variation Genetic differences both within and among populations caused 
by subtle differences in the human DNA sequence. These 
mutations lead to a permanent change in the chemical structure 
of a gene. Single nucleotide polymorphisms (SNP) are the most 
common types of genetic variation in humans. These variations 
are what make every human unique. Evolution relies on genetic 
changes being passed from one generation to the next.  
 
GWAS A study design that has no initial hypothesis regarding the 
genes that might be involved in the disease. Thousands of 
genetic variants are analysed simultaneously, and this approach 
has proved to be particularly successful in elucidating the 
genetic bases of common diseases and complex traits. 
 
Linkage analysis The analysis method traditionally used to identify genes of 
importance for disease, which has been used successfully for 
mapping genes that underlie monogenic Mendelian diseases. 
SNPs that lie close to the disease gene are identified, as they 
tend to be inherited together with the disease gene. The 
transmission and inheritance of this particular chromosomal 
fragment is then studied within a family. 
 
Mendelian error  This describes an allele (a variant form of the same gene), in an 
individual, that is supposed to not have been received from 
either of the person’s biological parents by Mendelian 
inheritance. This implies that the expected parent of an 
individual would then not actually be the parent indicated. This 
type of error is often due to a mistake in the genetic analysis, 
for example, a genotyping error or erroneous assignment of 
individuals as relatives when in fact they are not. Statistical 
genetics analysis is used to detect these errors. 
 
Mendelian inheritance  The manner in which traits and diseases related to a single gene 
are passed down from parents to their children.  
 
Minor Allele Frequency  This concept is used to determine how common or rare an allele 
is in the population, which is necessary to determine which 
SNPs in a GWAS that are of importance for the disease, being 
studied.  
 
Monogenic Monogenic inheritance occurs when a single gene influences 
the phenotype. 
Nuclear family A family group that consists only of the father, mother, and 
children. 
Polygenic Polygenic inheritance occurs when several genes act together to 
influence the phenotype. 
Definitions in brief 
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Population stratification Within a population, the prevalence of a disease may vary due 
to differences in ethnicity and heredity, which is unrelated to 
the disease but due to sampling from populations of different 
ancestries, giving rise to different subgroups with different 
genetical backgrounds, in which some individuals are more 
prone than others to a disease. In an association analysis, as 
opposed to a linkage analysis, this may lead to over-
representation of the disease in a proportion of the disease cases 
where certain alleles in the population suffering from disease 
would appear to be associated with the disease although they 
may not have any disease-associated effects, i.e., false-positive 
results.  
 
Recessive Genes that influence the phenotype only in the homozygous 
state. 
 
Segregation The process whereby pairs of alleles are separated into different 
gametes (reproductive cells/sex cells, i.e., sperm and egg cells). 
This occurs during meiosis (a two-part cell division process that 
produces sex cells that have half the number of chromosomes as 
the parent cell). 
 
SNP A variation in a single nucleotide that occurs at a specific 
position in a genetic sequence, where each variation is present 
to some appreciable degree within a population. 
 
 
Paper II 
 
Bacterial taxon In general, a taxon is used within the field of microbiology to 
systematically classify all living organisms into a common 
taxonomic system. There are different levels within this system, 
such as phylum, class, order, family, genus, and species, with 
species forming the basic unit. 
 
Diversity The range of different bacteria that co-exist within a specific 
bacterial community, described in terms of richness and 
evenness. 
 
Evenness The relative number (abundance) of the different species in a 
bacterial community. In T-RFLP, the area of the peak, i.e., the 
T-RF, reflects the number of each taxon, where a large area 
indicates a greater abundance than a small area.  
 
Richness The total number of species in a bacterial community. In T-
RFLP, each peak/T-RF reflects a bacterial taxon. 
 
 
Definitions in brief   
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Paper III 
 
Gut tropism The process of supplying the gut tissues with appropriate cells 
of the immune system, whereby the cells move from the 
inductive sites though a process called homing towards a 
specific stimulus, for example, an antigen found within the 
effector sites. 
 
Homing Cell-surface glycoproteins on lymphocytes and other leukocytes 
that mediate adhesion to specialised blood vessels, called high 
endothelial venules (HEVs). Several different classes of 
lymphocyte homing receptors have been identified, and they 
appear to target different surface molecules (addressins) on the 
HEVs in different tissues. This adhesion process plays a crucial 
role in the trafficking of lymphocytes. 
 
Oral-associated lymphoid tissues Lymphoid tissues that are located in the region of the oral 
cavity that encompass the nose-associated lymphoid tissue 
(NALT) and the cervical lymph nodes (CLN). 
 
 
Paper IV 
 
Adjuvant Agents that increase the action of the principal drug or affect 
the absorption, mechanism of action, metabolism or excretion 
of the primary drug in such a way as to enhance its effects. 
 
Effector sites Regions of the mucosal immune system in which effector cells 
after extravasation, retention, and differentiation perform their 
actions. 
 
Gastric administration The feeding of an antigen to an experimental animal using a 
sterile feeding needle inserted through the oesophagus into the 
stomach. This is the most common method for achieving oral 
tolerance in experimental animal models. 
 
Inductive sites Regions of the mucosal immune system where antigens that are 
selectively sampled from mucosal surfaces are transported and 
presented by DCs to naïve T and B cells, resulting in the 
induction of primary immune responses. 
 
MALT This is defined as the mucosa-associated lymphoid tissues and 
comprises the nose-associated lymphoid tissue (NALT), the 
gut-associated lymphoid tissue (GALT), and the bronchus-
associated lymphoid tissue (BALT). 
 
Definitions in brief 
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Oral administration The feeding of an antigen to an experimental animal using a 
pipette inserted into the oral cavity, mimicking the natural route 
of an antigen. 
 
Primary lymphatic organs The sites at which lymphocytes develop (bone marrow and 
thymus). 
 
Secondary lymphatic organs The sites at which lymphocytes become activated and immune 
responses are induced (i.e., the lymph nodes, spleen and 
MALT). 
 
Waldeyer´s ring This lymphoid structure is found in humans and is believed to 
be equivalent to the NALT in mice. It consists of the unpaired 
nasopharyngeal tonsil (adenoid), the paired palatine tonsils, the 
unpaired lingual tonsil, and the paired tubule tonsils at the back 
of the pharynx.  
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INTRODUCTION 
 
Recurrent aphthous stomatitis (RAS) 
This is one of the most common and most challenging categories of oral mucosal lesions managed by 
clinicians, entailing great discomfort for patients causing problems with eating, drinking, swallowing, 
and speaking. In the U.S., RAS has even been reported as the most common oral mucosal lesion 
(Kleinman et al., 1994, Rees & Binnie, 1996). Despite this it is also one of the most poorly 
understood. RAS has been defined as an inflammatory condition of unknown aetiology that is 
characterised by painful, recurrent single or multiple ulcerations of the oral mucosa (Graykowski et 
al., 1966, Francis, 1970, Natah et al., 2004). The lesions may occur as a continuum that extends from 
occasional single ulcerations resulting in mild symptoms to more continuous episodes with persistent 
severe ulcerative lesions, causing more severe symptoms over an extended period of time.  
 
 
Clinical and histopathological characteristics 
RAS presents as well-demarcated single or multiple, round or ovoid, shallow, inflammatory ulcers in 
the oral mucosa, with the surrounding regions being clinically unaffected. These lesions consist of a 
necrotic centre covered with a yellowish or greyish-white pseudo-membrane surrounded by a raised, 
thin, erythematous halo (Figure 1). While the ulcers can be extremely painful, they do not bleed unless 
the pseudo-membrane is scraped off.  
 
Lesions of this type are most commonly found in the non-keratinised oral mucosa, such as the labial 
and buccal surfaces. They may also present in the soft palate, ventral parts of the tongue, and floor of 
the mouth. They are rarely found on keratinised surfaces of the mouth, such as the gingiva, hard 
palate, or dorsum of the tongue. In addition, they are uncommonly found further down in the tonsils, 
uvula, and oropharynx, although when they are present in these areas they are highly debilitating for 
the patient and more difficult to treat. The shape of the aphthous lesion reflects its location. Those 
located on the lip or cheek mucosa are rounded or slightly elongated, whilst those in the vestibule or 
sulci or on the floor of the mouth can be elongated or linear.  
 
This condition is generally categorised into three different types according to the size and number of 
lesions present. The most common category is 'minor RAS', which accounts for approximately 80% of 
all RAS cases with lesions of a diameter <10 mm, followed by the category of 'major RAS', with 
lesions of a diameter >10 mm (Truelove & Morris-Owen, 1958). The third category of RAS is 
'herpetiform RAS', which is the most rare type with a prevalence of approximately 5% with up to a 
hundred millimetre large lesions covering the oral mucosa (Cooke & Armitage, 1960). The three types 
of RAS are all classified according to the International Classification of Diseases (ICD) created by the 
World Health Organization (WHO) with the ICD code K12.0 [which is concerned with recurrent oral 
aphthae with the sub-definitions of aphthous stomatitis (minor and major), Bednar aphthae, 
periadenitis mucosa necrotica recurrens, recurrent aphthous ulcers, and stomatitis herpetiformis], 
(http://apps.who.int/classifications/icd10/browse/2016/en). The ICD codes are used as a diagnostic 
tool to monitor the incidence and prevalence of diseases and other health problems, providing a 
picture of the general health situation in countries and populations worldwide. 
 
 
Introduction   
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Figure 1. RAS lesion, located on the inside of the lower left lip and revealing the surrounding halo and the central 
ulceration coated by a pseudo-membrane. 
The natural course of RAS can be divided into the following four stages: 
• Premonitory 
• Pre-ulcerative 
• Ulcerative 
• Healing 
In general, the earliest tissue changes observed under the microscope are found within the epithelium. 
It is during the later stages that an inflammatory infiltrate in the connective tissue signals the 
development of an aphthous lesion. 
 
Premonitory stage  
During this stage, which can last up to 24 hours, many patients sense prodromal symptoms, such as a 
tingling or burning sensation with hyperaesthesia or pain (Stanley, 1972). The mucosa feels tense and 
sometimes it feels roughened or raw. No clinical changes are usually apparent. This is the area in 
which the lesion will subsequently develop.  
 
Since biopsy specimens of true premonitory stages of RAS are difficult to obtain, not much is known 
about the histopathological characteristics and immunological processes during this stage. Changes are 
the most apparent in the epithelium where vacuolation of individual supra-basal cells occurs. 
(Stenman & Heyden, 1980) The underlying connective tissue shows no marked infiltration of 
inflammatory cells.  
 
Pre-ulcerative stage  
During this period, which lasts from 18 hours up to 3 days, the oral mucosa becomes slightly 
erythematous and a macule or slightly raised papule appears (Stanley, 1972). One nodule or several 
pin-headed nodules are seen, and with time an induration occurs. Gradually, a superficial membrane or 
coating emerges and the characteristic erythematous halo develops. At this stage the patient feels 
moderate pain.  
 
The oral epithelium increases in thickness due to both a slight hyperplasia (an increase in the volume 
of a tissue due to an increased number of cells) and hypertrophy (an increase in the volume of a tissue 
due to enlargement of the cells), with extensive distribution of vacuolated keratinocytes throughout the 
spinous layer, which sometimes coalesce to form minor, intra-epithelial vesicles (Stenman & Heyden, 
1980). In addition, slight degeneration of the supra-basal epithelial cells is observed. A minor 
mononuclear infiltrate of lymphocytes is seen within the epithelium. The connective tissue becomes 
	
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slightly oedematous with evidence of dilated capillaries and some accumulation of lymphocytes and 
plasma cells. At this stage, the number of mononuclear cells infiltrating the lamina propria is not high, 
and individual cells can easily be distinguished. The ducts and lobules of the minor salivary glands in 
the area of the developing aphthous lesion may also be surrounded by a mononuclear infiltrate 
(Stanley, 1972). The surrounding erythematous halo represents a localised vasculitis (Jurge et al., 
2006).  
 
Ulcerative stage  
This period varies greatly between patients, in the range of 1–16 days. The central part of the 
superficial membrane undergoes necrosis and is sloughed off, leaving behind a shallow, well-defined 
ulcer (Stanley, 1972). The necrotic centre is then covered with a yellowish or greyish-white fibrinous 
pseudo-membrane and the surrounding thin erythematous halo becomes raised. The ulcer continues to 
enlarge over a couple of days until it reaches its maximum size. Several ulcers may coalesce to form 
larger lesions of up to 1 cm or more in diameter. During this period, the pain experienced by the 
patient is severe and greatly debilitating. Once the ulcer has reached its maximum size, it begins to 
shrink. The covering fibrinous pseudo-membrane now thickens and adheres to the underlying ulcer so 
as to create a protective barrier (Stanley, 1972). For the patient, this results in a gradual decrease in the 
level of pain to a feeling of slight discomfort.  
 
This phase has from a histopathological perspective been nicely reviewed by Stanley (1972). An 
increase in the number of infiltrating immune cells is observed at this point throughout the tissue, 
especially in the epithelium. The oedema intensifies within the epithelium and the tissue starts to 
disintegrate upwards from the basal layer and is predominantly infiltrated by mononuclear cells and by 
some neutrophils. As the ulcer develops, the number of neutrophils increases and gradually they mix 
with the infiltrating mononuclear cells. There is a loss of the marginal epithelium with a fibrinous 
pseudo-membrane being formed on top. Subsequently, a purulent exudate accumulates at the junction 
of the marginal epithelium and the lamina propria, separating the epithelium even more from the 
underlying tissue. Mononuclear lymphocytes predominate in the connective tissue. Additional 
neutrophils are confined to the margins, i.e., the breach between the epithelium and the fibrinous 
pseudo-membrane and occasionally in adjacent tissues where the mononuclear lymphocytes are found. 
Neutrophils progressively become the dominant cell type, although plasma cells, eosinophils, and mast 
cells can also be detected. The infiltration of immune cells now becomes so intense that it is difficult 
to distinguish the architecture of the lamina propria. The infiltration of immune cells may extend deep 
into the connective tissue down to the underlying skeletal muscle. The number of neutrophils begins to 
decrease in the peripheral tissues that are distal to the ulceration. Plasma cells become a more 
prominent feature, and the superficial layers of the connective tissue contain many eosinophils. When 
the lesion stops expanding the inflammation decreases and numbers of inflammatory cells decline. 
Epithelial cell death is a key event in the development of ulcerations in RAS. In healthy epithelium, 
the most superficial cells, which are at the end of their life cycle, are simply desquamated off, as 
opposed to RAS lesions, which are characterised by top-to-bottom apoptosis such that dead cells 
slough off, leading to the formation of an ulcer (Al-Samadi et al., 2015). 
 
The area adjacent to the ulcer is defined as the epithelium-covered area extending from the edge of the 
ulcer and sideways to the periphery of the biopsy. The infiltrate lateral to the ulcer is different from 
that at the centre of the actual ulceration (Schroeder et al., 1983). An infiltrate that consists 
predominantly of lymphocytes (outnumbering the neutrophils) is observed in this area (Mills et al., 
1980, Hayrinen-Immonen et al., 1991). Monocytes/macrophages are also numerous in the tissues 
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adjacent and lateral to the ulcer. The number of mast cells is increased in the lamina propria (Lehner, 
1969, Schroeder et al., 1984, Natah et al., 1998). 
 
Healing stage  
After 4–35 days, usually <21 days, the ulcer heals without clinically observable scar formation. The 
few lesions that are large and persist for longer periods of time heal with scarring. Granulated tissue is 
now found under the fibrinous pseudo-membrane (Stanley, 1972). This tissue contains numerous 
immature capillaries. In the epithelium, numerous proliferating epithelial cells are found. With time, 
the granulated tissue becomes collagenised, resulting in a decrease of vascularity and further the 
epithelium heals and becomes intact once again. Cells that mediate chronic inflammation, particularly 
plasma cells, may persist in the deeper zone of the lamina propria. The minor salivary glands in the 
area may exhibit minimal focal peri-ductal and peri-alveolar fibrosis, ductal ectasia, and a mild, focal 
infiltrate of cells that mediate chronic inflammation (Stanley, 1972). Unless the skeletal muscle 
bundles are damaged, scarring does not occur. Aphthous lesions heal more slowly than other mucosal 
wounds, presumably due to the massive infiltrate of lymphocytes which requires time to resolve the 
inflammation (Eversole, 1994). 
 
 
Historical context 
Hippocrates (460–370 BC) was the first known person to use the term 'aphtha', although he may have 
been referring to thrush rather than specifically aphthous stomatitis (Sircus et al., 1957). Later, in 'The 
Winter´s Tale' (Paulina, verse 2.2.32) and 'Romeo and Juliet' (Juliet, verse 3.2.90), William 
Shakespeare (1564–1666), described characters who declared that they would be cursed with blisters 
of the tongue for speaking the untruth. It could be RAS to which they were referring, since the tongue 
is a common site for this type of mucosal lesion (Rogers, 1977). The term 'aphthous' is derived from 
the Greek word 'aphtha', which was first introduced in the mid-17th century and means 'set on fire' 
(Oxford Dictionaries), which describes very well the burning sensation that patients experience during 
episodes of aphthous lesions.  
 
In 1778, Jourdain-Berchillet discussed aphthae in considerable detail in his treatise on 'Diseases and 
Surgical Operations of the Mouth', although once again this may be a description of thrush. The first 
valid clinical description of RAS appeared in 1898 in a paper published in German by Kümmel and 
Mikulicz (1898). This was followed by the first description of RAS in the English language by Sibley 
in 1899. He described what is now recognised as minor RAS and attributed the cause to psychic stress, 
terming them 'ulcus neuroticum mucosae oris' or 'neurotic ulcers' (Sibley, 1899). In 1911, Sutton 
presented the first case of what is now known as major RAS and coined the phrase 'periadenitis 
mucosa necrotica recurrens' (Sutton, 1911). However, careful reading of this article reveals scarce 
mention of the glandular structures; instead, it states that the 'deeper glands' were hardly affected 
(Rogers, 1977). The third type of ulcer, the herpetiform type, was first described by Cooke and 
Armitage (1960), who pointed out their inability to discover a viral pathogen by cytological, 
serological, cultural or histopathological methods. Even so, they promoted the term 'herpetiform', 
since it accurately describes the clinical appearance of the lesions. 
 
 
Epidemiology 
In general, the epidemiological literature on oral mucosal lesions is fairly limited, as compared to the 
literature on dental caries and periodontal disease, the two major diseases of the oral cavity (Kleinman 
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et al., 1991). For RAS the prevalence varies widely where it has been estimated to be somewhere 
between 5% and 60% (Ship, 1972, Jurge et al., 2006), with a prevalence of approximately 20% in the 
general population (Akintoye & Greenberg, 2014). It is important to acknowledge that the different 
diagnostic criteria adapted at different oral medicine centres around the world may influence the 
estimated prevalence rates, as might the patient selection criteria (for example, geographic location, 
age- and gender distribution, genetic disposition, socio-economic status, and exposure to different 
environmental factors) (Axell & Henricsson, 1985, Shulman, 2004, Rivera-Hidalgo et al., 2004). 
Moreover, in calculating the prevalence, the time period considered, i.e., point prevalence (presence of 
lesions upon examination), period prevalence (history of lesions during a specified period of time) or 
life-time prevalence (presence of lesions during any point in life) (Kleinman et al., 1994, Shulman, 
2004, Rivera-Hidalgo et al., 2004), is of importance, as is whether the population studied is selected at 
random or not (Shulman, 2004, Rivera-Hidalgo et al., 2004). 
 
Axell et al. estimated the point prevalence of RAS in 1976 and 1985 as 2.0% in the general population 
of adults (≥15 years of age) in Sweden and the 2-year prevalence of RAS as 17.7% based on the same 
study population, including a total of 20,333 individuals (Axell, 1976, Axell & Henricsson, 1985). In 
1990, the point prevalence was similarly estimated as 1.9% in another, smaller Swedish adult 
population (Salonen et al., 1990), whereas in 2013 the point prevalence was estimated as 0.5% 
(Robledo-Sierra et al., 2013). The results of this last study were, however, based on a non-referral 
adult Swedish population, who were registered by general dental practitioners, whereas the other 
studies were based on adults in the general population for whom the diagnosis was established by oral 
medicine specialists, which may explain in part the variability seen in the first three studies, as 
compared to the last study.  
 
In the United States, two studies with large cohorts have been conducted in which the prevalences of 
RAS have been estimated. The first was the National Survey of Oral Health in U.S. school children 
(OHSC), which was conducted between 1986 and 1987 and involved children and adolescents in the 
age range of 5–17 years, including a total of 39,206 individuals (Kleinman et al., 1994). The second 
study was the Third National Health and Nutrition Examination Survey (NHANES III), which was 
conducted between 1988 and 1994 and focused on civilian, non-institutionalised individuals ≥2 
months, and involved clinical examinations of 33,994 individuals. The point prevalence from the 
OHSC survey was 1.2% and the life-time prevalence was 36.5%. From the NHANES III survey, the 
point prevalence for RAS was 0.89% based on data from the adult population aged ≥17 years, 
including a total of 17,235 individuals (Rivera-Hidalgo et al., 2004, Shulman et al., 2004). In 
subsequent studies based on the data from these two studies, the point prevalences were estimated as 
1.2% (OHSC) and 1.5% (NHANES III), the annual prevalence as 20% (NHANES III), and the 
lifetime prevalence as 40% (OHSC) in children and adolescents (Shulman, 2004), and based on the 
NHANES III study, the prevalences were estimated as 0.85% in adults and 1.5% in children 
(Chattopadhyay & Chatterjee, 2007).  
 
The Swedish study carried out by Axell et al. (1985) and the American OHSC and NHANES III 
studies represent large probability samples from the general population. Another large study has also 
been conducted in which the life-time prevalence was estimated as 38.7% in men and as 49.7% in 
females (Embil et al., 1975). This study differed from the others in that it was based on populations 
from six different continents, including 21 countries, whereas the other three studies were based on 
populations within a single country (i.e., Sweden or the U.S.). Furthermore, the study population was 
more homogenous, including 635 armed-forces recruits and 9,897 health-profession students, as 
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opposed to the samples from the general population used in the other studies. In addition, the life-time 
prevalence was estimated rather than the point prevalence or period prevalence (in the other studies).  
 
Several studies of RAS have reported a trend towards predominance of females (Embil et al., 1975, 
Miller & Ship, 1977, Axell & Henricsson, 1985), although studies reporting no gender differences 
(Miller et al., 1980, Kleinman et al., 1994) or a slight predominance of males (Rivera-Hidalgo et al., 
2004, Chattopadhyay & Chatterjee, 2007) also exist. The most common period of life to suffer from 
this condition is before one reaches 40 years of age (Axell & Henricsson, 1985, Ship et al., 2000, 
Rivera-Hidalgo et al., 2004, Shulman et al., 2004, Chattopadhyay & Chatterjee, 2007), with increases 
in prevalence with age being observed for children and adolescents (Miller et al., 1980, Kleinman et 
al., 1994). Furthermore, several studies have shown significantly higher prevalences of RAS for 
whites than for blacks (Kleinman et al., 1994, Shulman, 2004, Rivera-Hidalgo et al., 2004, 
Chattopadhyay & Chatterjee, 2007), for non-smokers than for smokers (Rivera-Hidalgo et al., 2004, 
Chattopadhyay & Chatterjee, 2007), and for people with higher socio-economic status (Ship, 1972, 
Natah et al., 2004, Jurge et al., 2006, Akintoye & Greenberg, 2014). Interestingly, an association 
between herpes labialis and RAS has been demonstrated in some studies (Ship, 1972, Embil et al., 
1975, Shulman, 2004, Rivera-Hidalgo et al., 2004) but not in others (Chattopadhyay & Chatterjee, 
2007). 
 
One problem with studying the prevalence of RAS is that it is greatly under-diagnosed, which renders 
epidemiological data unreliable. This is mainly due to the fact that there is, as of now, no curative 
treatment and a lack of consensus regarding the different treatment strategies available. Another 
limiting factor is that the criteria for the diagnosis of RAS are still relatively vague, which makes it 
difficult to compare selected study populations with regards to the diagnosis made and the inclusion 
and exclusion criteria. Furthermore, since RAS shows a recurring pattern, estimates of prevalence are 
more difficult to access, since over- or under-reporting is not uncommon. Thus, at the time of 
questioning/examination, the patient may: (i) have forgotten that they have had episodes of lesions 
during the time period in question; (ii) not be aware that they actually suffered from the specific 
condition; (iii) believe that they suffered from the condition when in fact they did not; or (iv) recall 
lesions at time-points other than those at which the lesions occurred (Kleinman et al., 1994, Rivera-
Hidalgo et al., 2004). In addition, as the rates of allergies and autoimmune diseases have increased 
over the last decade (Okada et al., 2010), it is tempting to speculate that they may also influence the 
prevalence of RAS, even though there is currently no evidence to support this linkage. 
 
 
Terminology 
Currently, the terminology used for RAS is undergoing modification and there is still no widely 
accepted nomenclature for this condition. The categories RAS, aphthous-like ulcerations, and non-
aphthous-like ulcerations have been proposed to differentiate between the different types of 
ulcerations (Scully, 2006, Scully, 2012). More recently, RAS has been suggested to have two 
presentation forms (simplex and complex aphthosis) and three morphological appearances (minor, 
major, and herpetiform) (Baccaglini et al., 2011). All three morphological types can be found within 
the two presentation forms. The differences between the presentation forms and 
morphological/clinical forms of RAS are illustrated in Table 1 and Figure 2. Complex aphthosis can 
be further subdivided into primary and secondary groups, where the underlying cause of the primary 
type remains idiopathic. The causes of secondary complex aphthosis include hematinic deficiencies, 
various systemic deficiencies and drug reactions (Baccaglini et al., 2011). 
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It remains a matter of debate as to whether the oral ulcerations associated with these hematinic 
deficiencies, various systemic deficiencies, and drug reactions, are truly RAS or instead represent oral 
ulcers that closely resemble RAS. The truth may lie somewhere in the middle, in that some systemic 
conditions are associated with RAS whilst others are not. Rather than being a single entity, RAS may 
instead present with different phenotypes, whereby the more common forms display discrete ulcers 
that typically develop during childhood or adolescence, abate to some degree with age, are not 
associated with any of yet defined systemic disorder, and may be associated with a positive family 
history of recurrent oral ulcerations (Scully, 2012). In the absence of a standard nomenclature, it is 
difficult to define the aetiology of RAS. It is imperative that research groups around the world agree 
on the terminology to be used for all studies conducted on RAS, to uncover the true aetiology of this 
condition. It is also important to mention that this issue is complicated by the fact that some patients 
present with more than one morphological/clinical appearance at any given phase of the disease, and 
that changes in the presentation form and morphological/clinical appearance may occur over time. For 
example, a patient who predominantly presents with aphthous lesions of the major type may also 
suffer from lesions of the minor type, whereas the opposite pattern is rarely observed, i.e., a patient 
who mainly suffers from lesions of the minor type and who suffers simultaneously from lesions of the 
major type. Furthermore, a patient who mainly suffers from lesions of the minor type may proceed to 
suffer from lesions that are predominantly of the major type for a period of time and vice versa. 
 
Table 1. Classification of recurrent aphthous stomatitis (RAS). 
 Presentation forms of RAS lesions 
 Simplex Complex  
Incidence Common Uncommon  
Frequency Episodic Episodic or continuous  
Duration Short-lived lesions Persistent lesions  
Number Few Few to many  
Recurrence rate Three to six lesions/year     Frequent or continuous ulcerations  
Rate of healing Rapid  Slow  
Grade of pain Low to moderate Moderate to severe  
Grade of disability Low to moderate Moderate to severe  
Location Limited to the oral cavity May present with genital lesions  
 Morphological/Clinical appearances of RAS lesions 
 Minor Major Herpetiform 
Size (mm) < 10a >10 1-2a 
Shape Round to ovalb Round to ovalb Round to oval 
Number 1–5 1–10 10–100 
Location Non-keratinised mucosa Non-keratinised mucosa Any intra-oral site 
Duration (days) 4–14 >30 <30 
Recurrence rates (months) 1–4 <1 <1 
Evidence of permanent 
scarring 
Uncommon Common Uncommon 
aLarger if coalesced. bMay appear as crater-forming. 
Adapted from: Porter et al. Recurrent Aphthous Stomatitis. Crit Rev Oral Biol Med. 1998; 9(3):306-321., Rogers RS III. Complex aphthosis. 
Adv Exp Med Biol. 2003; 528: 311–316, Baccaglini et al. Urban legends: recurrent aphthous stomatitis. Oral Dis. 2011 Nov;17(8):755-70, 
and Akintoye et al. Recurrent Aphthous Stomatitis. Dent Clin North Am. 2014 April; 58(2):281-297. 
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Figure 2. Clinical images illustrating the three morphological/clinical appearances of RAS lesions (minor, major and 
herpetiform). 
 
Diagnosis 
For the diagnosis of RAS, the clinical picture and the history of the patient are of importance. There 
are currently no clinical tests designed specifically for RAS, and from the histopathological 
perspective this condition presents as non-specific ulcerations of the oral mucosa, which does not help 
the clinician or pathologist to establish unambiguously the diagnosis. However, the analysis of a 
biopsy may help to rule out other potential diagnoses, and there are diagnostic tests available that can 
be used to exclude other diseases.  
 
There are several differential diagnoses associated with RAS, with the most common one being 
infection with the herpes simplex virus (HSV). The lesions of these two conditions are normally 
localised to different areas, with RAS lesions located in the non-keratinised mucosa and herpes lesions 
being found on keratinised surfaces. Herpes lesions may also in some cases occur only unilaterally, 
which is not the case for aphthous ulcers. In addition, there is a risk of transmission of the infection for 
HSV, since there is a viral aetiology. The symptoms of the two conditions are similar once the lesion 
has been established, with pain and soreness resulting from the ulceration. However, for HSV 
infection, it is not uncommon for the patient to experience heightened pain 24 hours before the debut 
of an ulcer, as well as post-herpetic pain. For aphthous lesions, prodromal symptoms can be present, 
although the severity is not as extensive as is sometimes observed for HSV infection. The simplest 
way to verify a herpes simplex diagnosis and exclude a diagnosis of RAS is to perform a virus 
detection test. Moreover, since the aetiologies of the two conditions differ, the strategies for their 
treatment differ. Interestingly, as previously mentioned in the section 'Epidemiology', several reports 
have indicated an association between RAS and HSV, whereby patients with RAS more commonly 
present with herpes labialis than do control subjects. 
Other recommended differential diagnoses are (Natah et al., 2004, Jurge et al., 2006, Baccaglini et al., 
2011, Chavan et al., 2012):  
• Behçets syndrome 
• Inflammatory bowel diseases (IBD; Crohn´s disease and ulcerative colitis) 
• Gluten-sensitive enteropathy 
• Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) 
• Hematinic deficiencies  
• Cyclic neutropenia and benign familial neutropenia 
• Primary and secondary immunodeficiencies, including infection with human 
immunodeficiency virus (HIV) 
• Mouth and genital ulcers with inflamed cartilage (MAGIC syndrome) 
	 	 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• Sweet´s syndrome 
• Food hypersensitivity 
• Drug reactions  
 
 
Pathogenesis 
Currently, it is unclear if RAS qualifies as a disease per se or if it is part of a broad spectrum of 
underlying systemic disorders (Baccaglini et al., 2011). Clearly, RAS has a multi-factorial aetiology, 
in that multiple endogenous and exogenous factors contribute to establishing an inflammatory process 
in the oral mucosa. The particular locations of the ulcerations have baffled researchers for decades. 
Why do specific lesions occur at particular locations as opposed to a more generalised inflammation of 
the oral mucosa? The oral cavity provides a range of environments in which ideal milieus occur 
randomly that favour the development of aphthous lesions in particular (Miller et al., 1977). However, 
the compositions of these niches are currently unknown. 
 
 
Aetiology 
Despite decades of research, the origin of RAS remains to be uncovered. Traditionally, research on 
RAS has had a mono-causal approach, which has in part been detrimental, since the aetiologies of 
many disease entities are known to be multi-factorial. In this aspect, RAS is probably similar. 
Individuals who are prone to RAS may share certain endogenous features (factors in the oral milieu, in 
combination with genetic susceptibility and systemic factors) that create immunological dysregulation, 
which triggers lesion development when the individual is exposed to certain exogenous components 
(foodstuffs, medications, local trauma, pathogens and/or psychological factors). This hypothesis is 
presented in greater detail in terms of 'The RAS model' in the 'Hypothesis' section of this thesis. Whilst 
the roles of the oral microbiota composition and host genetics are presented in detail in the papers 
appended to this thesis, this particular section focuses on other factors of importance such as the 
mucosa, saliva, immune system and food components, also believed to contribute to the aetiology of 
RAS. The remaining endogenous factors (systemic factors) and exogenous factors (medications, local 
trauma, pathogens and psychological components) have been reviewed extensively elsewhere. 
 
Mucosa 
The oral mucosa itself most probably plays a role in RAS. This tissue consists of a stratified squamous 
epithelium and does not, unlike the gut mucosa, have a natural adsorptive capacity. Instead, it shows 
regional variations in permeability that are in direct correlation with the thickness of the epithelial 
barrier (Squier, 1991). Aphthous lesions tend to occur in non-keratinised mucosa. It has been proposed 
that this is due to the fact that antigenic stimulation is more likely in the lining mucosa than in the 
masticatory mucosa, since the former has a lower degree of keratinisation and possibly higher 
permeability than the latter (Subramanyam, 2011). This could also explain why RAS is less common 
in smokers, since it is believed that tobacco increases the degree of keratinisation. Paradoxically, 
patients with RAS have been reported to be significantly less likely to be smokers than control 
subjects, and patients with RAS who do smoke have been found to smoke fewer cigarettes than the 
controls (Atkin et al., 2002, Natah et al., 2004). Furthermore, local traumas are known to result in 
aphthous lesions in patients who suffer from RAS (Wray et al., 1981, Natah et al., 2004, Jurge et al., 
2006). The oral cavity is easily traumatised because it has high functional activity with large 
masticatory forces and close contact between soft and hard tissues, i.e., the oral mucosa and teeth. 
Thereby, the non-keratinised mucosa is also more easily traumatised, since it is not as thick as the 
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keratinised mucosa. Other pre-disposing factors for RAS, such as psychological stress, nutritional 
deficiencies, and hormonal imbalances, may alter the epithelial integrity of the mucosal lining, 
resulting in aphthous lesions (Subramanyam, 2011). In addition, patients with RAS who lead stressful 
lives seem to be more prone to para-functional habits that cause trauma to the oral mucosa, e.g., 
chewing of the lips resulting in an aphthous lesion (Albanidou-Farmaki et al., 2008). It has also been 
demonstrated that the degree of keratinisation of the oral mucosal tissue in patients with RAS is 
significantly lower than that in a group of controls (Banoczy & Sallay, 1969). Macroscopic 
hyperkeratosis of the oral mucosa and the presence of leukoplakia have not been observed in patients 
with RAS (Sallay & Bánóczy, 1968).  Similarly, patients with leukoplakia rarely suffer from RAS 
(Sallay & Bánóczy, 1968). Currently, there are no studies that have conclusively examined the oral 
mucosal properties of patients with RAS. 
 
Saliva 
In general, the salivary flow rate does not seem to be impaired in patients with RAS, either during the 
acute or the remission phase (Wu-Wang et al., 1995, Brozovic et al., 2002, Mohammad et al., 2013). 
Recently, increased salivary levels of IL-2 have been demonstrated in patients with RAS, who 
presented with active ulcers at the time of sampling, as compared to healthy controls. Interestingly, the 
highest increases in the level of this pro-inflammatory cytokine were observed in the age group of 16–
30 years and in females (Kalpana et al., 2014), which are groups suggested to hold an increased risk of 
RAS. Elevated levels of TNF-α have also been detected in patients during the period when the lesions 
are present (Boras et al., 2006, Eguia-del Valle et al., 2011), as well as during the remission phases of 
the disease (Boras et al., 2006). In contrast, for IL-6, there were no differences in the levels detected 
during either the active or passive phase between the patients with RAS and the controls (Boras et al., 
2006). In addition, reduced salivary levels of epidermal growth factor (EGF) during both the active 
and passive stages of the condition have been reported (Adisen et al., 2008). This change in EGF 
levels may disturb the mucosal integrity and hinder mucosal healing. In addition, lower levels of 
vascular endothelial growth factor (VEGF), which is important for angiogenesis and wound healing, 
have been found in patients suffering from major RAS (but not in those with minor RAS) during the 
active phases of the disease but not during the passive phases, as compared to control subjects 
(Brozovic et al., 2002). Salivary and peripheral blood neutrophils of patients with RAS exhibit 
significantly lower phagocytic activities than those of controls, although no significant differences in 
phagocytic activity were observed when the neutrophils of the two different locations of the same 
patients were compared (Kumar et al., 2010). In a pilot study involving patients with RAS, differential 
MUC7 glycosylation was observed, which might alter the function of the salivary mucins in terms of 
their protective properties against mucosal pathogens (Zad et al., 2015). Although there have been 
several reports on the constitution of saliva and its possible effects on the development of RAS, there 
is no conclusive evidence to support the role of saliva in this condition. 
 
Immune system 
While the immunopathogenic mechanisms underlying RAS remain unclear, they most likely involve 
local and/or systemic stimulation that results in an atypical cytokine cascade, which in turn leads to 
enhanced innate and cell-mediated immune responses directed towards focal areas of the oral mucosa. 
Here, a T cell-mediated immune response is likely to be a central feature due to the heavy infiltration 
of T cells into the epithelium, possibly as the consequence of the entry of an endogenous or exogenous 
antigen, resulting in damage to the epithelium. Furthermore, the ulcers seen in RAS have features 
suggestive of vasculitis.  
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Support for the role of T cells is strengthened by the fact that CD3+ T cells are central inflammatory 
cells found in tissue specimens from RAS lesions, where CD4+ T cells comprise approximately 50% 
and CD8+ T cells approximately 20% of the T-cell population (Hayrinen-Immonen et al., 1991). 
During the pre-ulcerative stage, CD4+ T cells predominate over CD8+ T cells, with a CD4+/CD8+ ratio 
of 2:1, which changes during the ulcerative stage, where the CD8+ T cells predominate, with a 
CD4+/CD8+ ratio of 1:10, while in the healing phase, the CD4+ T cell numbers increase again, yielding 
a CD4+/CD8+ ratio of 10:1 (Savage et al., 1985, Porter & Scully, 1991). Patients who are infected with 
HIV and suffer from AIDS, who show a progressive decline of the CD4+ T-cell populations in their 
peripheral blood and a reversal of the CD4+CD8+ ratio, commonly manifest with aphthous lesions. 
The prevalence of RAS in these patients is not increased but the severity of the condition is, which is 
consistent with the systemic changes in the T-cells ratios for this condition and the local changes in T-
cell ratios typical of the ulcerative lesions. Therefore, the systemic defect is believed to amplify the 
local defect in immune regulation (MacPhail & Greenspan, 1997). Furthermore, the proportions of 
CD4+CD25high regulatory T cells in peripheral blood samples have been reported to be decreased in 
patients with RAS during both the acute and remission phases (Lewkowicz et al., 2005, Lewkowicz et 
al., 2008). The Tregs of patients with RAS are also reported to have impaired function, since they are 
less efficient at suppressing the cytokine production of CD4+ effector T cells than are the Tregs of 
healthy individuals (Lewkowicz et al., 2008).  
  
Support for the role of vasculitis comes from the fact that RAS is a major feature of Behçets disease, 
which is a systemic vasculitis disorder. Early reports suggested an immune complex–mediated 
vasculitis in patients with RAS (Schroeder et al., 1984, Dagalis et al., 1987) whereby antibody-antigen 
immune complexes form and are deposited into the blood vessel walls, causing inflammation. 
Increased levels of anti-endothelial cell antibody (AECA), an autoantibody that is associated with 
autoimmune vascular damage, has been reported in blood samples from patients with RAS, whereas 
the absence of anti-neutrophil cytoplasmic antibody (ANCA) in these samples suggests that 
neutrophil-mediated vasculitis is not involved (Healy et al., 1996). Increased levels of AECA were 
found during both the active and passive phases of RAS (Healy et al., 1996). 
 
During the ulcerative stage, neutrophils become the dominant cell type in the actual ulceration, 
although they are also occasionally observed intravascularly and in areas characterised by 
mononuclear cell infiltrates, i.e., in the areas peripheral to the ulcer (Hayrinen-Immonen et al., 1991). 
The migration and chemotactic function of neutrophils (Abdulla & Lehner, 1979, Dagalis et al., 1987) 
as well as their phagocytic function (Ueta et al., 1993) have been reported to be normal in patients 
with RAS. However, a more recent report has described significant reductions in phagocytic activity 
for salivary and peripheral blood neutrophils in patients with RAS compared to control subjects 
(Kumar et al., 2010). Moreover, the production of oxygen radicals, which are required for the process 
of phagocytosis, has been found to be similar in the neutrophils of patients with RAS and control 
subjects (Wray & Charon, 1991). Interestingly, aphthous lesions are a prominent feature of cyclic 
neutropenia, which is a rare haematological disorder that is characterised by recurrent episodes of 
neutropenia (abnormally low concentrations of neutrophils in the blood). In addition, patients infected 
with HIV who present with major RAS lesions have been observed to show signs of neutropenia 
(MacPhail et al., 1991). At present, the precise role of neutrophils in the development and/or healing 
of the lesions of RAS is unclear, though it is suspected that they play an active role given that they are 
so dominant throughout the tissue in the ulcerative stage.  
 
During the ulcerative stage, numerous macrophages loaded with phagolysosomes that contain the 
debris of neutrophils are observed, indicating that the main function of these cells is to clear the 
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remnants of neutrophils from these tissues (Schroeder et al., 1983). The proportion of CD11b+ 
macrophages has been reported as approximately 14%, particularly in the periphery of the lymphoid 
cell infiltrate, whereas monocytes are found in low numbers (Hayrinen-Immonen et al., 1991).  
 
Mast cells, which represent approximately 2–5% of the inflammatory cells in RAS lesions, have been 
found mainly in the richly vascularised connective tissue that lies beneath the basement membrane 
(Hayrinen-Immonen et al., 1991), i.e., the sub-epithelial lamina propria, as opposed to the epithelium, 
in which only a few mast cells have been detected (Natah et al., 1998). Mast cells are present in 
several-fold higher numbers in aphthous lesions than in normal mucosa (Schroeder et al., 1983). A 
significant increase in the number of mast cells is apparent when one compares the RAS lesions to oral 
traumatic ulcers or the healthy tissues of control subjects, revealing clear signs of 
activation/degranulation in the RAS lesions, which indicates an active role for these cells in the 
immunopathogenesis in RAS (Natah et al., 1998). 
 
Approximately 5–12% of the cells found in RAS lesions comprise B cells that stain positively for 
CD19, which is a prominent B-cell marker (Hayrinen-Immonen et al., 1991). The B cells are found 
both in the epithelium and in the lamina propria (Griffin, 1981), particularly in the periphery of the 
lymphoid cell infiltrate (Hayrinen-Immonen et al., 1991). Activated B cells are rarely found in RAS 
lesions, which suggests that T cells are the predominant lymphocytes in this condition (Hayrinen-
Immonen et al., 1991). However, a B cell-mediated mechanism may also be implicated that involves 
antibody-dependent, cell-mediated cytotoxicity (ADCC), and possibly also immune complexes (Jurge 
et al., 2006). 
 
TNF-α, which is a major pro-inflammatory cytokine, is secreted by activated monocytes, 
macrophages, B cells, T cells, and mast cells. It has an important role in the recruitment of immune 
cells by inducing the up-regulation of adhesion molecules on endothelial cells, thereby stimulating 
neutrophil chemotaxis and T-cell proliferation (Natah et al., 2000). The expression of TNF-α has been 
found to be higher in patients with RAS than in control subjects, suggesting that this condition is 
characterised by high-level expression of this cytokine (Taylor et al., 1992, Buno et al., 1998, Natah et 
al., 2000). Furthermore, increased levels of TNF-α have been found in samples of saliva collected 
from patients with RAS (Eguia-del Valle et al., 2011). In addition, treatment strategies that involve the 
use of Thalidomide and Pentoxifylline, which prevent the synthesis of endogenous TNF-α, have been 
shown to be successful in treating RAS (Jurge et al., 2006). Besides TNF-α, increased levels of IL-6, 
an interleukin that has both pro-inflammatory and anti-inflammatory effects, seem to play important 
roles in the disease process of RAS (Yamamoto et al., 1994, Lewkowicz et al., 2005), as well as IFN-γ 
(Buno et al., 1998, Lewkowicz et al., 2005). IL-10 is an anti-inflammatory cytokine that is expressed 
at lower levels in patients with RAS than in controls (Buno et al., 1998, Lewkowicz et al., 2005). This 
suggests that suppression of the inflammatory reactions is defective in patients with RAS. IL-2 is 
another important pro-inflammatory cytokine, the binding of which to the IL-2 receptor on T cells 
results in the induction of proliferation and increased cytokine secretion, as well as stimulation of the 
secretion of pro-inflammatory cytokines IL-1, TNFα, and TNF-β. Increased plasma levels of IL-2 and 
increased expression of the IL-2 receptor by the activated peripheral lymphocytes have been reported 
during the active phases of RAS lesions (Sun et al., 2000). Polymorhisms in the genes encoding 
cytokines thought to be of importance in RAS development have been reported. In one study, no 
specific polymorphisms in the gene for TNF-α was found (Bazrafshani et al., 2002b), whereas in other 
studies such polymorphisms have been reported (Guimaraes et al., 2007, Sun et al., 2013). 
Polymorphisms of the gene that encodes IL-6 have been observed (Bazrafshani et al., 2002a, Karakus 
et al., 2014).  While variations in certain IL-10 SNPs have been noted (Najafi et al., 2014) no 
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differences in the inheritance patterns of specific IL-10 polymorphisms have been reported 
(Bazrafshani et al., 2003). 
 
Food components 
The involvement of food components and preservatives in the aetiology of RAS has been discussed in 
the literature for many decades. However, no studies have specified the foods that are relevant for 
RAS development or the exact mechanisms by which these foods trigger lesion development. An 
association between coeliac disease and aphthous ulceration has been reported in approximately 5% of 
cases (Tursi et al., 2001, Field & Allan, 2003). It has also been discussed whether gluten sensitivity in 
patients with RAS can arise in the absence of coeliac disease (Wray, 1981), since gastro-intestinal 
symptoms may not always be present and other features of coeliac disease are seen in these patients 
(Field & Allan, 2003). However, there are also studies that indicate no association between coeliac 
disease and RAS (Yasar et al., 2012), since a gluten-free diet may not always alleviate the symptoms 
(Hunter et al., 1993). The association of RAS with coeliac disease has not been completely resolved 
(Field & Allan, 2003). Cow´s milk protein allergy has also been suggested as being linked to RAS 
(Calderon et al., 2008, Besu et al., 2009, Besu et al., 2013a, Besu et al., 2013b). Again, an unequivocal 
association has not been established.  
 
Studies within this field have mainly been based on anamnestic data, elimination/provocation diets, 
allergy testing or combinations of the three aspects. Studies based on anamnestic findings suggest that 
patients with RAS consume a diet that differs from that of controls, whereby the patients with RAS 
report a higher intake of acidic foods (Gonul et al., 2007), lower daily consumption of calcium, iron, 
vitamin B1, and vitamin C, and higher consumption of preservatives, such as benzoic acid and 
cinnamaldehyde (Ogura et al., 2001). In a non-referral, adult Swedish population, the incidence of 
self-reported allergies was significantly higher for patients with RAS than for the controls, as 
registered by general dental practitioners (Robledo-Sierra et al., 2013). In addition, patients with atopy 
have been reported to associate ingestion of certain foods with the development of ulcers (Wilson, 
1980). Self-reporting of food allergies is, however, known to over-estimate the prevalence of allergies 
(Prescott et al., 2013). Nevertheless, the incidence of food allergies is increasing globally (Yu et al., 
2016).  
 
Elimination and/or provocation diet interventions have in part been successful in treating RAS, in that 
a proportion of the patients in each study have experienced a reduction of symptoms concomitant with 
the elimination of certain foods (Hay & Reade, 1984, Wright et al., 1986, Nolan et al., 1991, Wray et 
al., 2000). However, there are also studies that show that this type of intervention has no effect on 
lesion development (Eversole et al., 1982). Apart from an immediate type I hypersensitivity reaction a 
delayed-type IV hypersensitivity reaction could also be involved in RAS, since it has been shown that 
there is often a time delay between when the particular food component is ingested and when the 
clinical symptoms appear. This makes it difficult to define which food component represents the 
triggering factor, as a considerable number of different foods are consumed each day. Furthermore, it 
should be stressed that this type of diet requires a high level of persistence on the part of the patients. 
Patch-testing and contact urticaria testing are well-known methods for identifying Type I and Type IV 
allergic reactions of the skin. Patch-testing of patients with RAS led to the conclusion that this 
diagnostic tool may indeed be a useful adjunct for identifying food allergies in these patients (Nolan et 
al., 1991, Wray et al., 2000). Ultimately, despite extensive research efforts within this field to date the 
roles of food components in the aetiology of RAS are still unknown. 
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Treatment strategies 
At present, there is no cure for RAS. Instead, all the available treatment strategies are aimed primarily 
at relieving symptoms, such as pain, and secondarily focus on promoting healing and reducing the 
duration and frequency of lesions. While various topical and systemic therapies have been used to 
treat RAS, there are few publications demonstrating the efficacies of the different substances applied. 
Currently there is no consensus available regarding appropriate treatment regimens. 
 
A systematic Cochrane review from 2012 of systemic treatments involving tablets and injections 
revealed that the studies of treatments for this condition are not sufficiently comprehensive 
(Brocklehurst et al., 2012). Out of 25 randomised control trials (RCTs) in which 21 different 
interventions were assessed, not one single treatment was found to be effective. This was mostly due 
to the poor methodology used and the fact that not all drugs used for the treatment of RAS were 
included. It should also be appreciated that different drugs are more or less effective in different 
patients, and that systemic interventions are most often applied to patients with a more severe and 
persistent form of RAS for whom topical treatments strategies have failed. The 
immunomodulatory/anti-inflammatory interventions included in this systematic review were Beta-
glucan, Clofazimine, Colchicine, Levamisole, Montelukast (leukotriene receptor antagonist), 
Pentoxifylline, Prednisone and Sulodexide. Other interventions studied were camel thorn, 
homeopathy, LongoVital (herbal plus vitamin), Longovital (herbal alone), multi-vitamin, propolis, 
sub-antimicrobial doxycycline, tetracycline, and vitamin B12. 
 
A protocol for a systematic review of topical treatment strategies has also been registered in the 
Cochrane database but it has yet to be completed (Taylor J. Topical interventions for recurrent 
aphthous stomatitis (mouth ulcers). Cochrane Database of systemic reviews 2013). This type of 
treatment involves, for example, the use of antiseptics, anti-inflammatory agents, and analgesics 
(chlorhexidine mouthwash or gel, triclosan gel, topical diclofenac, amlexanox), antibiotics 
(doxycycline gel), topical corticosteroids (triamcinolone acetonide, fluocinolone acetonide, Clobetasol 
proprionate), hyaluronic acid (gel), topical anaesthetics (lidocaine spray or gel), and other modalities 
(laser therapy and natural substances) (Belenguer-Guallar et al., 2014). 
 
In Sweden, the Swedish Agency for Healthy Technology Assessment and Assessment of Social 
Services (SBU) proposed to compare the effects of rinsing with Clobetasol proprionate 0.025% or 
Aureomycin (tetracycline), which are drugs commonly used in Sweden for the treatment of RAS, in a 
systematic review (http://www.sbu.se/globalassets/publikationer/upplysningstjanst/pdf_er/skoljning-
med-klobetasolgel-eller-aureomycin-tetracyklin-vid-aftosa-munsar-afte.pdf). Unfortunately, no 
comparative studies of these two drugs have been performed, so there was no possibility to perform 
the planned comparison.  
 
 
 
Mucosal immunity 
 
The mucosal immune system 
The immune system, which comprises all the mucosal surfaces of the body (commonly referred to as 
the mucosal immune system) plays a dual role: on the one hand it is required to protect the body from 
harmful antigens (pathogens) by inducing protective immunity, while on the other hand it needs to 
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induce tolerance towards harmless antigens (food proteins and the commensal microbiota). These two 
important roles are complete counterparts, and ideally, when the body is exposed to harmful pathogens 
an inflammatory process is initiated to eliminate these pathogens whilst tolerance to food proteins and 
the commensal microbiota is maintained. However, on occasion, the immune system has difficulties 
deciding between when to induce protective immunity and when to induce tolerance, resulting in 
immunoregulatory diseases, such as autoimmune diseases and allergies. 
 
This part of the immune system is strategically located at the entrance points of the body, and it is 
constantly exposed to numerous antigens from the external environment. The mucosal immune system 
is found in the ocular cavity, the respiratory tract (nose, sinus, trachea and lungs), the gastro-intestinal 
tract (oral cavity, oesophagus, stomach, and small and large intestines), and the female urogenital tract 
(uterus, bladder, and vagina) (Lamichhane et al., 2014). The associated secretory glands of these 
compartments (the lachrymal, salivary and mammary glands) are also included. The epithelium acts in 
part as a physical barrier with tight junctions between the cells, as well as the mucus layer overlying 
the epithelium (Kim & Surh, 2015). Fluids secreted from the associated glands contain antimicrobial 
factors that create a biochemical barrier (Kiyono & Azegami, 2015). However, antigens may penetrate 
this barrier, necessitating the assistance of innate and adaptive immune responses (Kim & Surh, 2015).  
 
The mucosal immune system is composed of inductive sites, which are areas in which antigens, 
selectively sampled from mucosal surfaces, are transported and presented by dendritic cells (DCs) to 
naïve T and B cells, inducing a primary immune responses, and effector sites, which are areas in 
which effector cells, after extravasation, retention, and differentiation, perform their actions. The 
respiratory and gastro-intestinal compartments of the mucosal immune systems in humans and mice 
are shown in Table 2. The mucosa-associated lymphoid tissues (MALTs), which are considered as 
inductive sites of the mucosal immune system, consist mainly of the nose-associated lymphoid tissues 
(NALTs) and the gut-associated lymphoid tissues (GALTs). The bronchus-associated lymphoid 
tissues (BALTs) are also classified as MALT structures but since they are not found in mice and only 
occasionally found in humans, they will not be discussed further here. All MALT structures consist of 
a follicle-associated epithelium (FAE) that contains micro-fold (M) cells. The FAE overlies the 
follicular zones of B cells and naïve- and memory T cells with surrounding para-follicular zones that 
contain T cells and DCs, and where high endothelial venules (HEVs) are also found (Pabst, 2015) 
(Figure 3). At the bottom of the follicular zone lies a germinal centre. These tissues also have efferent 
lymphatics. MALT structures therefore resemble lymph nodes but they lack afferent lymphatics and 
are not encapsulated (Brandtzaeg, 2010). In general, the antigen is taken up by the M cells in the FAE 
and presented to DCs, which process the antigen into peptides and load them onto their MHC class I 
or class II molecules and transport them to the para-follicular T-cell zones. The antigen is then 
presented to the naïve T cells, causing them to proliferate and differentiate into antigen-specific T 
cells. These cells support the induction of IgA-producing B cells and their differentiation into plasma 
cells in the follicular zones. Thereafter the B and T cells migrate to the regional lymph nodes through 
lymph vessels, and then through the circulation to the effector sites (Lamichhane et al., 2014).  
 
The major immunoglobulin within the mucosal immune system is secretory immunoglobulin A 
(SIgA), as it predominates in most secreted bodily fluids. IgA is produced by plasma cells locally at 
mucosal surfaces. IgA attaches to the polymeric immunoglobulin receptor (pIgR) found on mucosal 
epithelial cells, which allows for transcytosis into the cell and then secretion into the mucus. During 
transcytosis a fragment of the pIgR is cleaved off, while the remainder remains attached to the IgA 
molecule. This complex forms the secretory component (SC). The SC is not found in the systemically 
circulating IgA but only in the mucosal secretory IgA. At the mucosal surface and in the lumen, the 
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function of SIgA is to bind and agglutinate bacteria and other antigens so as to facilitate their 
clearance, to neutralise bacterial toxins, and to prevent penetration of the mucosal membrane by these 
molecules. In addition, the SIgA-antigen complex can be taken up by M cells in the FAE, thereby 
inducing an adaptive immune response (Shakya et al., 2016). 
 
Lymph nodes play an important role in protecting the body against foreign antigens, since they are the 
sites of the primary immune responses. Antigen-presenting cells (APCs) display antigens to naïve 
lymphocytes, which become reactive and undergo clonal expansion to produce new lymphocytes and 
plasma cells (Willard-Mack, 2006). Antibodies are produced by the plasma cells and are secreted into 
the lymph, while activated lymphocytes are transported by the circulation to effector sites where 
harmful antigens are eliminated (von Andrian & Mackay, 2000). Under normal conditions, the 
lymphocytes then leave the effector site and home to the lymph nodes located in the area from which 
they originated from (Miyasaka & Tanaka, 2004).  
 
 
Table 2. The respiratory and gastro-intestinal compartments of the mucosal immune systems in humans and 
mice.  
 Human Mouse 
Inductive sites   
Upper respiratory tract Waldeyer´s ring and ILFs NALT and ILFs 
   
Gastro-intestinal tract GALT (PPs, ILFs and appendix) 
  
Local/regional lymph nodes MLNs, CLNs 
Effector sites   
Upper respiratory tract Lamina propria of the nasal mucosa 
   
Gastro-intestinal tract Lamina propria of the oral cavity and intestinal mucosa 
  
Secretory glandular tissues Salivary glands 
  
Surface epithelium FAE and IEL compartments 
Abbreviations: ILF, isolated lymphoid follicle; NALT, nose-associated lymphoid tissue; GALT, gut-associated lymphoid tissue; PP, Peyer´s 
patch; FAE, follicle-associated epithelium; IEL, intraepithelial lymphocyte. 
 
Adapted from: Brandtzaeg et al. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 2008 Jan;1(1):31-7, 
and Brandtzaeg. Function of Mucosa-Associated Lymphoid Tissue in Antibody Formation. Immunol Invest. 2010;39(4-5):303-55. 
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Figure 3. Schematic of a Peyer´s patch, which is a mucosa-associated lymphoid tissue (MALT) structure found in the 
intestine.  All MALT structures consist of a follicle-associated epithelium (FAE), that contains micro-fold (M) cells. The FAE 
overlies the follicular zones of B cells and naïve- and memory T cells, with surrounding intra-follicular/para-follicular zones 
that contain T cells and DCs. At the bottom of the follicular zone lies a germinal centre. T, T cell; B, B cell; DC, dendritic 
cell; IEL, intraepithelial lymphocyte; FoDC, follicular dendritic cell. Adapted from Shakya et al. 2016. Mucosal vaccine 
delivery: Current state and a pediatric perspective. J Control Release. 240:394-413. 
 
 
The nasopharyngeal immune site 
The nose forms the point of entry to the upper respiratory tract and in mice it is divided into two 
distinct passages separated by the nasal septum. Each nasal passage extends from the nostril to the 
nasopharynx and consists of a main chamber that is composed of a lateral wall, a septal wall, a roof, 
and a floor (Harkema et al., 2006). The lumen of the main chamber is lined with a richly vascularised 
and innervated mucosa, consisting of the surface epithelium and the underlying lamina propria.  
 
The NALT in rodents comprise bilateral lymphoid cell aggregates that are present on both sides of the 
nasopharyngeal duct located dorsally to the cartilaginous soft palate, and are believed to be analogous 
to the Waldeyer´s ring in humans (Kuper et al., 1990, Brandtzaeg et al., 2008). This tissue is 
recognised as the major MALT structure in the upper respiratory tract, and is believed to be an 
inductive site for mucosal immune responses, similar to the Peyer´s patches (PP), which are the GALT 
equivalent in the intestine (Kiyono & Fukuyama, 2004). The NALT is covered by a FAE that contains 
M cells similar to those found in the gut epithelium and contains a follicular zone, as well as a para-
follicular zone (Kiyono, 2013). The NALT together with the isolated lymphoid follicles (ILFs) and 
draining CLNs make up the inductive sites of the nasal immune system. Equivalently, the nasal 
mucosa, FAE, and associated IELs make up the effector sites.  
Antigens and vaccines are inhaled through the nose and transported via the nasal mucosa through the 
M cells of the FAE, where the DCs in the lamina propria are loaded with the antigen and migrate to 
the NALT where they present the antigens to naïve T cells and B cells. Activated and memory B and 
T cells then migrate from the NALT via the HEVs to the CLN (Kuper et al., 1992) where the immune 
response is amplified (Zuercher, 2003). These cells then pass into the circulation and home to the 
effector sites, such as the lamina propria of the nasal passages, and to exocrine glands, such as the 
submandibular glands (Kiyono, 2013). 
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In normal adult, female BALB/c mice, the NALT contain approximately 1×106 cells (Heritage et al., 
1997). Approximately 30% CD4+ T cells and 10% CD8+ T cells have been reported in the NALT (Wu 
et al., 1996, Heritage et al., 1997, Asanuma et al., 1997). However, in another study, the percentage of 
CD4+ T cells (but not CD8+ T cells) was different (Rodriguez-Monroy et al., 2007). The ratios of 
CD4+ T cells to CD8+ T cells in the NALT and MLN have been reported to be similar (3.9 and 3.8 
respectively), and somewhat higher than in the CLN (2.9) (Asanuma et al., 1997). The majority of the 
CD3+ T cells in the NALT co-express CD45RB, which suggests T cells with a naïve phenotype (Wu et 
al., 1996). Furthermore, the percentage of CD11c+ DCs in the NALT has previously been reported as 
approximately 3% (Nacer et al., 2014). In addition, the percentage of CD11b+Ia+ (MHC class-II) 
macrophages has been reported as 4.5% (Heritage et al., 1997), indicating that there could be a greater 
proportion of CD11b+ than CD11c+ APCs in this compartment. The B cell to T cell ratio has been 
estimated at approximately 50% B cells and 50% T cells (Wu et al., 1996, Heritage et al., 1997, 
Asanuma et al., 1997).  
 
Although the NALT is recognised as the central structure responsible for antigen-specific immune 
responses of the upper respiratory tract, it has also been proposed that there are other, additional 
inductive sites that are of importance, i.e., the NALT-independent pathways. This arose from the 
discovery of respiratory M cells, which possess the functional characteristics of classical M cells but 
reside in epithelium separated from the NALT (Kim et al., 2011). After the antigens have been 
sampled by the respiratory M cells, they are loaded onto DCs in the lamina propria, and then 
transported onwards in a fashion similar to that of the NALT-dependent pathway. 
 
 
The oral immune site 
From the mouth, exogenous antigens are taken up by the oral mucosa or swallowed down into the gut. 
The oral cavity is lined with a stratified squamous epithelium, which does not have a natural 
adsorptive capacity, unlike the gut and the respiratory epithelium. The latter two consist of a single 
layer of epithelium (apart from the most anterior parts of the nose, which are lined with a stratified 
squamous epithelium), whereas the oral mucosa shares features with the skin and exhibits regional 
variations in permeability that are in direct correlation to the thickness of the epithelial barrier (Squier, 
1991). The areas that are exposed to the highest levels of wear, i.e., the attached gingiva, hard palate, 
and dorsum of the tongue are covered by a keratinised epithelium, which hinders passage through the 
epithelium. In contrast, the surfaces that are not as exposed, i.e., the labial and buccal surfaces of the 
mouth, as well as the soft palate, ventral parts of the tongue, and floor of the mouth, are covered by a 
non-keratinised mucosa, which is more permeable.  
 
Unlike the nose and the intestine, the oral cavity of mice lacks a clear inductive MALT structure of its 
own, like the NALT and GALT, respectively. Instead, this region displays effector sites, such as the 
epithelium and lamina propria lining the oral cavity, as well as the salivary glands. In humans, the 
Waldeyer´s ring is located in the transition zone between the oral cavity and the nasopharynx, thereby 
establishing an inductive site in close proximity to the oral cavity and being exposed to both airborne 
and alimentary antigens. In addition, in mice, the NALT lie in close proximity to the oral cavity. 
Therefore, there are a variety of lymphoid tissues within the naso-oropharyngeal cavities, i.e., the 
NALT in mice and Waldeyer´s ring in humans, as well as the ILFs scattered throughout these mucosal 
passages. However, the interplay between the nasal and oral compartments is not fully understood.  
 
A unique feature of the oral cavity is that it is protected by both the mucosal immune system, 
manifested through the oral mucosa, saliva, and salivary glands, and the systemic (peripheral) immune 
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system, through the gingival crevicular fluid (Walker, 2004, Kiyono, 2013). The principal cell type of 
the oral epithelium is the keratinocyte, although there is also a large proportion of DCs among which 
the Langerhans cells predominate. 
 
It has been proposed that antigens are sampled from the lumen of the oral cavity and loaded onto DCs 
that migrate to regional lymph nodes, i.e., the CLNs, where they present the antigens to naïve T cells 
(Eriksson et al., 1996). While, the exact mechanisms of antigen up-take are currently not known, the 
most prominent subsets in the mouse oral mucosa are CD11cnegCD11b+ APCs and CD11c+CD11b+ 
DCs (Mascarell et al., 2008). The antigen-specific T cells and B cells in the CLN then migrate to the 
lamina propria of the oral cavity and salivary glands, where they exert their effector functions. 
 
The submandibular glands display a predominance of IgA-producing cells but they also contain high 
numbers of T cells. Approximately 50% of the lymphocytes are CD3+ T cells, whereas both CD4+ T 
cells and CD8+ T cells are found in equal numbers. CD4negCD8neg cells are also found. However, 
CD4+CD8+ T cells are essentially lacking (Kiyono, 2013). At least 95% of the IgA found in the saliva 
is produced by plasma cells located in the salivary glands (Brandtzaeg, 2013). In the CLN, there are 
approximately 80% CD3+ T cells and 20% B cells. Among the T cells, approximately 50% are CD4+ 
and 20% are CD8+ (Asanuma et al., 1997).  
 
 
The gastro-intestinal immune site 
The gastro-intestinal tract extends from the oral cavity to the anus, encompassing the largest mucosal 
surface, and it is continuously exposed to various antigens. However, since the upper gastro-intestinal 
tract (oral cavity, pharynx, oesophagus, and stomach) contains few lymphoid tissues compared to the 
lower gastro-intestinal tract (small intestine and large intestine), the majority of immune cells are 
found in the latter (Mowat & Agace, 2014). This is also one of the reasons why the lower gastro-
intestinal tract is the most extensively studied compartment of the mucosal immune system. The 
induction of oral tolerance within the intestine occurs mainly in the small intestine, whereby only this 
compartment will be reviewed in the current section. 
 
Villi are finger-like projections, characteristic of the small intestine, that extend into the lumen to 
increase the surface area of the epithelium and allow for greater uptake of intestinal antigens. The 
epithelium is dominated by enterocytes, which form a simple, columnar layer and have a strong 
absorptive capacity, since they consist of microvilli, which increase the surface area even more. 
Underneath the epithelium lies the lamina propria, and it is within these two segments that most of the 
immune cells reside. Interspersed within the intestinal epithelium lie the GALT structures, comprising 
the PPs and ILFs. Together with the MLNs they form the inductive sites of the lower gastro-intestinal 
tract. Equivalently, the effector sites are the intestinal mucosa, the FAE, and the IELs. As with other 
MALT structures, the PPs consist of follicular B-cell areas and para-follicular T-cell areas that are 
covered by a FAE that contains M cells. The PPs number approximately 8–10 in mice (Kunisawa et al., 
2008). In contrast to the PPs, the ILFs consist of B-cell zones but no clearly evident T-cell zones 
(Mowat & Agace, 2014).  
 
Antigens are sampled across the intestinal epithelium via a number of different routes, either to the 
GALT or to the lamina propria. In the GALT, this is accomplished through one of two routes (Pabst & 
Mowat, 2012): (i) through the M cells in the FAE of the PPs and ILFs, where the antigens are then 
loaded onto DCs; or (ii) the antigens are sampled directly from the lumen by DCs in the underlying 
tissue extending their processes through the FAE. In the remainder of the small intestine, antigens are 
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sampled across the epithelium to the lamina propria through the following routes (Pabst & Mowat, 
2012, Kim & Surh, 2015): (a) small antigens may pass directly across the epithelium by para-cellular 
diffusion through pores in the tight junctions that connect the epithelial cells; (b) larger antigens can 
be taken across enterocytes by transcellular routes, i.e., passing through the epithelial cells; (c) by 
exosomes; (d) by CX3CRX1-expressing macrophages that extend their processes through the 
epithelial barrier; (e) through apoptotic bodies derived from intestinal epithelial cells; and (f) by 
capturing antigens passed on via goblet cells.  
 
It has been proposed that the microbiota is mainly sampled through the GALT, and that food antigens 
are taken up by DCs in the lamina propria rather than through the GALT (Pabst & Mowat, 2012). 
Ultimately, the PPs may not play as important a role in the induction of oral tolerance to food proteins 
as previously described, since oral tolerance has been shown to be established in the absence of PPs 
(Spahn et al., 2001, Spahn et al., 2002, Kraus et al., 2005). Irrespective of the route, all drainage of 
immune cells occurs to the MLN before they migrate onwards to the effector sites.  
 
 
Tolerance 
Induction of tolerance mainly occurs within the intestinal immune site, since (as mentioned above) the 
gastro-intestinal tract comprises the largest mucosal surface and is continuously exposed to various 
antigens, such that the majority of immune cells are found here (Mowat & Agace, 2014). This is also 
one of the reasons why it is the most extensively studied compartment of the mucosal immune system. 
Induction of tolerance to food antigens in the small intestine is commonly referred to as 'oral 
tolerance', which represents the normal immune response to the harmless protein antigens to which 
humans and animals are exposed via the mucosal route. The intestine has the capacity to distinguish 
harmless antigens from potential pathogens and to develop active antigen-specific tolerance towards 
the former. This is vital for maintaining a healthy immune balance and avoiding pathological immune 
reactions. The abrogation of oral tolerance is thought to underlie the development of allergies and 
inflammatory bowel disease (Pabst & Mowat, 2012), both of which are growing concerns globally 
(Okada et al., 2010).  
 
 
Terminology 
'Oral tolerance' is defined as the body´s ability to prevent reaction to a harmless, orally administered, 
soluble antigen, for example, a food antigen, thereby avoiding an aggressive immunological response 
specifically in the small intestine. This term should be distinguished from 'mucosally induced 
tolerance', since oral tolerance affects both the local and systemic immune responses, whereas 
mucosally induced tolerance involves gut bacteria and only induces a local response in the other parts 
of the intestine, for example, the colon (Pabst & Mowat, 2012). Induction of oral tolerance is therefore 
confined to the gastro-intestinal tract, more specifically the small intestine. However, mechanisms for 
tolerance induction must exist along the entire respiratory, gastro-intestinal, and urogenital tracts, 
since they are all mucosal surfaces, parts of the mucosal immune system, and are exposed to large 
amounts of antigens. Currently, there is no fully established terminology for tolerance induction that 
refers to all parts of the mucosal immune system. 'Mucosal tolerance' has been suggested as a more 
appropriate term (Kim & Surh, 2015) for tolerance that is induced specifically towards dietary 
antigens. However, this phrasing is confusingly similar to the term 'mucosally induced tolerance', 
which is proposed to describe tolerance induction to gut bacteria in the intestine. The induction of 
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tolerance in the oral cavity has been referred to as 'oral mucosal tolerance' (Novak et al., 2008). 
Ultimately, there is a need for a more stringent and concise terminology within this area. 
!
 
Historical context  
The concept of oral tolerance was first introduced in the 19th century by Dakin (1829). He observed 
that the development of contact dermatitis in South American Indians to poisonous ivy could be 
prevented by chewing the leaves of this plant. In 1911, Wells and Osborne demonstrated 
experimentally that feeding egg protein to guinea pigs could inhibit systemic anaphylaxis to this food 
component (Wells & Osborne, 1911). Later, in 1946, Chase showed that by pre-treating animals orally 
with an allergenic compound to which they had not earlier been exposed, for example, 2:4 
dinitrochlorobenzene (a known allergen used for experimental sensitisation in humans), a degree of 
protection was obtained that was higher than if the compound had been given intravenously, 
cutaneously or parenterally prior to a challenging sensitisation (Chase, 1946). The mechanism by 
which the immune system acts non-responsively to antigens was not well understood at the time. 
 
The importance of the small intestinal epithelium for oral tolerance induction was demonstrated in the 
1980s. Initially, in 1983, Strobel et al. showed that it was not the antigen single-handedly that induced 
tolerance but that it had to be confined within serum, since mice became tolerant after serum transfer 
from an OVA-fed mouse to a naïve donor mouse. Therefore, this tolerogenic moiety was named 'the 
serum factor' (Strobel et al., 1983). Subsequently, Bruce and Ferguson demonstrated, in 1986, that 
parenteral administration of an antigen was not sufficient to induce tolerance but that gut processing 
seemed to be required (Bruce & Ferguson, 1986). In 1990, Peng et al. showed that the tolerogenic 
activity in serum was not correlated to the serum levels of antigen absorbed by the intestine but that it 
was time-dependent, since serum collected 5 minutes after the feeding of OVA was unable to transfer 
tolerance despite the fact that significant levels of immunoreactive OVA were present (Peng et al., 
1990). Instead, it required approximately 45–60 minutes in BALB/c mice. In addition, in 1994, Furrie 
et al. showed that severe combined immunodeficiency (SCID) mice, which lack functioning mature B 
and T cells, failed to generate the oral tolerance-inducing serum factor (Furrie et al., 1994). Therefore, 
a fully functioning intestinal immune system is a requirement for oral tolerance induction. An attempt 
was made to characterise the features of the serum factor (Furrie et al., 1995), but this issue remained 
unsolved until the beginning of the 21st century when it was shown to consist of exosomes (Karlsson 
et al., 2001). Exosomes are small membrane-bound vesicles that are secreted by the fusion of 
intracellular multi-vesicular late endosomes/lysosomes with the plasma membranes from the small 
intestinal epithelial cells after processing of the sampled antigen, and the exosomes are then 
transported to the circulation and disseminated to different locations within the body. Exosomes have 
been detected throughout the body in physiological fluids, for example, broncho-alveloar lavage 
(BAL) fluids (Admyre et al., 2003), serum (Caby et al., 2005), urine (Pisitkun et al., 2004), breast milk 
(Admyre et al., 2007), and saliva (Ogawa et al., 2008), and they are believed to mediate 
communication between cells. Furthermore, they express MHC class II molecules that are loaded with 
antigens (Ostman et al., 2005) and can possibly initiate antigen presentation either by themselves or 
through exosome uptake by other APCs resulting in the activation of T cells.  
 
 
Induction of oral tolerance in the small intestine 
Several factors influence the induction of oral tolerance, such as the age, genetic background, and 
immunological status of the animal, as well as the nature of the antigen and the dose and frequency of 
administration. Low doses of antigen favour active suppression, whereby an inhibitory environment is 
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created by the induction of a multitude of different Treg subsets, among which the FoxP3+ Tregs are 
the most important and well-characterised. High doses of antigen initiate T-cell activation, resulting in 
clonal anergy or the deletion of antigen-specific T cells (Gregerson et al., 1993, Friedman & Weiner, 
1994, Chen et al., 1995). Multiple feedings of antigen are more effective at inducing oral tolerance 
than a single feeding, while continuous feeding of an antigen in the drinking water enhances 
suppression to both Th1 and Th2-type responses, as compared with a single feed or feeding the 
antigen once per day over several days (Faria et al., 2003). 
 
Tregs are immunosuppressive cells that are essential for maintaining peripheral tolerance, preventing 
the development of autoimmunity and limiting chronic inflammatory diseases. They are broadly 
classified into two subsets: the thymus-derived regulatory T cells (tTregs), which acquire their 
regulatory capacity in the thymus; and the peripherally-derived regulatory T cells (pTregs), which 
acquire their regulatory function in the periphery through the differentiation of conventional CD4+ T 
cells (Abbas et al., 2013, Li et al., 2015). FoxP3+ Tregs employ an array of mechanisms to maintain 
oral tolerance through either the secretion of suppressive molecules or cell-cell interactions. Tregs 
secrete inhibitory cytokines (e.g., TGF-β and IL-10), express granzymes (which results in the cytolysis 
of effector T cells), diminish local IL-2-inhibiting effector T-cell proliferation through metabolic 
disruption, and/or modulate the maturation or function of DCs (Vignali et al., 2008). The type of Treg 
activity is dictated by the environmental context, as well as on the location of the inflammation 
(Chaudhry & Rudensky, 2013). 
 
A multi-step process for the induction of oral tolerance in the small intestine has been proposed 
according to the following (Hadis et al., 2011, Pabst & Mowat, 2012, Kim & Surh, 2015) (Figure 4): 
 
1) Sampling of the antigen and migration of DCs to the draining lymph node  
CD11c+CD103+ DCs, which represent the most abundant subset of APCs in the 
lamina propria of the small intestine, sample antigens from the gut lumen and 
migrate to the MLN. CX3CR1+ macrophages play an important role in sampling 
the antigens and loading them onto the CD11c+CD103+ DCs. Migration to the 
MLN is assisted by the up-regulation of CD62L and CCR7, markers that are 
expressed on the lymphocytes, which allows them to enter the secondary lymphoid 
tissues via HEVs. CCL19 and CCL21 are the ligands for CCR7 expressed by the 
lymphatic endothelium and in the MLNs that help guide the cells.  
 
The MLN are a pre-requisite for the establishment of oral tolerance, as surgical 
removal of the MLN (Worbs et al., 2006), as well as the lack of this lymph node 
due to genetic mutation (Spahn et al., 2001, Spahn et al., 2002) have been shown to 
prevent the induction of oral tolerance. Furthermore, in CCR7-deficient mice, the 
ability of cells to migrate into the MLN is impaired (Worbs et al., 2006, Jang et al., 
2006). There also seems to be a distinct difference in function between CD103+ 
DCs and CX3CR1+ macrophages, in that CD103+ DCs are less efficient at 
sampling antigens themselves from the intestinal lumen (Farache et al., 2013, 
Chang et al., 2013) and require the assistance of CX3CR1+ macrophages for this 
activity (Niess et al., 2005, Hadis et al., 2011, Mazzini et al., 2014). 
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2) Presentation of the antigen to naïve lymphocytes in the lymph node 
In the MLN, the CD11c+CD103+ DCs present the antigens to naïve B and T cells, 
such that they become activated.  
 
3) Induction of gut tropism and differentiation of FoxP3+ Tregs 
The CD11c+CD103+DCs produce retinoic acid (RA) from dietary retinoids 
(vitamin A) through the activity of the enzyme retinaldehyde dehydrogenase 2 
(RALDH2). The local stromal cells in the lymph node also perform this task. This 
stimulates gut tropism by inducing the expression of the gut-homing receptors α4β7 
and CCR9 on activated antigen-specific T cells, which favours homing to the small 
intestinal mucosa. It also stimulates the differentiation of FoxP3+ Tregs assisted by 
TGF-β. The induction of FoxP3+ Tregs is putatively more important for the 
induction of oral tolerance than anergy and the deletion of T cells. In the absence of 
FoxP3+ T cells, oral tolerance does not develop. 
 
Adding TGF-β to a culture that contains CD11c+CD103+ DCs induces the 
differentiation of FoxP3+ Tregs; this phenomenon does not occur when TGF-β is 
added to CD11c+CD103neg DCs. The latter cells cannot expand the Treg population 
in vitro (Coombes et al., 2007). Furthermore, CD11c+CD103neg DCs require the 
addition of exogenous TGF-β in order to metabolise vitamin A (retinol) from the 
diet into RA through the action of RALDH2, which is not necessary for 
CD11c+CD103+ DCs (Coombes et al., 2007, Benson et al., 2007, Sun et al., 2007). 
Mice that are fed a vitamin A-deficient diet, have severely impaired capacity for 
gut homing of activated CD4+ T cells, resulting in reduced numbers of these cells 
in the lamina propria of the small intestine (Iwata et al., 2004, Cha et al., 2010). 
 
4) Homing of antigen-specific T cells and FoxP3+ Tregs to the lamina propria and 
secondary expansion of the FoxP3+ Tregs 
The activated antigen-specific T cells and the FoxP3+ Tregs home back to the 
intestinal lamina propria. Then the FoxP3+ Tregs undergo secondary expansion 
under the influence of IL-10 produced by the resident CX3CR1+ macrophages. 
These latter cells cannot migrate within the lymph vessels and are not very good at 
priming naïve T cells. Their functions are instead expressed within the local 
mucosa, where they sample antigens from the intestinal lumen and load them onto 
the DCs, while also facilitating the local differentiation of Tregs.  
 
Besides promoting the differentiation of FoxP3+ Tregs, CD103+ DCs are unable to 
produce the pro-inflammatory cytokines IL-6 and TNF-α and instead produce the 
anti-inflammatory cytokines IL-10 and TGF-β (Kim & Surh, 2015). Interestingly, 
most CD4+ T cells in the lamina propria display an activated or memory phenotype, 
even in the absence of pathogens (Kim & Surh, 2015).  
 
5) Dissemination of the FoxP3+ Tregs putatively promotes systemic tolerance 
Some of the Tregs are then believed to exit the mucosa via the lymph or blood and 
spread throughout the immune system, promoting systemic tolerance. 
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6) Involvement of the liver in the induction of systemic tolerance 
Apart from the gut processing of the antigen, it has been demonstrated that the liver 
assists in establishing systemic tolerance from intestinally derived antigens, 
whereby a certain fraction of the antigens is transported from the GALT and/or 
lamina propria of the intestine to the MLN and then on to the PLNs and through the 
thoracic duct to the circulation, whereas another fraction is transported through the 
portal vein to the liver and then onwards through the circulation. 
 
The portal vein drains blood from the intestine to the liver. Injecting an antigen 
directly into the portal vein without first passing it through the intestine is known to 
induce oral tolerance (Thomson & Knolle, 2010). Moreover, hindering the blood 
flow away from the liver by inserting a porto-caval shunt prevents the induction of 
oral tolerance (Callery et al., 1989, Yang et al., 1994). 
 
It is currently not clear as to whether a proportion of the effector T cells and FoxP3+ Tregs disseminate 
through the circulation from the local lamina propria to other mucosal sites of the body during the 
induction of oral tolerance. This dissemination pattern has however been established for B cells, which 
migrate from the inductive sites to effector sites through the circulation assisted by adhesion 
molecules and chemokine-chemokine receptors (Brandtzaeg, 2013). Experiments conducted in mice 
and humans show that activated B cells migrate from the GALT to the salivary glands (Brandtzaeg, 
2013). However, the NALT may be more important for the production of memory/effector B cells that 
are destined for the salivary glands rather than the GALT (Brandtzaeg, 2013). Therefore, regional 
antigen stimulation may be more effective initiating appropriate immune responses than immune 
induction at more distal sites. This could be due to significant differences in the compositions and 
functions of the immune systems at the various sites, for example, regarding homing properties. The 
effects of oral tolerance are impaired T-cell proliferation by clonal deletion, clonal anergy or bystander 
suppression, decreased expression of pro-inflammatory cytokines, and a reduced systemic delayed-
type hypersensitivity (DTH) reaction. 
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Figure 4. Induction of oral tolerance in the small intestine. A multi-step process for the induction of oral tolerance has been 
proposed as follows, resulting in clonal anergy, clonal deletion, as well as the induction and differentiation of Tregs: 1) 
sampling of the antigen and migration of DCs to the draining lymph node; 2) presentation of the antigen to naïve 
lymphocytes in the lymph node (not shown in the illustration); 3) induction of gut tropism and differentiation of FoxP3+ 
Tregs; and 4) homing of antigen-specific T cells and FoxP3+ Tregs to the lamina propria and secondary expansion of the 
FoxP3+ Tregs. Antigen sampling through the intestinal epithelium occurs in the GALT: (i) through M cells in the FAE of the 
PPs and ILFs, where the antigens are then loaded onto DCs; or (ii) antigens are sampled directly from the lumen by DCs in 
the underlying tissue extending their processes through the FAE. Antigens are sampled across the intestinal epithelium to the 
lamina propria through the following routes: small antigens may pass directly across the epithelium (a) by para-cellular 
diffusion through pores in the tight junctions that connect the epithelial cells; (b) larger antigens can be taken across 
enterocytes by transcellular routes, i.e., passing through the epithelial cells; (c) by exosomes; (d) by CX3CRX1-expressing 
macrophages that extend their processes through the epithelial barrier; (e) through apoptotic bodies derived from intestinal 
epithelial cells; and (f) by capturing antigens passed on through goblet cells. Routes c), e), and f) are not shown in the 
illustration. Figure adapted from Yu W et al. 2016. Food allergy: Immune mechanisms, diagnosis and immunotherapy. Nat 
Rev Immunol. doi:10.1038/nri.2016.111. Oral tolerance model adapted from Pabst O and Mowat AM. 2012. Oral tolerance 
to food protein. Mucosal Immunol. 5(3):232-239 and Kim KS and Surh CD. 2015. Induction of immune tolerance to dietary 
antigens. Adv Exp Med Biol. 850:93-118. DC, dendritic cell; FAE, follicular-associated epithelium; GALT, gut-associated 
lymphoid tissue; ILF, isolated lymphoid follicle, M cell, microfold cell; PP, Peyer´s patch, Treg, regulatory T cell. 
 
 
Induction of tolerance in the nasal and oral cavities 
There must also be mechanisms for establishing tolerance within the nasal and oral cavities since 
inflammation due to nasal and oral microbiota, food antigens and other environmental factors are 
rarely seen in these regions. In addition, post-operative infections are seldom observed within the oral 
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cavity, despite the high bacterial load in saliva, which continuously enters the surgical wound.  
 
It has previously been demonstrated that DCs from the oral cavity have the capacity to induce FoxP3+ 
Tregs in vitro, as has been shown in the intestine (Yamazaki et al., 2012). However, the mechanism of 
induction seems to be different in the oral cavity, and is not dependent upon CD103+ DCs, RA, and 
RALDH, as is the case in the intestine (Yamazaki et al., 2012). Other reports have indicated that it 
may not be the CD11c+CD11b+ DCs that transport the antigens sampled from the lumen of the oral 
cavity to the CLN, as has been observed in the intestine, where CD103+ DCs transport antigens to the 
MLN, but instead the antigens in the oral cavity are transported by CD11cnegCD11b+CX3CR1+ cells 
(Mascarell et al., 2011). Furthermore, the expression of RALDH2 is higher in the lingual mucosa than 
in the intestinal mucosa (Mascarell et al., 2011). Moreover, it has been demonstrated that RA-
producing skin-derived DCs are capable of triggering the generation of Tregs, although these cells are 
CD103neg and not CD103+ as in the intestine (Guilliams et al., 2010). These results indicate that the 
induction of FoxP3+ Tregs outside of the intestine is dependent upon the production of RA by RALDH, 
however CD103+ DCs may not necessarily be involved. Instead, the process may be dependent upon 
CD11cnegCD11b+CX3CR1+ cells, at least with regards to the oral-associated lymphoid tissues. Both 
CD103+ and CD103neg DCs have been identified in the NALT (Lee et al., 2015). Previously, no 
evidence was found to support the notion that mucosal airway DCs can capture pathogens from the 
lumen of the nasal passage by extending their dendrites (Kim et al., 2011). Recently, CD11c+ DCs 
have however been shown to sample the luminal content through dendrites in the nasal passage (Qin et 
al., 2015). Whether or not CD11cnegCD11b+CX3CR1+ cells are present in the NALT is currently 
unknown.  
 
Previous studies comparing the homing patterns of the NALT and PPs have demonstrated that T cells, 
generated in the NALT, preferentially home back to the same site, as well as to the CLN and MLN. 
Reciprocally, T cells from these nodes home successfully to the NALT. However, it has been shown 
that cells from the PPs do not home as successfully to these sites and that cells from these sites do not 
home as effectively to the PPs (Kuper et al., 1992). In studies of the homing preferences mediated by 
the lymphocyte integrins and adhesion molecules on HEVs, it has been observed that homing to the 
PPs is heavily dependent upon interactions between the integrin α4β7 and the mucosal addressin cell 
adhesion molecule 1 (MAdCAM-1) (Nakache et al., 1989, Berlin et al., 1993) Conversely, the homing 
of conventional T cells of the NALT is mediated by homing receptor L-selectin and Peripheral node 
addressin (PNAd) interactions, whereas the homing of CD4+CD25+ Tregs are more dependent on 
interactions between P-selectin glycoprotein ligand 1 (PSGL-1) and CD44-HA interactions (Ohmichi 
et al., 2011). The HEVs in the NALT strongly express PNAd, in contrast to other lymphoid tissues 
(Berlin et al., 1993). In addition, the interactions that occur between α4β7 integrin on lymphocytes and 
mucosal addressin cell adhesion molecule 1 (MADCAM-1) on HEVs is of greater importance for 
lymphocyte homing to the PPs than for lymphocyte homing to the NALT (Ohmichi et al., 2011, 
Kawashima & Fukuda, 2012). The PNAd and L-selectin interactions, although of greater importance 
in the NALT, are also of importance for recirculation and homing to all the PLN and MLN, including 
the CLN (Lyszkiewicz et al., 2011). Here, homing is also mediated by interactions between α4β7 and 
MADCAM-1 (Lyszkiewicz et al., 2011). Although the NALT is a MALT tissue that is similar to the 
PPs, its expression pattern of vascular addressins, which are the counter-receptors for the lymphocyte 
homing receptors, is more similar to that of the PLN (Kawashima & Fukuda, 2012). The ability to 
home to the oral cavity has not been extensively studied. However, SLIT immunisation in mice results 
in the dissemination of immunity according to homing patterns similar to those observed for the 
NALT (Brandtzaeg, 2013). Collectively, the roles of the nasal and oral cavities in the induction of 
tolerance have not been as well elucidated as those of the intestinal compartment.  
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Lymph nodes and tolerance 
Studies have shown that the removal of specific CLN that drain the nasal mucosa abrogates oral 
tolerance, and that this can be restored by transplantation of a lymph node from the same site, but not 
by replacing it with a PLN or MLN (Wolvers et al., 1999, Kraal et al., 2006). In these studies, the 
NALT remained intact but could not establish oral tolerance on its own. Surgical removal of the MLN 
also prevents the induction of oral tolerance (Worbs et al., 2006). These results imply that only certain 
lymph nodes are crucial for the induction of oral tolerance, and that specific lymph nodes are able to 
compensate for the absent functions of other lymph nodes, if required. 
 
 
 
RAS as a consequence of tolerance abrogation 
That food components might be factors of importance for the aetiology of RAS remains a highly 
debated issue within this field of research. For a specific subgroup of patients with this condition, 
dysregulation of the immune responses to particular food constituents may occur, resulting in an 
untoward hypersensitivity or allergic reaction in which RAS emerges as part of the clinical picture. 
However, there is currently a lack of knowledge as regards to the tolerance mechanisms operating in 
the oral cavity, as the majority of knowledge of tolerance stems from studies of the intestine. Before 
clinical investigations can be carried out on how tolerance may be abrogated in patients with RAS, 
more extensive pre-clinical studies of tolerance mechanisms must be conducted. 
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HYPOTHESIS 
 
During the course of this thesis, I have constructed and implemented a theoretical frame called 'The 
RAS Model', to study the aetiology of RAS (Figure 5). This model has allowed me to examine the 
roles of both endogenous and exogenous factors in the development of this condition. However, the 
focus of this thesis has been on the following endogenous factors: host genetics; the oral microbiota 
composition; and immune regulatory networks. 
 
The overall hypothesis, in accordance with on-going research and results from our department, is that 
individuals who suffer from RAS acquire a genetic susceptibility for this condition where there in 
certain individuals exists a hereditary component. Furthermore, these individuals, despite forming a 
largely heterogeneous group, may share certain factors/features locally in the oral cavity, which are 
also influenced by the genetic make-up of the individual. These factors/features modulate a specific 
type of immune response, when exogenous antigens penetrate the oral mucosa, resulting in oral 
ulcerations.  
 
The local factors in the mouth that influence susceptibility to RAS comprise alterations to: the oral 
microbiota composition; the structure and permeability of the oral mucosa; the composition of the 
saliva; and the immune response to antigens. These local factors together with the genetic 
susceptibility of the host and various systemic factors, such as systemic disease, hematinic deficiencies 
and/or a hormonal imbalance, enable certain exogenous stimuli, such as different food components, 
medications, local trauma, pathogens, and/or psychological factors, to trigger lesion development. An 
altered oral microbiota might promote degradation of the mucin-layer that coats the oral mucosa, 
thereby promoting increased permeability, which in turn would facilitate exposure of the underlying 
tissues to antigens, thereby causing ulcerative lesions. Changes to the composition of the saliva might 
also facilitate this process by reducing the clearance of oral bacteria, allowing for the selection of 
bacteria in the oral cavity, which would increase degradation of the salivary components. Furthermore, 
structural changes to the oral mucosa could promote increased permeability. In addition, an altered 
immune response would facilitate the development of the ulceration. 
 
To define precisely the aetiology of RAS, it is essential to consider it as a multi-factorial condition and 
to focus on both endogenous and exogenous factors that could potentially trigger the disease and drive 
the formation of lesions. Effective treatment strategies can be developed only when the aetiology of 
RAS has been detailed and fully understood. 
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Figure 5. The RAS model. Both endogenous and exogenous factors are suggested to contribute to the development of an 
aphthous lesion. The endogenous factors (on the left) consist of local factors in the oral milieu, such as the oral microbiota, 
the oral mucosa, the saliva, and the local immune system, together with genetics and systemic factors, such as systemic 
disease, hematinic deficiencies and/or a hormonal imbalance. The exogenous factors (on the right), which trigger lesion 
development in individuals who are pre-disposed to RAS by some or all of the suggested endogenous factors, consist of 
ingested substances, such as food components and medications, local trauma, pathogens (e.g., bacteria and viruses), and 
psychological factors (e.g., stress). Furthermore, the food components are proposed to be divided into type I and type II 
foods. Type I foods represent acidic foods (e.g., citrus and tomatoes), which in this model are hypothesised to generate an 
etch wound of the oral mucosa, as opposed to the type II foods (e.g., cow´s milk protein and gluten), which are suggested to 
provoke a hypersensitivity or allergic reaction. 
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OBJECTIVES 
 
Studies I and II are clinical studies that involved patients with RAS and that were designed to explore 
the underlying mechanisms of this condition by investigating the roles of host genetics and the oral 
microbiota composition in the development of RAS. Furthermore, since food components are 
considered potential exogenous triggering factors, we also explored the immunoregulatory networks 
involved in the induction of tolerance within the oral cavity based on existing knowledge of the 
tolerance mechanisms in the intestine. Therefore, the second part of this thesis, including Studies III 
and IV described the results of pre-clinical studies that were conducted in mice to explore the roles of 
the oral-associated lymphoid tissues, encompassing the NALT and CLN. 
 
 
Scientific questions 
 
The studies that make-up this thesis were designed to answer the following scientific questions: 
 
 
STUDY I:  
• Are there specific patterns of association and segregation of genetic variants that 
are passed down to the offspring within families with RAS? 
 
• Which signalling pathways and genes are linked to the genetic basis of RAS? 
STUDY II: 
• Do the oral microbiota profiles of patients with RAS and healthy control subjects 
differ? 
 
• Does the oral microbiota profile change in relation to disease activity in patients 
with RAS? 
STUDY III: 
• Are there any differences in the phenotypes of the APC and T-cell populations of 
the oral-associated lymphoid tissues, as compared to the intestinal lymphoid 
compartment, the MLN, and the peripheral lymphoid compartment, the PLN? 
 
• Are there any differences in the cellular proliferative responses in vitro between the 
NALT and CLN, as compared to the MLN and PLN? 
STUDY IV: 
• Does the passage of an antigen through the oral cavity contribute to the overall 
immunological response and the degree of tolerance induced, as compared to the 
situation in which this passage is bypassed and the antigen is instilled by gavage 
directly into the stomach? 
 
• Are the activation patterns of ovalbumin (OVA) -specific CD4+ T cells and of Treg 
differentiation different when the OVA antigen is administered via the oral route 
rather than the gastric route? 
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MATERIALS AND METHODS 
 
Detailed descriptions of the patients recruited and the materials and methods used in the different 
studies are found in the respective papers. Described below are the most important details of the 
materials, the study designs and experimental designs, and short descriptions of the various methods 
used and the statistical analyses employed. 
 
 
 
Materials 
 
Patients 
Studies I and II include patients with RAS and control subjects, from whom the guidelines of the 
World Medical Association Declaration of Helsinki were followed. Written informed consent was 
obtained from all the patients and control subjects after they were fully informed about the aims of the 
studies and the methods to be used. In addition, for all the enrolled children, written parental consent 
was also obtained. Both studies were approved by the Regional Ethics Review Board in Gothenburg. 
 
All patients were selected from the referral population at the Clinic of Oral Medicine, Public Dental 
Health, Gothenburg, Region Västra Götaland, Sweden, in the period 2010–2013 or from our, 'Afte 
Studie' Facebook page (www.facebook.com). The use of social media has in our experience been 
useful for coming into contact with patients who are suffering from RAS and who have an interest in 
contributing to scientific research. Many patients with RAS have learned through previous encounters 
with dental and health-care units that there is a lack of consensus regarding the available treatment 
regimens. Therefore, these patients do not always seek medical help and are infrequently referred to a 
specialist clinic like our own, unless they are suffering from a severe form of RAS. Thus, social media 
have provided an excellent forum for recruiting a representative cohort of individuals who are 
suffering from this condition. Furthermore, enrolling individuals for research purposes can entail 
logistical challenges. In this aspect, social media provide an efficient mode of rapid communication. 
The control subjects for Study I consisted of family members and for Study II consisted of 
individuals recruited from local Public Dental Health clinics across the region. Clinical data 
concerning the study subjects were recorded as single data entries in the web-based Medview 
programme used for research purposes (Jontell et al., 2005). 
 
For both Study I and Study II the following inclusion and exclusion criteria were applied to patients 
with RAS, as some individuals participated in both studies, which were run to a certain extent in 
parallel: 
 
Inclusion criteria 
• Episodes of aphthous ulcers at least once a month during the past year 
 
Exclusion criteria 
• Diagnosis of other oral mucosal lesions 
• Severe caries or periodontal disease 
• Smoking 
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• Excessive consumption of alcohol (alcohol intake more than three times weekly) 
• Use of antibiotics or anti-bacterial mouth rinses during the previous month 
• Use of drugs for the treatment of mouth ulcers in the previous six months 
 
In Study I 16 families with RAS were enrolled, comprising a total of 91 individuals. Overall, 66 
individuals were considered to be affected by the disease because they had suffered from RAS at some 
point in their life (in the past or the present), and 25 individuals were considered to be healthy because 
they had never suffered from RAS. The healthy individuals served as controls for their affected family 
members. Therefore, no additional control subjects were enrolled. The rationale used here was that 
family members are more similar genetically than are individuals randomly selected from a 
population. In general, family members without a disease differ from members with a disease with 
regards to aspects of importance for the disease, which is of interest in genetic studies of the type 
conducted here. Thus, the probability of finding differences related to disease between healthy and 
diseased individuals within a family are greater than when comparing randomly chosen individuals. 
Moreover, family-based studies avoid the problem of population stratification bias. 
 
In Study II 60 patients with RAS were included, with 42 of the patients presenting with lesions upon 
sampling. For six of the patients, it was not clear from their oral medical journals whether or not they 
presented with an ulcer upon sampling. These individuals were therefore excluded from certain parts 
of the analysis. However, sampling was not carried out in the ulceration itself but instead in the 
healthy buccal mucosa, distant from the ulcer(s). Equal numbers of healthy age- and gender-matched 
control subjects were included, and a prerequisite was that the patients and controls were not related to 
each other or shared a common household, as this could influence their oral microbiota profiles. 
 
 
Mice 
Studies III and IV are pre-clinical studies involving experiments on mice that were bred and housed 
under standard conditions in the animal facility of the University of Gothenburg according to 
institutional guidelines. Both studies were approved by the Regional Ethics Review Board in 
Gothenburg. For Study III BALB/c mice were used, and for study IV BALB/c mice and DO11.10 
TCR transgenic mice were used. For Study III, all the mice were fed a conventional diet. For Study 
IV, the experimental groups were administered ovalbumin (OVA grade V) as well as conventional 
chow, and the control groups were fed phosphate-buffered saline (PBS) in addition to the normal diet.  
 
BALB/c – This is a laboratory-bred strain of the common house mouse, albino in colour (white coat 
with pink eyes), and one of the most widely used inbred strains for animal experiments. The strain was 
developed by H.J. Baggs in 1913 from a stock of mice obtained from a pet dealer and named the 'Bagg 
albino', and later was inbred by E.C. MacDowell in 1923 (Potter, 1985). The name BALB/c originates 
from the strain name ('BALB' from 'Bagg albino') and 'c' from the genotype of the colour locus 'c/c'. 
Some common sub-strains have been derived over the years. These mice are particularly well suited to 
experiments in cancer research and immunology. In addition, since it is a Th2-dominant mouse strain 
(Watanabe et al., 2004), it is particularly appropriate for studies on allergy. 
 
DO11.10 TCR transgenic mice – This is a transgenic mouse strain on a BALB/c background with T-
cell receptors that are MHC class II-restricted, i.e., the CD4+ T cells present with a T-cell receptor 
(TCR) that recognizes exclusively the immunodominant epitope OVA323–339 (Robertson et al., 2000). 
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This strain was originally developed by researchers at Washington University in St Louis, St Louis, 
MO, USA (Murphy et al., 1990) and has proven particularly useful for studies of tolerance induction. 
 
 
Samples 
Studies I and II – Sampling of the buccal mucosa was carried out with a sterile swab (Isohelix/Cell 
Projects Ltd., Harrietsham, Kent, UK) at a location distant from the ulcer(s). The buccal mucosa is a 
representative localisation for aphthous ulcers and represents an extensive area of the oral mucosa. All 
participants were requested not to brush their teeth and not to consume any food or beverage within 1 
hour prior to sampling, as a number of these participants were enrolled in both studies, which were in 
part running in parallel. For Study I, one dentist collected all the samples using a standardised 
technique, according to the protocol of the manufacturer (Isohelix/Cell Projects), except for the family 
members who lived far from Gothenburg, who sampled themselves at home under careful instruction 
from the clinician and returned the samples by post. In Study II, two dentists participated in the 
collection of samples using the same standardised technique.  
 
Study III – the following lymphoid tissues were dissected from BALB/c mice: the NALT; CLN (Ln. 
mandibularis, Ln. mandibularis accessorius, and Ln. parotideus superficialis, all of which are 
superficial lymph nodes); MLN (Lnn. jejunales); and PLN (Ln. subiliacus, Ln. axillaris proprius and 
Ln. axillaris accessorius). A detailed description of the locations of the various lymphoid tissues is 
provided in Paper IV. 
 
Study IV – The equivalent lymphoid tissues as were used in Study III were dissected from DO11.10 
TCR transgenic mice that were undergoing the DO11.10 TCR transfer model. In addition, the 
following samples were collected from BALB/c mice that were undergoing the oral tolerance model: 
broncho-alveolar lavage (BAL) fluid; blood; and spleens. 
 
 
 
Study designs/experimental designs 
Studies I and II were case-control studies, whereby Study I was based on patients and their family 
members, i.e., a family-based case-control study, and Study II was based on patients and age-and 
gender-matched control subjects. 
 
Study III consisted of two parts. The first part was based on a flow cytometric analysis of cells from 
the BALB/c mice, and the second part involved in vitro stimulation of the murine cells with a mitogen. 
 
Study IV involved two separate experimental designs. The first one involved the DO11.10 TCR 
transfer model, and the second one involved an oral tolerance model. 
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Methods 
 
Genome-wide association studies (GWAS) (Study I) 
GWAS allows examination of the entire human genome at high resolution, across all the 
chromosomes, without the need for an initial hypothesis as to which genes might be involved in a 
particular disease (Hirschhorn & Daly, 2005). Previously, genetic analysis of a disease involved 
carefully selecting potential candidate genes to be analysed in so-called 'candidate gene studies'. With 
GWAS, thousands of SNPs can be analysed simultaneously in different SNP arrays. The results of a 
GWAS are used to identify the most common genetic variations that are likely to influence the risk of 
developing a certain disease (i.e., SNPs that occur more frequently in people with a particular disease 
than in people without the disease) or to identify heritable quantitative traits (biological traits that 
show continuous variation, for example, body mass index, blood pressure, and blood lipid levels) that 
are potential risk factors for disease development. These types of studies are particularly valuable for 
studying common, complex diseases that are polygenic in nature, as opposed to diseases that entail 
Mendelian inheritance (Ott et al., 2011). However, GWAS cannot specify the actual causal genes, only 
the genetic variants that are associated with a disease. Different GWAS approaches can be adopted, 
and in this study, linkage analysis and association analysis were combined, where the linkage was 
dependent upon association. This allowed for the investigation of genetic variants separately within 
each family (linkage analysis) and the segregation of a genetic variant within the population as a 
whole (association analysis).  
 
 
Terminal-restriction fragment length polymorphism (T-RFLP) (Study II) 
This method, which was developed by Liu et al. (1997), has been widely used to study bacterial 
communities in complex environments, such as the oral cavity, using variations in the 16S rRNA 
gene, which is present in most bacteria. The 16S rRNA gene contains 1500 bp and is built up of 
various sequences, some of which are highly conserved among bacteria, while others are from variable 
regions (V-regions) that differ in sequence between bacterial species. Nine V-regions (V1-V9), 
ranging in length from 50 bp to 100 bp (Wang et al., 2007), have been identified. All the V-regions are 
included using this method, in contrast to other methods, for example, next-generation sequencing 
(NGS) where only particular V-regions are analysed. In T-RFLP, the 16S rRNA gene is amplified and 
the terminal fragment is fluorescently labelled at the 5´-end during the polymerase chain reaction 
(PCR), thereby facilitating its detection. The PCR products are then digested with a specific restriction 
enzyme, and the labelled fragments are separated and detected using capillary electrophoresis. Only 
the fluorescently labelled fragments are analysed. The rest are ignored. Each fragment generates an 
individual peak, a terminal-restriction fragment (T-RF), the size of peak being dependent upon the 
length of the fragment, which represents a specific bacterial taxon, while the pattern of the peaks 
reveals the bacterial profile of an individual. The principles of T-RFLP are illustrated in Figure 6. In 
general, T-RFLP permits differentiation to the genus level, and occasionally even to the species level.  
Only the dominant genera are identified with this method, as it is a semi-quantitative method that 
allows determination of the presence or absence of a bacterium but is not able to specify the 
abundance of this bacterium. Moreover, this technique does not differentiate between dead and live 
bacteria.  
Materials and methods 
 
 49
 
Figure 6. The principles of Terminal-restriction fragment length polymorphism (T-RFLP). This method is based on 
variations in 16S rRNA genes within bacterial populations. In Study II, bacterial DNA samples were prepared from swabs 
taken from the intact buccal mucosa of the study subjects and used as a template for PCR amplification of the 16S rRNA 
genes using universal primers. The PCR products were digested with a restriction enzyme that yielded a fragment fingerprint 
representative of a specific bacterial species, and the cleaved PCR products were detected with a fragment analyser. The size 
of each fragment/height of each peak is representative of an individual bacterial genus/species. 
 
 
Flow cytometry (Studies III and IV) 
This method is widely used to measure the optical and fluorescence properties of individual particles 
(e.g., cells) based on light scattering (light deflected around the edges of a cell after being struck by 
light from the excitation source) or fluorescence emission (the light that is emitted (sent out) by an 
atom or molecule when it passes from a higher energy state back to the original lower energy state 
after being struck by light from the excitation source). Light scattering gives information about the 
structural and morphological properties, i.e., size and granularity, while the fluorescence emission 
gives information about the fluorescent properties of the cells. These features are detected by staining 
the particles with dyes or monoclonal antibodies using intra- and/or extra-cellular staining. There are 
various applications for flow cytometry, for example, cell counting, cell sorting, and the detection of 
biomarkers. The main components of flow cytometers are the fluidics, optics (excitation and 
collection), electronic network (detectors), and a computer (Adan et al., 2016) (Figure 7). 
 
• Fluidics: This involves the ordering of the particles into a single stream through 
hydrodynamic focusing. The sample in solution is injected into the flow cytometer 
through a central channel/core, which is enclosed by an outer sheath that contains 
a faster-flowing fluid (e.g., PBS). As the fluid in the outer sheath moves, the 
particles in the central channel/core are dragged downwards into a single stream of 
particles. In the absence of hydrodynamic focusing, the exit of the central 
channel/core would be blocked due to all the cells wanting to exit at the same 
time.  
 
• Optics: After hydrodynamic focusing, each particle in the stream passes through 
one or more beams of light. The source of the light is most commonly a laser 
beam. The optic step is divided into two parts: excitation and collection. Excitation 
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involves focusing the light source on the particles, whereby lenses are used to 
shape and focus the laser beam so that the light will hit the particles at the right 
angle. Collection involves transmitting the light scatter or fluorescent light of the 
particle to an electronic network. Light emitted from the particle-laser beam 
interaction is collected by a detector after passing through a filter and is converted 
to voltage, which allows detection of the signal. Light scattered in the forward 
direction is collected by a detector known as the forward scatter channel (FSC). 
The FSC is roughly equivalent to the particle´s size and is useful to distinguish 
between living cells and dead cells or cellular debris. Light scattered in a sideways 
direction is collected by the side scatter channel (SSC) and provides information 
regarding the granularity, i.e., the granular content of a particle, which corresponds 
to the complexity of the cell. In addition, various optical mirrors and filters are 
used to separate and direct specific wavelengths of the collected light to the 
appropriate optical detectors.  
 
• Electronic network: This involves detecting the signal and converting it into 
digital data. The obtained signal is analogue in form and must be converted to a 
digital signal for computer processing. 
 
• Computer: This is used to analyse the data. Different software packages are 
available for the analysis of flow cytometry data, i.e., the fluorescence properties 
of the particles. The most common gating strategy used is FSC and SSC plotting. 
 
 
 
Figure 7. The principles of flow cytometry. The panel to the left shows light scattered in the forward direction 
(corresponding to the particle´s size), as well as light scattered in the sideways direction (providing information on the 
granularity, i.e., the granular content of a particle). The panel to the right shows the main components of flow cytometry. 
Adapted from Adan et al. 2016. Flow cytometry: Basic principles and applications. Crit Rev Biotechnol.1-14. 
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Cell proliferation assays (Studies III and IV) 
This method is used under in vitro conditions to measure the rate of proliferation of cells at a certain 
time-point when the cells are exposed to a specific proliferation-inducing agent, for example, an 
antigen or a mitogen. As the entire course of proliferation is not analysed it is necessary to select a 
time-point at which the process of proliferation has begun but before all the cells have proliferated or 
the medium has been completely depleted. Mitogens are molecules that can activate T cells and/or B 
cells regardless of the antigen-specificity of the cells. Some mitogens are lectins that bind to 
carbohydrates found in the cell membrane of the lymphocytes. However, there are also mitogens that 
are not lectins, and thus induce proliferation through other mechanisms. A mitogen can activate a large 
proportion of lymphocytes, such as 5–10%. Conversely, the proportion of cells that are activated after 
exposure to a specific antigen is fractions of a per mille of lymphocytes. Commonly used mitogens are 
phytohaemagluttinin (PHA; mitogenic for human cells) and concanavalin A (Con A; mitogenic for 
murine cells). A pre-defined number of cells are seeded into the wells of a 96-well plate, after which 
the proliferation-affecting agent is added to a certain number of the wells. The remainder of the wells, 
which contain cells but not the proliferating agent, functions as control wells. The plate is then 
incubated at 37°C in an incubator. Thymine is one of the nucleotides in DNA and thymidine is a 
nucleoside (a nucleotide that lacks the phosphate group). Since thymidine closely resembles thymine, 
it is easily incorporated into the DNA strand. Thus, the cell proliferation test plate is removed from the 
incubator, 3H-thymidine is added, and the plate is re-incubated for an additional period of time. 
Proliferating cells incorporate the radioactive thymidine into their DNA during each round of cell 
division. After the incubation step, the cells are harvested by washing the cells from the plate. The cell 
materials, and especially the radioactive DNA, adheres to a filter and the number of cells in the well or 
the number of cell divisions during incubation is measured using a scintillation counter (Kruisbeek et 
al., 2004).  
 
 
The DO11.10 TCR transfer model (Study IV) 
In general, an adoptive cell transfer implies the transfer of cells from a donor to a recipient, for 
example, from one strain of mouse to another, for the purpose of studying a specific cell line of 
interest. Regarding T cells, a successful adoptive T-cell transfer depends on the ability to select cells 
from a donor or to engineer genetically cells with targeted antigen-specificities, and thereafter induce 
the cells to proliferate while preserving their effector functions and homing abilities in a recipient 
(June, 2007). The labelled cells are either endogenously fluorescent, i.e., isolated from a transgenic 
mouse that expresses the fluorescent protein of interest, or the cells are labelled before transfer 
(Matheu et al., 2011). In the current study, DO11.10 TCR cells were transferred from DO11.10 TCR-
transgenic mice into BALB/c mice, according to a modified version of the protocol devised by Kearny 
et al. (1994). DO11.10 mice have an abundance of OVA-specific T cells, which does not represent the 
natural state. However, DO11.10+CD4+ T cells allow for the detection of OVA-specific CD4+ T cells. 
The KJ1.26 monoclonal antibody is used to detect these cells (of the clone KJ1.26) by binding to the 
T-cell receptor (TCR), that they express (Murphy et al., 1990). The use of DO11.10 and KJ1.26 cells 
has proven valuable for uncovering many of the intricate details of T cell-mediated immunity.  
 
 
The oral tolerance model (Study IV) 
The most common way of inducing tolerance in an experimental animal model involves three separate 
phases:  
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• Initial exposure: The mouse, preferably a young naïve mouse, is fed a specific 
antigen (e.g., OVA) through the mucosal route in the diet (food or water). The 
naïve mouse has not previously been exposed to this antigen so the animal 
develops tolerance. 
 
• Sensibilisation: In this phase, the mouse is immunised with the same antigen (in 
this case OVA) in combination with an adjuvant [e.g., Freund´s complete adjuvant 
(FCA), to initiate a Th1-type response)] or Alum (aluminium hydroxide, to initiate 
a Th2-type response). The animal is challenged with the antigen through a non-
mucosal route, for example, with an injection into the skin or blood-stream. The 
adjuvant enhances the immune response if tolerance has not previously been 
developed. However, if tolerance has already been established the adjuvant does 
not contribute to an increased immune response but rather induces a decreased 
response or no response. Responses to other antigens are not affected. 
 
• Challenge: The mouse is exposed to a high dose of OVA to evoke an 
immunological reaction. The route of administration dictates the animal´s 
physiological response: if nasally, the outcome is airway allergy; administration of 
the antigen by gavage gives diarrhoea; and administration through the skin results 
in a delayed-type hypersensitivity reaction (DTH). 
 
In this particular study a modified version of the acute model of allergic airway disease was adopted 
(Meyer-Martin et al., 2014). 
 
 
Enzyme-linked immunosorbent assay (ELISA) (Study IV) 
This is a plate-based assay technique designed for the detection and quantification of 
peptides/proteins, antibodies or hormones in a sample using antigen-antibody reactions and a colour 
change based on an enzyme-linked conjugate and an enzyme substrate (Aydin, 2015). There are three 
different types of ELISA: direct assay; indirect assay; and capture assay (sandwich). 
 
• Direct assay: This is the simplest form of ELISA. An antigen is fixed to a solid 
surface by adsorption to the assay plate. Then, a labelled primary antibody is added 
to bind to the antigen. The primary antibody is labelled with an enzyme [horse- 
radish peroxidase (HRP) and alkaline phosphatase (AP) are the most commonly 
used]. This results in the formation of an antigen-antibody-enzyme complex. Any 
excess of the complex is washed away and the enzyme activity is detected by 
adding an enzymatic substrate to produce a visible signal colour, which can be 
measured spectrophotometrically and compared to a standard curve to calculate the 
quantity of antigen in the sample.  
 
• Indirect assay: The antigen is fixed to a solid surface of the plate in the same way 
as for the direct assay. Then, an unlabelled primary antibody is added, followed by 
a labelled secondary antibody. This results in the formation of an antigen-antibody-
enzyme complex. Any excess of the complex is washed away and the enzyme 
activity is detected by adding substrate. 
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• Capture assay (sandwich): A capture antibody is attached to the plate. The 
antigen binds to the capture antibody, after which a primary antibody is added, 
followed by a labelled secondary antibody, which allows for detection of the 
antigen-antibody-enzyme complex. 
 
To increase the specificity of the method, i.e., to ensure a stable antigen-antibody-enzyme complex 
that is not mistakenly washed away, biotinylation may be applied. The antibody to be linked to the 
enzyme (the primary antibody or the secondary antibody, depending on whether the assay used is 
direct or indirect) is labelled with biotin and the enzyme is labelled with streptavidin. Biotin and 
streptavidin have a high affinity for each other. Lastly, the antigen-antibody-enzyme complex is 
detected in a spectrophotometer, a fluorometer or a luminometer.  Determination of the antigen 
concentration in a sample requires the production of a standard curve using antigens of a known 
concentration. The concentration of antigen in a sample can then be calculated using the optical 
density (OD) values.  
 
This method was used to detect the total IgE levels in sera of the mice, as well as the OVA-specific 
IgE and IgG1 and IgG2a. The latter three factors were detected using specific kits, as described in 
Paper IV. The production of OVA-specific IgE and eosinophil recruitment to the lungs are both 
common features of allergic airway inflammation in OVA-immunized mice. These parameters are 
however, easily affected, which implies that the production of OVA-specific IgE and the recruitment 
of eosinophils may decrease despite the fact that the selected OVA dosage may not be sufficient to 
induce oral tolerance. A previous study has shown that there is a hierarchical pattern of suppression 
during the induction of oral tolerance, whereby IgG1 (produced during a Th2-type response) is more 
resistant to suppression. Therefore, IgG1 may be a better parameter to measure if one wants to 
determine whether or not oral tolerance has truly been induced (Keller et al., 2006). 
 
 
Cytospin (Study IV) 
This is a rapid cytological method that has been specifically designed to collect and concentrate 
hypocellular fluids. After the actual cytospin is completed, other methods, such as 
immunocytochemistry, can be performed to identify the cells. This method can also be used to identify 
cells that have previously been processed for flow cytometry. Initially, the cells are washed in a 
protein-containing medium, for example, a culture medium or a serum- and/or albumin-based PBS 
solution. Thereafter, a maximum of 0.5×106 cells/ml are re-suspended in up to 500 µl of the solution 
(in the current study, 100,000 BAL cells in 500 µl were used), and each sample is pipetted into a 
plastic chamber, placed in a cytocentrifuge, and forced by centrifugation onto a glass slide 
(Shanholtzer et al., 1982). The cells can be spun at various speeds and times depending on the cell 
type (in the current study, we used 800 rpm for 3 minutes). The volume-to-cell ratio must be 
sufficiently dilute to ensure the formation of a monolayer of cells. The slides are then dried, fixed, and 
stained (for Study IV staining with May–Grünwald/Giemsa stain was performed). For the current 
study, 200 cells were counted for each sample and classified as eosinophils, neutrophils or other 
nucleated cells (Figure 8). The percentage of each cell type was calculated as the percentage fraction 
of the total number of cells. Eosinophils are typically present in samples from patients with allergies 
and asthma. Neutrophils are the most abundant type of white blood cells and are the first cells to arrive 
at the site of an infection. 
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Figure 8. Light microscopy image of a cytospin preparation of murine bronch-oalveolar lavage (BAL) fluid stained with 
May–Grünwald/Giemsa. The arrows indicate an eosinophil, a neutrophil, and other types of nucleated cells, which were the 
cells that were counted in Study IV using the IMAGEJ software (http://imagej.nih.gov/ij/). The percentage of each cell type 
was calculated as the percentage fraction of the total number of cells. 
 
 
 
Statistical analysis 
Study I – The data were analysed using the free, open-source, whole genome association analysis 
software PLINK ver. 1.07, (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007) and the 
licensed software SNP & Variation Suite ver. 8, (http://goldenhelix.com/SNP_Variation/) (Golden 
Helix Inc., Bozeman, MT, USA). These software packages are used for complex analyses and the 
visualisation of genomic and phenotypic data, which allows for the management of data, the 
performance of statistical checks for quality control, and the carrying out of basic association testing. 
Data management was performed with the PLINK software, and quality controls were carried out 
using the SNP & Variation Suite software. For testing linkages in the presence of association, the 
GWAS approach chosen for this particular study, the dFAM analysis (family-based association for 
disease trait), was run in PLINK. The dFAM test allows for comparisons to be made between family 
members (linkage analysis), as well as between different families (association analysis). dFAM 
incorporates the transmission disequilibrium test (TDT), the sibling TDT, and case-control data into a 
single Cochran-Mantel-Haenszel test for each marker. Since they are all incorporated into the same 
test, it is not possible to distinguish the results of one test from another. A genome-wide significant 
threshold of 5×10-8 was applied. This threshold has been proposed for declaring a significant 
association in a GWAS, since it corresponds to a p-value of 0.05 after a Bonferroni (Dunn´s) 
correction for 1 million independent tests. In a GWAS, thousands of genetic variants are analysed, 
which is both costly and labour-intensive. Therefore, there is a limit to the sample size. However, 
since variants that contribute to complex diseases are likely to have modest effects, the use of large 
sample sizes is important. Since multiple testing is performed, the p-values must be corrected. 
Therefore, this threshold has been proposed (Risch & Merikangas, 1996). Thereafter, set-level 
statistics, in the GeneTrail2 software, were used for pathway analysis of the data. GeneTrail2 is a web-
interface that provides access to different tools for the statistical analysis of molecular signatures 
(https://genetrail2.bioinf.uni-sb.de/) (Stockel et al., 2016). This approach allows one to ascertain if a 
certain biological pathway is significantly enriched or depleted among the identified genes to an extent 
greater than would be expected by chance. Eventually, a pathway is declared to be significantly 
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enriched if the upper-tailed p-value (H1: µ>µ0) of a test is significant, and is judged to be depleted if 
the lower-tailed p-value (H1: µ<µ0) is significant. The specific test chosen for this particular step was 
over-representation analysis (ORA), which relies on a reference set for comparison. The test examines 
whether the entries that belong to a certain pathway are more or less present in the data-set, as 
compared to the reference set. In an enrichment analysis, multiple pathways are tested simultaneously, 
which requires p-value adjustments. False discovery rate (FDR) adjustments were made with the 
Benjamini-Yekutieli procedure. FDR corrections identify the rate of type I errors (false-positive 
predictions) in null hypothesis testing when conducting multiple comparisons. The Benjamini-
Yekutieli procedure controls the FDR. The significance level was set at p<0.05. The minimum size of 
the pathway was 2 genes and the maximum size was 700 genes. 
 
Study II - Multivariate analysis was used to project associations for the microbial patterns between 
the patients with RAS and the controls, as well as within the group of patients with RAS. This was 
achieved using a Partial Least Squares-discriminant analysis (PLS-DA) in the SIMCA P+ ver. 13 
software (Umetrics AB, Umeå, Sweden). Thereafter, univariate data analysis was performed, 
according to the SIMCA analysis, on relevant T-RFs (corresponding to different bacterial taxons) 
using the Fisher’s exact test. Adjustments for mass-significances were not performed, since the 
univariate analysis was based on SIMCA results, where only the most important peaks were analysed 
further. The Fisher´s exact test is used to compare small data-sets with two independent unpaired 
groups with binomial data (only two possible outcomes; the T-RFs do not assume numerical values). 
Univariate data analysis regarding richness was performed using the Mann-Whitney U-test, as the data 
were not normally distributed according to The D´Agostino-Pearson omnibus normality test. If the 
data had passed this test an unpaired t-test would have been preferred for the richness analysis. The 
Mann-Whitney U-test is a non-parametric test that is used for the comparison of two independent 
groups (equivalent to the Students t-test used for a normally distributed data-set). All the univariate 
analyses were performed in GraphPad Prism, with p-values <0.05 being considered statistically 
significant. Furthermore, Shannon’s Index (! = !− !"#$!"!!!! ) was used to estimate the diversity 
(richness and evenness). A high H-value represents a diverse and equally distributed bacterial 
community, whereas a low H-value characterises a bacterial community with lower levels of diversity. 
A H-value of 0 represents a community with just one taxon. Evenness within a group was calculated 
with Shannon’s Evenness Index (E=H/lnS), which assumes a value between 0 and 1, where 1 
represents complete evenness. The statistical methods used in this study are explained in detail in 
Paper II. 
 
Study III - Statistical analysis was conducted using the Kruskal-Wallis test followed by Dunn´s 
correction for comparisons of the percentages of cells in the various lymphoid compartments. Here p-
values <0.05 were considered statistically significant. The reason for using this statistical test was that 
there were a fair number of outliers in the data-set, suggesting that the data were not normally 
distributed. However, the number of mice was too low to explore this notion. Therefore, a non-
parametric test was applied, in this case the Kruskal-Wallis test, which is the equivalent of a one-way 
ANOVA (used with a normally distributed set of unpaired, numerical data when comparing three or 
more groups that are independent). For this reason, the Kruskal-Wallis test is not as powerful as the 
one-way ANOVA. Non-parametric tests are based on median values and therefore, they handle 
outliers more adequately. To use the median value the data are sorted in ascending order and the 
middle value represents the median. This means that 50% of the values lie above the median and 50% 
lie below the median value. This is why the median is shown with percentages. Within these tests a 
number of tests are performed step-wise to compare the groups. Therefore a post hoc test is required 
(Tukey´s test for the one-way ANOVA and Dunn´s correction for the Kruskal-Wallis test). 
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Corrections must be made when many tests have been carried out, in order to adjust the level of 
significance for the number of tests that have been performed. 
 
Study IV - Statistical analysis was conducted using the Kruskal–Wallis test followed by Dunn´s 
correction for comparisons of the percentages of cells in the various lymphoid compartments. For 
comparisons of the OVA-fed mice and the PBS-fed control mice, the Mann-Whitney U-test was 
performed since, as this is a non-parametric test for the comparison of two independent groups 
(equivalent to the Students t-test used for a normally distributed data-set). Here p-values <0.05 were 
considered statistically significant. A correlation analysis was conducted using the Spearman´s rank 
correlation, as the data were assumed not to be normally distributed; if instead the data had been 
normally distributed a Pearson´s correlation coefficient would have been used. The correlation 
coefficient is a measure of linear association between two variables. A coefficient of 1 implies a strong 
positive correlation, whereas a coefficient of -1 implies a strong negative correlation. A coefficient of 
0 corresponds to a weak correlation. For the correlation analysis, the data from all of the different sites 
and for both routes of administration was processed in the same analysis. 
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RESULTS 
 
Detailed descriptions of the results are found in the respective papers. Therefore only the most 
important findings are presented below. 
 
STUDY I 
This study was conducted using a genome-wide association approach designed as a family-based case-
control study in which a total of 16 families with RAS (N=91) were included and each individual 
provided a buccal swab sample. The family members that had never suffered from RAS (N=25) 
served as controls for the individuals that suffered from this condition at the present time or that had 
suffered from RAS at some point in the past (N=66).  
 
Are there specific patterns of association and segregation of genetic 
variants that are passed down to the offspring within families with RAS? 
In total 547,644 SNPs derived from across all the chromosomes, were analysed in the CoreExome 
array, with a certain proportion of the SNPs being removed due to high rates of missing calls or 
Mendelian inconsistencies or low minor allele frequencies, leaving a total of 288,452 SNPs for the 
final analysis. The specific aim was to test for linkage in the presence of association in the selected 
families, thereby allowing comparisons within the family using linkage analysis, and on a population 
level, comparing between the families, using association analysis. This step was performed with a 
dFAM test. 
 
The dFAM analysis revealed that none of the included SNPs reached the genome-wide significant 
threshold of 5×10-8. Therefore, no pattern of association or segregation of genetic variants that were 
passed down to the offspring within these families was detected. Moreover, no specific gene with a 
Mendelian pattern of segregation for the disease as a whole was detected, which means that no one 
specific gene was found to be more significant than any other gene with respect to causing RAS. This 
confirms previous findings that RAS is not a monogenic disease.  
 
Which signalling pathways and genes are linked to the genetic basis of 
RAS? 
The top 1000 associated SNPs with the best p-values from the dFAM analysis were selected for the 
subsequent pathway analysis. The KEGG and Reactome pathway databases were applied to identify 
pathways that influence the risk of developing RAS. From the KEGG database, the Ras signalling 
pathway, the PI3K-Akt signalling pathway, pathways in cancer, circadian entrainment, and the Rap 1 
signalling pathway were identified. In the Reactome database, the G alpha (i) signalling events 
pathway and the peptide ligand-binding receptors were recognised as being of importance. The SNP 
rs4705140, which corresponds to the gene PPP2R2B, was found to be significantly overrepresented in 
the above analysis. The rs4705140 SNP was linked to the PI3K-Akt signalling pathway, the 
dopaminergic synapse pathway, and the mRNA surveillance pathway. Overall, these results give clues 
as to the signalling pathways and genes that influence the risk of developing RAS. 
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STUDY II 
For this case-control study, 60 patients suffering from RAS and 60 age- and gender-matched control 
subjects were selected. Buccal swabs were obtained at a single time-point, with 42 of the patients 
presenting with a lesion upon sampling. The bacterial DNA was extracted and the 16S rRNA gene was 
analysed using the T-RFLP methodology. Multivariate analyses were performed to identify 
differences in the oral microbiota profiles between the patients and controls, as well as between the 
patients. Furthermore, univariate testing was conducted to analyse the T-RFs that were identified as 
being of importance in the multivariate analyses, so as to separate the groups. In addition, diversity 
measures were carried out.  
 
Do the oral microbiota profiles of patients with RAS and healthy control 
subjects differ? 
A wider range of T-RFs (each T-RF corresponding to a specific bacterial taxon) was identified in the 
controls than in the patients (156 versus 118, making up a total of 192 different T-RFs in the overall 
study population). Despite this, the richness was equal between the two groups as well as the diversity 
measured with Shannon´s diversity index. However, the Shannon´s evenness index showed a slight 
tendency towards a higher value in the patient group, as compared to the control group, indicating that 
the numbers of bacteria within the different taxa may be lower in the RAS group than in the control 
group.  
 
Comparing the oral microbiota profiles between the two groups, differences were observed, in that the 
patients clustered together as one group and the controls clustered together as another group, with both 
groups being separate from one another, indicating a difference in their microbiota profiles. 
Furthermore, the univariate analysis revealed a number of T-RFs that were associated with the 
patients, and others that were associated with the controls. Overall, these results indicate a difference 
in the oral microbiota profiles between patients with RAS and control subjects. With this 
methodology, it is however not possible to determine the specific differences in the profile, regarding 
the represented bacterial taxons. However, in an in silico analysis, the T-RFs present in the patients 
with RAS did not correspond to the bacterial species Streptococcus sanguinis, Streptococcus oralis or 
Helicobacter pylori, which have previously been associated with RAS. 
 
Does the oral microbiota profile change in relation to disease activity in 
patients with RAS? 
A more comprehensive analysis of the oral microbiota profiles within the group of patients with RAS 
was performed, whereby the patients were sub-divided into the following groups: 1) Presence of a 
lesion (reflecting whether or not the patient presented with a lesion at the time of sampling); 2) Lesion 
size [reflecting whether the patient suffered from minor RAS (Ø<10 mm) or major RAS (Ø>10 mm) 
at the time of sampling]; and 3) Regular medication (reflecting whether or not the patient was on 
medication at the point of sampling). These parameters were chosen because they could potentially 
influence the composition of the microbiota. The study group comprised 60 patients in total, with 30 
individuals who suffered from minor RAS and 30 individuals who suffered from major RAS at the 
time of sampling. Of the total group of 60 individuals, 42 presented with a lesion upon sampling (25 
with minor RAS and 17 with major RAS) and 24 individuals used some form of regular medication 
(excluding the use of antibiotics). 
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Multivariate analysis was performed to take into account the presence or absence of a lesion and if the 
patient suffered from minor or major RAS upon sampling. The use of medication was excluded, since 
the groups, based on the sub-division according to the type of medication, would have become too 
small and skewed to allow performance of a reliable analysis. Again, a difference in the oral 
microbiota was observed between the patients with RAS and the controls, whereby the patients that 
presented with a lesion upon sampling clustered furthest away from the controls, especially when the 
patients presented with a lesion of the major type upon sampling (Figure 9). In addition, for the peaks 
that were identified as being of importance in the patients with RAS as a whole compared to the 
control group, univariate analyses was performed now with the different subgroups of patients.  
 
Overall, the results showed that the presence of a lesion altered the oral bacterial composition and, to a 
certain extent, the size of the lesion also contributed to this change. The skewness of the groups must, 
however, be taken into consideration here, and it should be emphasised that the presence of a lesion 
appeared to have a greater impact on the composition of the microbiota than did the actual size of the 
aphthous lesion. Univariate analysis revealed that the use of medication did not seem to influence the 
composition of the oral microbiota. In conclusion, it was not possible to ascertain whether the 
presence of a lesion alters the microbiota of the oral cavity or if a changed microbiota triggers the 
development of lesions.  
 
 
Figure 9. Multivariate analysis reveals that the presence of lesions during sampling contributes to the observed differences in 
oral microbiota profiles between the patients with recurrent aphthous stomatitis (RAS) and control subjects. The patients with 
RAS were assigned to subgroups based on: 1) the size of the lesion (minor RAS Ø<10 mm and major RAS Ø>10mm); and 2) 
presenting with or not presenting with a lesion at the time of sampling (RAS Lesion/RAS No Lesion). A Partial Least 
Squares-discriminant analysis (PLS-DA) 3D-score scatter plot depicts the relationship between the X-variables, i.e., the 
buccal microbiota (identified as T-RFLP peaks) and the Y-variables, i.e., the study population (identified as minor RAS 
patients with and without lesions, major RAS patients with and without lesions, and control subjects). Each symbol 
represents the peak pattern of one individual. Individuals with similar buccal microbiotas cluster together, whereas 
individuals that have different microbiotal profiles are separated. The six major RAS patients for whom it was not known if 
they presented with a lesion upon sampling were excluded from this part of the analysis. R2Y indicates how well the variation 
of Y is explained, while Q2 indicates how well Y can be predicted. For this model: R2Y = 0.35 and Q2 = 0.03. 
Control 
Minor RAS No Lesion 
Major RAS No Lesion 
Major RAS Lesion 
Minor RAS Lesion 
Y 
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STUDY III 
For the identification and comparison of the different murine APC and T-cell subsets, BALB/c mice 
were sacrificed and the NALT, CLN, MLN, and PLN were dissected and prepared as single-cell 
suspensions before staining for flow cytometry. In addition, an in vitro proliferation assay involving 
treatment with the mitogen Con A was performed. Proliferation was estimated by radioactive 3H-
thymidine incorporation. 
 
Are there any differences in the phenotypes of the APC and T-cell 
populations of the oral-associated lymphoid tissues, as compared to the 
intestinal lymphoid compartment, the MLN, and the peripheral lymphoid 
compartment, the PLN? 
Overall, the oral-associated lymphoid tissues displayed certain variations in their APC and T-cell 
subsets compared to their intestinal and peripheral counterparts, the MLN and PLN, respectively. The 
largest differences were observed between the NALT and the other sites, i.e., the CLN, MLN, and 
PLN, although the CLN also displayed variances compared to the MLN and PLN, while showing 
features characteristic of both these tissues.  
 
The NALT had a greater abundance of APCs (approximately 4.2% of the live gated cells) as compared 
to the CLN, MLN, and PLN (approximately 1.5% for each). Differences in the activation patterns of 
the APC subsets, categorised based on the markers CD11c and CD11b, were also observed between 
the different sites. The CD11c+CD11b+ DCs, which were abundant in the NALT, displayed a low 
degree of activation with limited expression of CD40, CD86, and IAd (MHC class II), as compared to 
the CLN, MLN, and PLN (Figure 10). The CLN and PLN showed the highest degrees of activation of 
this subset, with similar expression levels of CD40 and CD86, which were higher than those of the 
MLN, whereas the expression levels of IAd were similar in all three sites (Figure 10). Furthermore, 
CX3CR1 and CD206, which are markers associated with a tolerogenic APC function, were more 
readily expressed in the CD11cnegCD11b+ APC subset, which was also found abundantly in the 
NALT, as compared to the CLN, MLN, and PLN, where the expression levels of these markers were 
similar (Figure 10). Overall, the NALT presented with the highest percentages of APCs among the 
lymphoid compartments; while the degree of activation of APCs was lower in the NALT, the 
tolerance-inducing capacity was greater than at the other sites.  
 
Results 
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Figure 10. Expression of markers associated with cell activation and the capacity for tolerance induction in various antigen-
presenting cell (APC) populations. The tissues of BALB/c mice were analysed by flow cytometry for the expression of CD40, 
CD86, IAd, CX3CR1, and CD206 in the nose-associated lymphoid tissue (NALT), cervical lymph nodes (CLN), mesenteric 
lymph nodes (MLN), and peripheral lymph nodes (PLN). The results are presented in representative dot plots. Each dot 
represents an individual mouse. The horizontal lines indicate the median values. *p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001, as analysed using the Kruskal-Wallis test with Dunn´s correction. 
 
In general, the proportions of CD4+ and CD8+ T cells were lower in the NALT than in the lymph 
nodes, i.e., the CLN, MLN and PLN, which displayed similar proportions of these cells (Figure 11). 
The number of tTregs (Helios+FoxP3+) was lowest in the NALT and highest in the CLN, whereas the 
distribution of pTregs (HeliosnegFoxP3+) was similar at all four sites (Figure 11). Interestingly, the 
NALT contained a high percentage of Helios+FoxP3neg CD4+ T cells, which was not observed for the 
other sites, which demonstrated similar (lower) percentages of these cells (Figure 11). This T-cell 
population has not been well-characterised in the literature but has been proposed to exert 
immunoregulatory functions.  
 
Figure 11. CD4, CD8, and regulatory T-cell (Treg) populations in various murine lymphoid tissues. The tissues of BALB/c 
mice were analysed by flow cytometry for the expression of CD4, CD8, Helios, and FoxP3 in the nose-associated lymphoid 
tissue (NALT), cervical lymph nodes (CLN), mesenteric lymph nodes (MLN), and peripheral lymph nodes (PLN). The results 
are presented in representative dot plots. Each dot represents an individual mouse. The horizontal lines indicate the median 
values. *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, as analysed using the Kruskal-Wallis test with Dunn´s 
correction. 
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Furthermore, the CD4+ and CD8+ T cells of the NALT expressed low levels of CD45RB, indicating 
that there are not many naïve T cells in this compartment in comparison to the other sites, where 
almost all the cells expressed this marker (Figure 12). Instead, the percentage of memory/effector T 
cells in the NALT was higher. In addition, the levels of expression of the homing markers α4β7, 
CCR4, and CCR9 on both the CD8+ and CD4+ T cells where higher in the NALT than in the other 
sites, which displayed low levels of these markers (Figure 12; only data for the CD4+ T cells are 
shown, as the same trend was observed for the CD8+ T cells). Overall, the results indicate that these 
cells have an effector T-cell function rather than a T-cell activation function, and that the homing 
capacity of the cells in the NALT is greater, with homing occurring to both the intestine and the skin. 
 
 
 
Figure 12. Expression of markers of activation and homing in the CD4+ T-cell populations. The tissues of BALB/c mice were 
analysed by flow cytometry for the expression of CD45RB, α4β7, CCR4, and CCR9 in the nose-associated lymphoid tissue 
(NALT), cervical lymph nodes (CLN), mesenteric lymph nodes (MLN) and peripheral lymph nodes (PLN). The results are 
presented in representative dot plots. Each dot represents an individual mouse. The horizontal lines indicate the median 
values. *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, as analysed using the Kruskal-Wallis test with Dunn´s 
correction. 
 
Are there any differences in the cellular proliferative responses in vitro 
between the NALT and CLN, as compared to the MLN and PLN? 
The cellular proliferation rates varied between the different sites; the NALT showed no proliferative 
response at all to stimulation with Con A, while the MLN showed the highest level of proliferation 
(Figure 13). The proliferation rates were similar for the CLN and PLN (Figure 13). The lack of 
induced proliferation shown by the cells in the NALT also indicates that this site is not of importance 
for T-cell activation. Instead, these cells may convey effector functions, whereby the low level of T-
cell proliferation observed in the NALT reflects an on-going active suppression by cells with a 
regulatory capacity. 
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Figure 13. Cellular proliferation following in vitro stimulation with concanavalin A (ConA). Single-cell suspensions (1×105 
cells/well) derived from the nose-associated lymphoid tissue (NALT), cervical lymph nodes (CLN), mesenteric lymph nodes 
(MLN), and peripheral lymph nodes (PLN) were cultured and stimulated with ConA (0.5 µl/well). Proliferation was 
estimated by radioactive thymidine incorporation. The results are presented in a representative dot plot (cpm = counts per 
minutes). Each dot represents an individual mouse. The horizontal lines indicate the median values. *p<0.05, and 
****p<0.0001, as analysed using the Kruskal-Wallis test with Dunn´s correction. 
 
 
 
STUDY IV 
In this study, both an oral tolerance model of induced airway hypersensitivity to OVA and a DO11.10 
TCR transfer model were used. 
  
Does the passage of an antigen through the oral cavity contribute to the 
overall immunological response and the degree of tolerance induced, as 
compared to the situation in which this passage is bypassed and the 
antigen is instilled by gavage directly into the stomach? 
Naïve BALB/c mice were fed a semi-effective dosage of 1 mg OVA through the diet by either oral or 
gastric administration. A low dose of OVA was intentionally administered to avoid establishing 
complete oral tolerance, which would have made it difficult to compare the two different routes of 
administration. Six days after OVA administration, the mice were immunised intraperitoneally with 10 
µg of OVA in Alum, and this was step was repeated 10 days after the first immunisation. Nine days 
after the last immunisation, a challenge was performed in which 100 µg OVA was administered 
nasally over four consecutive days, in order to evoke an airway hypersensitivity reaction. Twenty-four 
hours after the final challenge, BAL fluids, blood, and spleens were collected from the mice and 
analysed to determine if there was a difference in the immunological response between the two routes 
of antigen administration. Control mice were fed PBS, with half of them undergoing oral 
administration and half undergoing gastric administration, and then pooled to constitute a single 
control group that was used for both experimental set-ups. The experimental set-up is shown in Figure 
14. 
 
NA
LT CL
N
ML
N
PL
N
0
20000
40000
60000
cp
m
 x
10
3
*
****
** *
Results 
 64 
 
 
Figure 14. Experimental design of the oral tolerance model involving ovalbumin (OVA)-induced airway hypersensitivity in 
BALB/c mice.  
 
The two routes of administration were equally efficient at inducing tolerance in the model of airway 
hypersensitivity, as both groups of mice displayed significantly lower levels of OVA-specific IgE in 
their sera, as compared with the PBS-fed mice (Figure 15). It should also be mentioned that there was 
a difference in total IgE levels for the two groups compared with the control group. When the Kruskal-
Wallis test was used to compare the three groups together, the p-value for the gastric group versus the 
corresponding PBS-fed group was 0.03, and the p-value for the oral group versus the corresponding 
PBS-fed group was 0.059, which is close to the threshold of significance of p<0.05. When analysed 
with the Mann-Whitney U-test, there was a significant (p=0.01) difference between the oral group and 
the corresponding PBS group. Lastly, reduced numbers of eosinophils in the BAL fluids compared 
with non-tolerised PBS mice was observed (Figure 15). Our data indicate that passage of an antigen 
exclusively across the intestinal mucosa is sufficient to establish oral tolerance, and that the 
contribution of antigen passage through the oral cavity is negligible, at least in our experimental 
system for studying oral tolerance.   
 
 
 
Figure 15. The oral tolerance model using ovalbumin (OVA)-induced airway hypersensitivity in BALB/c mice. 
Hypersensitivity to OVA was measured in terms of the serum levels of total and OVA-specific IgE and the percentages of 
eosinophils in the broncho-alveolar lavage (BAL) fluids. Each symbol represents one animal (n=8 per group) and the 
horizontal lines show the median values for the group. *p<0.05 and **p<0.01, as analysed by the Kruskal-Wallis test with 
Dunn´s correction.  
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Are the activation patterns of ovalbumin (OVA)-specific CD4+ T cells and 
of Treg differentiation different when the OVA antigen is administered via 
the oral route rather than the gastric route? 
Here, the DO11.10 TCR transfer model was applied, in which naïve BALB/c mice were adoptively 
transferred with OVA-specific CD4+ T cells (labelled with CellTrace™ Violet, to allow detection of 
the cells) obtained from the spleens of DO11.10 TCR-transgenic mice (Figure 16). At 24 hours and 48 
hours after the cell transfer, the mice were exposed to a high dose of OVA (50 mg), through either oral 
or gastric administration. This dosing regimen, through gastric administration, is known to induce 
tolerance, as evidenced by a reduced DTH response upon challenge with the tolerising antigen (Hadis 
et al., 2011). Mice that were fed PBS in the same manners served as the controls. Groups of mice were 
killed at 1 hour, 1 day, 4 days, 8 days or 13 days after the last OVA exposure, and lymphoid tissues 
from the NALT, CLN, MLN, and PLN were collected and analysed by flow cytometry to detect OVA-
specific T-cell activation and Treg differentiation.  
 
 
 
Figure 16. Experimental design for the DO11.10 TCR transfer model.  
 
The overall immunological response in terms of the activation of OVA-specific CD4+ T cells and Treg 
differentiation did not differ considerably between the two routes, even though slight differences were 
observed. 
 
One hour after the last OVA exposure, the NALT displayed distinct proliferation of OVA-specific 
CD4+ T cells, as compared to the other sites after oral but not gastric administration of the antigen 
(Figure 17). The other sites all showed insignificant levels of proliferation, irrespective of the 
administration route, with the exception of the CLN, which displayed a slight increase at this time-
point after gastric administration. One day after the last OVA exposure the NALT displayed 
proliferation also after gastric administration, although the level was lower than for the orally fed 
group (Figure 17). Proliferation could now also be observed in the MLN for both routes of 
administration. For the CLN and PLN, the levels of proliferation were still negligible although a slight 
increase was observed for the CLN of the orally fed group. Lastly, on day 4, the majority of the cells 
had undergone cell division at all the sites in the mice that were fed OVA via the gastric route but not 
via the oral route; in the latter case, proliferation was lower, especially in the PLN (Figure 17). These 
results imply that the proliferation was initially slightly more rapid in the NALT after oral 
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administration. However, with time the gastric route of administration yielded the highest rates of 
proliferation.  
 
 
 
Figure 17. Proliferation levels of antigen-specific DO11.10+ CD4+ T cells 1 hour, 1 day, and 4 days after the last ovalbumin 
(OVA) exposure. BALB/c mice that were adoptively transferred with DO11.10 spleen cells and fed OVA through oral or 
gastric administration were analysed by flow cytometry for the presence of dividing DO11.10+ CD4+ T cells in the nose-
associated lymphoid tissue (NALT), cervical lymph nodes (CLN), mesenteric lymph nodes (MLN), and peripheral lymph 
nodes (PLN) at 1 hour, 1 day, and 4 days after the final OVA exposure. The results are presented in representative dot plots 
from the flow cytometry analysis, showing the percentages of dividing (CellTrace™ Violetlow) DO11.10+ T cells among the 
total CD4+ T cells. Each dot represents an individual mouse. The horizontal solid lines indicate the median values for each 
group. Comparisons of the different sites analysed by the Kruskal-Wallis test with Dunn´s correction, *p<0.05 and 
**p<0.01, are shown in the graphs. The median values for the mice exposed to PBS are shown as horizontal dotted lines, and 
the p-values compared with the OVA-exposed mice for each site are shown underneath each graph in italics, *p<0.05 and 
**p<0.01. This latter analysis was performed using the Mann-Whitney U-test. 
  
One hour after the last OVA exposure, no clear induction of Treg cells was observed. The only 
significant observation was a slightly lower proportion of Treg cells in the NALT than in the MLN of 
mice fed OVA via gastric administration (Figure 18). The percentages of Treg cells (FoxP3+CD69neg) 
and activated Treg cells (FoxP3+CD69+) in the OVA-fed mice were similar to those in the PBS 
controls, irrespective of the administration route. At day 1, the induction of Treg cells was still low for 
both routes of administration, although slight increases in the percentages of activated Treg cells were 
noted in the CLN, MLN, and PLN of mice fed OVA by the oral route, as compared with those fed 
PBS (Figure 18). However, at this time-point, there was no clear induction of activated Treg cells in 
the mice fed OVA through the gastric route. Lastly, on day 4, there was a small increase in the 
percentages of Tregs, the increase being most pronounced in the NALT and CLN for both feeding 
regimens, although no significant differences were observed (Figure 18). In addition, there was an 
increase in the percentages of activated Treg cells in the mice that were fed OVA orally, as compared 
with PBS-fed controls. A slight increase in the number of activated Treg cells was noted also for the 
gastric route of administration. These results imply that induction of Tregs occurs over time at all the 
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different sites but that it is modest, and that the largest increase in activated Tregs is observable after 
oral administration of the antigen, although it is still low as that achieved via the gastric route. 
 
 
 
Figure 18. Expression of CD69 and FoxP3 by the antigen-specific DO11.10+ CD4+ T cells 1 hour, 1 day, and 4 days after the 
last ovalbumin (OVA) exposure. BALB/c mice that were adoptively transferred with DO11.10 spleen cells and fed OVA via 
oral or gastric administration were analysed by flow cytometry for the expression of CD69 and FoxP3 in the DO11.10+ 
CD4+ T cells of the nose-associated lymphoid tissue (NALT), cervical lymph nodes (CLN), mesenteric lymph nodes (MLN), 
and peripheral lymph nodes (PLN) at 1 hour, 1 day, and 4 days after the final OVA exposure. The results are presented in 
representative dot plots from flow cytometry analysis, showing the expression levels of CD69 and FoxP3 in the DO11.10+ T 
cells among the total CD4+ T cells. Each dot represents an individual mouse. The horizontal solid lines indicate the median 
values for each group. Comparisons between the different sites were analysed by the Kruskal-Wallis test with Dunn´s 
correction, *p<0.05. The median values for the mice exposed to PBS are shown with horizontal dotted lines, and the p-values 
compared with the OVA-exposed mice for each site are shown underneath each graph in italics, **p<0.01 and ***p<0.001. 
This latter analysis was performed using the Mann-Whitney U-test. 
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Preliminary results are also provided regarding the activation pattern of the OVA-specific CD4+ T 
cells in the oral mucosa and intestinal mucosa after oral administration of an antigen but not after 
gastric administration (Figure 19). The same lymphoid tissues were dissected as in Study IV, apart 
from the NALT, which was not dissected for these preliminary results. In addition, the time-points 
varied, with days 5 and 12 included in the preliminary results, whereas the results for 1 hour, 1 day, 
and 4 days were included in the original study. 
 
The proliferation rates of the OVA-specific CD4+ T cells in the lymphoid tissues (CLN, MLN and 
PLN) on day 5 after OVA exposure were similar to those seen on day 4 in the published study. The 
highest proliferation was observed in the MLN and the proliferation rates for the oral mucosa and 
intestinal mucosa were similar to those for the lymphoid tissues (Figure 19). Regarding the activation 
of the OVA-specific CD4+ T cells, the lymphoid tissues showed strong activation (Figure 19). A 
similar degree of activation was observed in the oral mucosa, but not in the intestinal mucosa where 
the level of activation was lower (Figure 19). However, despite having a lower percentage of activated 
OVA-specific CD4+ T cells, the number of activated FoxP3+ Tregs was highest for the intestinal 
mucosa, whereas the other compartments displayed low numbers of these cells (Figure 19). Twelve 
days after OVA exposure, the rate of proliferation began to decrease, as did the percentage of activated 
OVA-specific CD4+ T cells in all the compartments (Figure 19). The percentages of activated FoxP3+ 
Tregs in the oral and intestinal mucosa increased markedly, especially in the intestinal compartment, 
compared to the lymphoid sites (Figure 19).  
 
These results imply that a local expansion of FoxP3+ Tregs occurs also in the oral mucosa after 
tolerance induction, as has previously been proposed for the intestine. However, this expansion of 
Tregs locally in the mouth appears to be delayed relative to the expansion that takes place in the 
intestinal compartment. Furthermore, our results support the notion that there are few activated cells 
within the lymphoid tissues, since they are inductive sites, and that these cells instead are found within 
the effector sites, such as the lamina propria. It is possible that the numbers of activated FoxP3+ Tregs 
in the oral mucosa would have reached levels similar to those in the intestinal mucosa if a later time-
point had also been included. Confirmation of these observations in repeated studies that include more 
mice and comparing the gastric and oral routes is required, especially if these studies would include 
the NALT as one of the lymphoid tissues. In addition, it would be of value to use the same time-points 
as were used in the original study. 
Results 
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Figure 19. Proliferation of antigen-specific DO11.10+ CD4+ T cells and the expression levels of CD69 and FoxP3 in various 
lymphoid compartments and in the oral mucosa and intestinal mucosa. Experimental design: BALB/c mice were injected 
intravenously with DO11.10 spleen cells. At 24 hours and 48 hours later, the mice were fed 50 mg ovalbumin (OVA) by oral 
administration. Mice were sacrificed 5 days or 12 days after the last OVA exposure, and cervical lymph nodes (CLN), 
mesenteric lymph nodes (MLN), and peripheral lymph nodes (PLN) were collected along with the oral and intestinal mucosa 
and analysed by flow cytometry. a) The lymphocyte and CD4 gating strategy for MLN, oral mucosa, and intestinal mucosa. 
b) Gating strategies for the DO11.10+ CD4+ T cells stained with CellTraceTM Violet, CD69, and FoxP3 from the MLN. c) 
Dot plots from the flow cytometry analysis showing the expression levels of CD69 and FoxP3 among the DO11.10+ CD4+ T 
cells. Each dot represents an individual mouse. The horizontal solid lines show the median value for each group. 
Comparisons between different sites analysed using the Kruskal-Wallis test with Dunn´s correction (* p<0.05 and ** 
p<0.01) are shown in the graphs. 
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GENERAL DISCUSSION 
 
The 'Discussion' section of this thesis is based upon several questions that have arisen during the years 
that I have spent working on understanding the different aetiological aspects of RAS. As the questions 
are of a general character they do not provide any definite answers but they are nevertheless intriguing 
to explore and reflect upon. Serious challenges lie ahead in defining a set of suitable diagnostic criteria 
for RAS, and in performing appropriately designed research studies with well-defined, stringent 
cohorts of patients using suitable methods for uncovering the aetiology of RAS, and thereafter 
establishing accurate management strategies for this group of patients.  
 
 
Is RAS a disease entity of its own that only manifests in otherwise healthy 
individuals, or can it also have an association with systemic factors? 
This question remains unsolved. RAS is indeed found in patients who are otherwise completely 
healthy. However, there are also patients who present with recurrent oral ulcers and who suffer from a 
systemic disease or allergy or are on some kind of medication. Do these ulcers represent actual RAS 
or merely aphthous-like ulcerations? The answer probably involves a combination of these options in 
that some systemic conditions, allergies, and medications may be associated with RAS whilst others 
are not. For some of the patients who suffer from a systemic disease, RAS may manifest itself as part 
of the clinical picture, whereas in other patients RAS may be present in combination with a systemic 
disease but these two conditions should be regarded as separate entities. It has been suggested that 
RAS is not a single entity but instead presents with different phenotypes. The more common forms 
display discrete ulcers that typically commence in childhood or adolescence, abate to some degree 
with age, are not associated with any yet defined systemic disorder, and may be associated with a 
positive family history of recurrent oral ulcerations (Scully, 2012). However, the use of the term 
'secondary complex aphthosis' has also been proposed, to describe associations with hematinic 
deficiencies, various systemic deficiencies and/or drug reactions (Baccaglini et al., 2011).  
 
As long as we do not know for certain that RAS is found simply in patients who are not affected by 
any systemic disease, allergy or any type of medication, I consider it reasonable to include patients 
who present with RAS that may be due to systemic factors, as long as the cohorts of patients within 
the studies are well-defined and grouped accordingly into homogenous subgroups. It may well be that 
there are different phenotypes of RAS, as is the case for several other diseases, such as Crohn´s 
disease (Gasche & Grundtner, 2005). Furthermore, in my clinical experience, those patients who 
suffer from RAS without any other clear underlying cause are not the dominant group and they 
respond well to treatment with for example, topical steroids. A larger fraction of the patients, who 
often suffer from a more severe form of RAS and are more likely to be resistant to the available 
treatment strategies, show some degree of association with systemic disorders.  
 
It is also important to acknowledge that RAS could be a pathological reaction pattern of the oral 
mucosa rather than a specific disease. This condition could be looked upon in the same way as a 
headache or fever, i.e., a general symptom that is manifested when there is a disruption of the 
homeostasis of the human body. As the range of possible pathological appearances in the oral mucosa 
is limited, different underlying immune mechanisms may result in similar types of lesions, such as 
ulceration, making it difficult to distinguish between RAS and aphthous-like ulcerations. Clearly, RAS 
is a multi-factorial condition in which numerous endogenous and exogenous factors contribute to 
General discussion 
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establishing an inflammatory process in the oral mucosa. Therefore, it is crucial to delve in details into 
the patient history, so as to understand which aetiological factors are of importance in that specific 
patient, since they may not be exactly the same as those in another patient with similar symptoms. 
Nonetheless, the patients may share certain common features, as has been explained in 'The RAS 
model' (Figure 5). 
  
 
What role does the genetic composition of an individual play in the development of 
RAS? 
From Study I, which is the first GWAS study of RAS, we could confirm the results of previous 
studies showing that RAS is not a monogenic disease but is instead polygenic due to complex 
inheritance patterns, in which interactions between multiple host genes and possibly also 
environmental factors influence the risk of development of RAS (Ship, 1965, Miller et al., 1977, 
Chavan et al., 2012). Candidate-gene studies on RAS have been carried out previously. However, in 
such studies it is difficult to determine which specific genes ultimately play roles in the disease. 
GWAS allows analysing the entire human genome, across all chromosomes, at high resolution. In this 
particular study, the chosen approach was to combine linkage analysis with association analysis, 
whereby the linkage analysis was dependent upon an association. This allowed assessments of the 
genetic variants passed down to the offspring within each family (linkage) and between the different 
families (association).  Furthermore, we identified signalling pathways that are involved in RAS and 
the genes responsible for the various pathways. The results, however, give only an indication of the 
genes and signalling pathways involved in RAS, and studies that include larger cohorts will have to be 
conducted, preferably still within families. An advantage that family-based case-control studies have 
over conventional case-control studies is that family members are more genetically similar than 
individuals who are randomly selected from a population. Family members without the disease are 
more likely to differ from those family members who have the disease with respect to aspects of 
importance for the disease, and the probability of finding differences related to a disease between 
healthy and diseased individuals within a family should be greater than when one compares random 
individuals. Therefore, family-based association testing, by conditioning on the family structure, is 
able to remove potential biases due to population stratification and environmental effects. However, 
this comes at the price of reduced power relative to population-based association studies. Although, 
the p-values generally are less significant, we also expect fewer false-positive findings due to 
population stratification and environmental effects. Thus, the choice of study design has to be made 
according to the study goals and the available resources. Besides including a larger family-based 
cohort, the pattern of inheritance is also of value for investigating further as well as the roles of 
environmental factors. For complex diseases, such as RAS, non-genetic risk factors tend to be of 
greater importance for disease development than the genetic variants themselves. It would be of value 
to conduct large-scale international studies to assess differences in ethnicity, to answer the question as 
to why people of certain nationalities seem to be at greater risk of developing RAS than others. Does it 
first and foremost have to do with the genetic basis of the individual or with the environmental factors 
to which that individual is exposed? 
 
Prior to the commencement of our study, two larger-scale genetic studies had been performed in RAS 
cohorts, studying the up- and down-regulation of genes in RAS. In 2004, Borra et al. performed a 
cDNA microarray analysis to quantify the expression of 1,176 genes in patients with active ulcerations 
at the time of biopsy. The results revealed enhanced activity of the Th1 gene cluster as compared to 
the Th2 gene cluster (Borra et al., 2004). Presented here are the genes that were identified by Borra et 
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al. (in parentheses are the genes that we found that belong to the same gene family). Up-regulated 
genes in RAS: MMP3 and MMP11 (MMP7); IL1B and IL5RA (IL4R and ILR6); and GNB1 (GNB4). 
Down-regulated genes in RAS: PDGFA (PDGFD and PGDFRB); MAS (MAS1); and CSF1 (CSF1R). 
Furthermore, in 2011, Lewkowicz et al. analysed the expression of Th1/Th2/Th3 and Th17-related 
genes in biopsies from patients who presented with active lesions at the time of sampling (Lewkowicz 
et al., 2011). In total, 86 genes related to T-cell activation were identified. Also, in that study, 
skewness towards a Th1-like gene profile was identified. Presented here are the genes that were 
identified by Lewkowicz et al. as being up-regulated in RAS (in parentheses are the genes that we 
found that belong to the same gene family): CCL7 (CCL21); IFN-γ (IFNGR1); CSF-2 (CSF1R); IL-6 
and IL-15 and IL18R1 (IL4R and IL6R); and TLR6 (TLR2). 
 
In parallel with identifying the genes and signalling pathways that are involved in RAS, it is essential 
to study the RNA and protein expression profiles and the related biomarkers to understand the precise 
roles of these pathways. This can be achieved by, for example, transcriptome analysis, along with 
targeted gene expression and protein analysis. In addition, it is of interest to correlate the genetic 
compositions of individuals with RAS to the compositions of the microbiota in their oral cavities, as 
there is mounting evidence that the oral microbiota profile in patients with RAS differs from that in 
control individuals (Bankvall et al., 2014, Hijazi et al., 2015, Seoudi et al., 2015, Kim et al., 2016). 
RAS has been suggested to be a condition in which Toll-like receptors (TLRs) are of importance 
(Borra et al., 2009, Hietanen et al., 2012). These proteins are known to be significant for innate 
immune responses when microbes penetrate the physical barriers of the body, for example, the oral 
mucosa. The microbes express pathogen-associated molecular patterns (PAMPs), which are 
recognised by extracellular TLRs, expressed on the cell surfaces of immune cells, such as DCs, 
macrophages, neutrophils, and B and T cells, as well as by non-immune cells, such as epithelial cells, 
fibroblasts, and endothelial cells. When the PAMPs bind to the TLRs an immune response is initiated 
that can contribute to establishing the oral ulceration, since TLRs are known to mediate inflammation 
when stimulated by PAMPs. In addition, TLRs have been reported to control epithelial barrier 
integrity, which ultimately affects the permeability of barrier tissues (Johnston & Corr, 2016). 
Interestingly, the expression patterns of TLRs have been reported to differ between patients with RAS 
and healthy control subjects (Hietanen et al., 2012). In the oral mucosa of controls and at healthy 
mucosal sites in patients with RAS, the superficial epithelial layers did not show TLR expression but 
tended to do so in the supra-basal and basal cell layers, creating an upper 'non-responsive to PAMPs' 
zone and a deeper 'reactive to PAMPs' dormant defence zone. However, in the oral mucosa of active 
lesions in patients with RAS, the presence of immune cells that expressed TLRs was considerable, 
with TLRs 1, 2, 5, 7, and 8 being found throughout the epithelium. Furthermore, the expression of 
TLR 4, 6, and 10 was detected further down in the epithelium but in layers higher up than in the 
controls. Limited expression of TLR3 was observed. PAMPs also stimulate the production of pro-
inflammatory cytokines, for example TNF-α, known to be increasingly expressed in RAS, which 
ultimately leads to the recruitment of TLR+ leukocytes to the lamina propria, thereby further 
enhancing TLR reactivity. This indicates that there are changes in TLR expression during the disease 
process. While polymorphisms in the TLR4 gene have previously been reported (Karasneh et al., 
2015), there remain major gaps in our knowledge of the relative importance of TLRs for RAS 
development and of polymorphisms in these receptors that could contribute to disease. Furthermore, 
genetics influences mucin glycosylation (Marionneau et al., 2001, Linden et al., 2008a), and since we 
have reported potential differences between patients with RAS and control subjects with respect to 
glycosylation patterns, it is also of importance to elucidate the role of genetics in mucin glycosylation 
for this condition given that this could also increase the permeability of the oral mucosa. Overall, 
extensive research efforts remain to be made before we can achieve a thorough understanding of the 
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genetic basis of RAS, the role of heredity, and what effects that environmental factors play in this 
disease. 
 
 
Does the oral microbiota play a role in the aetiology of RAS and if so, in what way? 
From Study II, which is the first report conducted to analyse the oral mucosal microbiota outside of 
the actual lesion in patients with RAS, we were able to conclude that there was a difference in the oral 
microbiota profile of the buccal mucosa distant from the ulcer. Certain bacterial taxa were found to 
pre-dominate in the microbiota of patients with RAS, while other taxa were more pre-dominant in the 
control subjects. Unfortunately, using T-RFLP, we could not identify the specific bacterial taxa. The 
differences in the oral microbiota profile were most striking when patients with RAS were compared 
to healthy age- and gender-matched control subjects. However, the differences could also be 
attributable to the size of the lesions, i.e., that the patient suffered from minor or major RAS. No 
SIMCA analysis was carried out for the effects of medication on the oral microbiota profile of the 
patients with RAS, since it was not possible to gather all medications into a single variable. Instead, 
medications would have had to be divided into subgroups, where patients on medications with similar 
effects would be grouped together. The subgroups would ultimately have become too small to allow 
for a reliable analysis. In addition, the effects of medication on the oral microbiota composition have 
been shown to be of limited importance (Dahlén et al., 2012). Antibiotics are the one group of drugs 
that have a major impact, which is why the use of antibiotics was one of the exclusion criteria for the 
study. It would however have been useful to have known the patient´s history of intake of antibiotics 
within previous three months, not just during the last month. 
 
Previously, research on the role of bacteria in RAS has taken a mono-causal approach, where it was 
believed that this condition was due to one bacterial species acting either as a direct pathogen or as a 
source of antigens that stimulated antibody production, which then cross-reacted with oral mucosal 
kerationocytes, resulting in the development of a lesion. In this context, several different bacterial 
species have been proposed, including Streptococcus mitis, Streptococcus oralis, and Helicobacter 
pylori. Although numerous articles on this topic have been published over the years, these theories 
remain unproven. The difficulties associated with resolving this issue, as well as the realisation within 
the medical research community that the complexity of many diseases lies in that they are multi-
factorial where the composition of the microbiota may be an essential factor, lead us to hypothesise 
that the oral microbiota as a whole is a contributing factor of importance for RAS. Since the 
publication of our study (Bankvall et al., 2014) a couple of years ago, other research groups have 
worked according to the same hypothesis. In 2015, Hijazi et al. reported the first characterisation of 
the most abundant bacterial populations in patients with RAS, as compared to healthy controls, using 
16S rRNA gene sequencing (Hijazi et al., 2015). A strength of that study is the homogenous cohort of 
patients, in that only patients with idiopathic RAS (i.e., without systemic diseases, allergies or 
medication) were enrolled using highly stringent methods. However, the sample size was small. The 
results showed no significant differences in overall bacterial diversity between the healthy sites of 
patients with RAS and the control subjects, which correspond well to the results of our study. 
Furthermore, no clustering within patient sample groups was identified using principle component 
analysis (PCA). Using PCA, the data-set is examined to see if there are any natural groupings of the 
material. For our data, we could not see any separations using PCA either. However, using PLS-DA, 
the SIMCA software found separations between the groups. Interestingly, in the study of Hijazi et al., 
at the genus-level there was a greater abundance of total Bacteroidales in the healthy sites of patients 
with RAS, who did not present with active ulcerations at sampling, as compared to the healthy 
controls (Hijazi et al., 2015). They concluded that this could be a contributing factor to the initiation of 
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the disease. Later, in 2015, Seoudi et al. explored the oral mucosal microbiota and the salivary 
microbiota profiles of patients with Behçets disease, using patients with RAS as a disease control and 
applying the human oral microbe identification microarray (HOMIM) and matrix-assisted laser 
desorption/ionization time-of flight analysis (MALDI-TOF) (Seoudi et al., 2015). No clustering was 
observed within the different groups. However, certain differences in the composition of the oral 
microbiota were reported, with increased colonization by Rothia dentocariosa being noted at non-
ulcerative sites of the patients with RAS, as well as an increased number of Neisseria and Veillonella 
in the healthy controls compared to the patients with RAS. Lastly, in 2016, Kim et al. published a 
study in which both the oral mucosa and salivary microbiota profiles were studied in patients with 
RAS and in healthy controls using pyrosequencing of the 16S rRNA genes (Kim et al., 2016). Here, 
sampling of the oral mucosa was carried out only in the lesions and not in the healthy mucosa. No 
differences in bacterial diversity were observed between the patients with RAS and the healthy 
controls, either in the oral mucosal microbiota of the RAS lesions or the salivary microbiota. 
Furthermore, decreased numbers of healthy core microbiota species, such as Streptococcus salivarius, 
and increased levels of rare species, such as Acinetobacter johnsonii, were observed at the lesion sites 
of the patients. It is important to acknowledge that sequencing techniques identify all the types of 
bacteria present in a sample, not only those from the actual sampling site but also those present due to 
sample contamination, which makes interpretation of the data for separating the relevant taxa from the 
background noise more challenging.  
 
The drawbacks of our own study are that only one microbiological technique was applied, and that the 
group of patients with RAS was highly heterogeneous in that some patients may have suffered from 
primary RAS, while others had secondary complex aphthosis or aphthous-like ulcerations (depending 
on which terminology is adapted). While all fours studies conducted in recent years conclude that a 
change within the oral mucosal microbiota is likely in patients with RAS it is currently not known to 
what extent and in what perspective this observation is of importance. Therefore, the question as to the 
role of the oral microbiota remains in part unanswered, especially with respect to causality, i.e., if the 
presence of a lesion alters the microbiota of the oral cavity or if a change in the oral microbiota 
triggers lesion development. Moreover, it is not clear when the change occurs. This is a crucial issue 
to clarify if one is to answer the question as to whether the changes in the oral microbiota give rise to 
the lesions or the other way round. To resolve this issue, it will be essential to follow patients over a 
longer period of time when they will intermittingly have lesions and lack lesions, as well as during the 
prodromal and healing phases, and to examine both the lesion itself and the surrounding healthy 
mucosa, to define when exactly the change occurs. Utilising different microbiological techniques will 
also be valuable, as different methods have different advantages and disadvantages and it is important 
to verify the results with more than one technique. 
 
Changes in the composition of the saliva may also be of importance for the alterations of the oral 
mucosal microbiota profile. A change in the oral mucosal microbiota may affect the ability to clear 
bacteria from the saliva or vice versa that the reduced ability to clear bacteria in patients with RAS 
results in the selection of bacteria within the oral cavity that create a different oral mucosal microbiota 
composition. Preliminary data from our research group reveal that patients with RAS have a reduced 
aggregation capacity for both Streptococcus sanguinis and Actinomyces naeslundii compared with the 
control subjects when un-stimulated whole saliva samples were collected from patients with RAS who 
did not present with lesions at sampling (unpublished observations). These bacterial species were 
selected because they are early colonisers and support the adherence of pathogenic bacteria 
(Kolenbrander & London, 1993). Mucins and secretory IgA facilitate aggregation of bacteria by saliva. 
We have previously demonstrated that the pattern of glycosylation of the mucin MUC7 in patients 
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with RAS seems to be different, in terms of having a less complex type of O-linked glycans attached 
to the protein backbone (making up the core structure of the mucin), to that of healthy siblings who do 
not suffer from RAS (Zad et al., 2015). MUC7, which is a common mucin of the oral cavity, has a 
more stable O-linked glycan profile than the other common mucin in the oral cavity, MUC5B, which 
is why MUC7 was studied rather than MUC5B. The types of glycans on MUC7 did not differ between 
the patients and the controls. However, the terminal glycan structures, especially the proportions of 
sialic acid and sialyl-Lewis X structures were decreased in the patients (Zad et al., 2015). The sialyl-
Lewis X epitope is thought to be of importance for the homing of leukocytes (Prakobphol et al., 1998, 
Prakobphol et al., 2005), specifically lymphocyte re-circulation in the HEVs of lymph nodes (Rosen et 
al., 1985). This may result in ineffective aggregation and attachment of bacteria to the mucin structure 
(Humphrey & Williamson, 2001, Linden et al., 2008b), which ultimately affects the capacity for 
clearance, since fewer leukocytes are able to enter the lymphoid tissues in the oral cavity. In fact, 
MUC7 has been shown to bind to oral streptococci, and this adherence is lost when sialic acid residues 
are removed from the MUC7 molecule (Murray et al., 1992). Therefore, besides identifying the 
bacterial species involved in the aetiology of RAS, it is also imperative to study the role of saliva by, 
for example, investigating the clearance capacity for bacteria and the structure and function of the 
mucin layer in these patients compared to healthy individuals. Furthermore, studies on possible 
alterations to the immunoglobulins, cytokine profile, and other signalling molecules in saliva are also 
warranted.   
 
Patients with RAS may display a reduced capacity to clear bacteria, which results in the selection of 
bacteria within the oral mucosa that can degrade the mucin layer, which contributes to the formation 
of an aphthous lesion. Therefore, it would also be of interest to investigate further the roles of the 
bacteria and how they affect the oral mucosa in terms of the immunological responses that are 
initiated. This would identify specific intracellular signalling pathways of importance and fully 
elucidate the role of the oral mucosal microbiota in the development of the lesions of RAS, allowing 
us to compare the results with already published observations on the role of the immune system in 
RAS. Most probably the oral microbiota affects both innate and adaptive immune responses (Hietanen 
et al., 2012). In addition, it has been reported that certain bacteria are directly involved in the aethio-
pathogenesis of RAS. As an example, A. johnsonii, which is a species associated with an increased 
risk of RAS given that the levels of this bacteria are increased in the ulcers, inhibits the proliferation of 
gingival epithelial cells and shows increased cytotoxicity towards the same cells in vitro as compared 
to S. salivarius, a bacterium that is also associated with an increased risk of RAS given that the levels 
of this bacteria are decreased in RAS lesions (Kim et al., 2016). In addition, the relative abundance of 
Streptococcus has been reported to be negatively associated with the concentrations of IL-1β and IL-8 
in saliva (Said et al., 2014), and since the levels of streptococci have been shown to be decreased in 
patients with RAS and the levels of A. johnsonii increased, this could contribute to ulceration and 
delayed healing of the RAS lesions. Understanding the functionalities of the bacteria residing within 
the oral mucosa of patients with RAS is of greater importance than being able to identify the exact 
bacterial species by name. It is imperative to determine which metabolites these bacteria produce and 
how they affect the oral mucosa and surrounding environment. The intestinal microbiota has strong 
implications for the health of individuals, such that disruption of the gut microbiota, i.e., microbial 
dysbiosis, causes inflammation that results in, for example inflammatory bowel disease. Therefore, 
there is no reason to doubt the importance of the role of the oral microbiota in oral mucosal diseases. 
In light of all the findings presented above, it is essential to explore further the roles of the oral 
microbiota, the saliva, and local immunoregulatory networks in the oral cavity.  
 
 
General discussion 
 
 77 
What role do the oral-associated lymphoid tissues play during induction of tolerance? 
Despite the intestine representing the largest mucosal surface and harbouring the highest number of 
immune cells, it has become evident that other parts of the mucosal immune system may also play a 
role in the induction of tolerance. The oral and nasal cavities form the entrance points for both the 
gastro-intestinal and upper respiratory tracts and are continuously exposed to vast amounts of antigens 
from the external environment. This awareness has initiated the development of new immunotherapy 
strategies, as well as the adoption of novel routes for vaccine delivery. There are, however, many 
questions to be answered before a full understanding of the mucosal immune system and its role in 
tolerance induction, not least the details of the interactions, dependencies, and differences between the 
various compartments, is achieved. 
 
The scientific questions posed in Studies III and IV were aimed at acquiring greater knowledge of the 
immune cells and immune mechanisms of the oral-associated lymphoid tissues, encompassing the 
NALT and CLN, as compared to the intestinal lymphoid compartment, the MLN, and the peripheral 
lymphoid compartment, the PLN. The overall question was to what extent and in which ways these 
two compartments contribute to the induction of tolerance. However, due to the extensive and intricate 
nature of this question, it has not been possible to answer it in full through these two studies alone, 
which was also not the intention. Thereby, many subsequent questions remain unanswered. In Study 
III, we investigated potential differences in the phenotypes of the APC and T-cell populations 
between the oral-associated lymphoid tissues, and studied the in vitro proliferative responses of the 
cells in the various compartments. Furthermore, in Study IV, we explored whether the passage of an 
antigen through the oral cavity contributes to the overall immunological response and degree of 
tolerance induced, as compared to a situation in which this passage is bypassed and the antigen is 
instilled by gavage directly into the stomach. In addition, we wanted to determine whether there are 
differences in the activation pattern of OVA–specific CD4+ T cells and in Treg differentiation when 
oral administration was compared to gastric administration.  
 
The general conclusion of Study III is that the oral-associated lymphoid tissues display differences in 
the phenotypes of the immune cell subsets found therein and the markers that they express, as 
compared to the intestinal and peripheral counterparts. In addition, there are differences in the in vitro 
proliferative responses between the different compartments. The greatest differences were observed 
between the NALT and the other sites, i.e., the CLN, MLN, and PLN, although the CLN also 
demonstrated certain differences compared to the MLN and PLN, displaying features characteristic of 
both. First, the NALT displayed a greater abundance of APCs, as well as differences in the proportions 
of the different subsets compared to the other sites, which showed percentages that were more similar 
to each other. Differences in the activation patterns of the APC subsets were also apparent between the 
different compartments, whereby the APCs of the NALT again showed a greater deviation from the 
cells of the other sites, since the APCs were less activated here. The APC populations of the NALT 
also seemed to possess a greater tolerance-inducing capacity compared to the other sites. Second, the 
NALT displayed lower proportions of T cells than the lymph nodes, which displayed similar 
proportions to each other. The number of tTregs was the lowest in the NALT and highest in the CLN, 
whereas the distribution of pTregs was similar for all four sites. The NALT also contained a greater 
abundance of Helios+FoxP3neg CD4+ T cells, which was not observed for the other sites, which 
between them demonstrated more similar proportions. This T-cell population has not been well 
characterised in the literature, even though it has been proposed to possess immunoregulatory 
functions (Abd Al Samid et al., 2016). Few naïve T cells were found in the NALT in comparison to 
the other sites, where almost all the cells were naïve. Instead, the proportion of memory/effector T 
cells in the NALT was higher. Furthermore, the expression of homing markers on T cells was higher 
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in the NALT than in the other sites, indicating that the homing capacity of the cells in the NALT is 
greater and that these cells have an effector T-cell function rather than a T-cell activation function. 
Lastly, the proliferation rates varied between the different sites, in that the NALT showed no 
proliferative response at all to stimulation. The lack of proliferation of the cells in the NALT also 
indicates that rather than being of importance for T-cell activation the cells at this site convey effector 
functions, despite the NALT being regarded as an inductive site. 
 
In Study IV, the two routes of administration were found to be equally efficient for inducing tolerance 
in a model of airway hypersensitivity, since both groups of mice displayed significantly decreased 
OVA-specific IgE levels in their sera, as compared with the PBS-fed mice. In addition, there were 
fewer eosinophils in the BAL-fluid compared with non-tolerised mice. Concerning the overall 
immunological response, the levels of activation of OVA-specific CD4+ T cells and Treg 
differentiation did not differ between the two routes, even though slight differences were observed. 
The rate of proliferation was initially slightly more rapid in the NALT after oral administration. 
However, with time, the gastric route of administration resulted in the highest rates of proliferation. 
Regarding the activation of OVA-specific CD4+ T cells, the results imply that despite the NALT being 
the first site to display proliferation of the OVA-specific CD4+ T cells, the degree of activation of 
these cells is low and remains low over time. In addition, an increase in the number of proliferating 
cells with time resulted in a decrease in the number of activated cells, irrespective of the feeding 
regimen used. Lastly, regarding the differentiation of Tregs, the results imply that there is induction of 
Tregs over time at all the different sites but that it is modest and that the largest increase in activated 
Tregs is observable after oral administration of the antigen, although it is still low compared to that 
achieved by antigen administration via the gastric route.  
 
That the NALT represents a MALT structure and is not a lymph node is probably the most significant 
reason why this compartment differs the most from the other sites. The NALT lacks afferent 
lymphatics, which leads to an exposure of antigen that is not as comprehensive as that seen in lymph 
nodes, since antigens do not reach the NALT through HEVs. Instead, sampling of antigens through M 
cells is more selective than through HEVs, whereby the presentation of antigens to T cells is not as 
extensive. MALT structures and lymph nodes are, however, all classified as inductive sites in which 
primary immune responses are initiated. Therefore, it was surprising to find that the NALT had more 
of an effector function than one for activation. This feature is supported by the following observations: 
(i) the patterns of markers expressed on the lymphocytes, whereby despite high levels of 
CD11c+CD11b+ DCs, the expression of activation markers was low, the expression of CD45RB was 
low (indicating few naïve T cells), and the expression of homing markers on the T cells was high;  (ii) 
the low rate of proliferation in vitro; and (iii) despite the initial rapid proliferation of the DO11.10 
CD4+ T cells, the rate of activation remained low over time. Therefore, there are several lines of 
evidence to support the idea of the NALT being more of an effector site. This may be controversial, as 
it is generally considered to be an inductive site. Instead, it may be a site that displays features that 
have nothing to do with activation or effector functions but instead has all to do with tolerogenic 
activities. It has been demonstrated that immature DCs that ultimately express low levels of activation 
markers stimulate naïve T cells to become Tregs (Maldonado & von Andrian, 2010). However, the 
NALT did not contain many Tregs. Instead, the CD4+FoxP3negHelios+ cells pre-dominated at this site. 
These cells have been reported to produce IL-10, indicating that they possess a regulatory function 
(Abd Al Samid et al., 2016). Furthermore, the NALT has been reported to contain a significant 
proportion of CD4negCD8negCD3+ T cells (Rodriguez-Monroy et al., 2007). These cells may comprise 
part of the Treg population, as well as naïve T cells with the potential to differentiate into different 
effector cells upon antigenic stimulation (Rharbaoui et al., 2005). Therefore, the naïve T cells may not 
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be found within the CD4+ and CD8+ T-cell fractions, as we could observe, but instead appear within 
this double-negative fraction. Resident macrophages within the intestinal lamina propria have been 
shown to express high levels of CX3CR1. These cells have been demonstrated to play important roles 
during the induction of oral tolerance, assisting with loading of the antigen onto migratory 
CD11c+CD103+ DCs and with the expansion of Tregs locally (Pabst & Mowat, 2012). We are able to 
show that the NALT displays the highest percentages of CX3CR1+ APCs, suggesting a similar 
expansion of Tregs in the nasal lamina propria.  
 
The rapid proliferation of DO11.10 CD4+ T cells in the NALT after oral administration is perhaps not 
that surprising, since the nasal and oral cavities lie in close proximity to one another, which makes it 
easy for the antigen to access the NALT from the oral cavity. One could speculate that proliferation in 
the CLN would be increased as well, since this lymphoid compartment lies close to both the NALT 
and the oral cavity. Moreover, both these lymphoid compartments drain to this site. However, there 
could be an aspect of time, in that drainage to the CLN does not occur as rapidly. Furthermore, it was 
surprising to discover that the rate of proliferation in the NALT soon increased also after gastric 
administration. This could be the result of the antigen after gastric administration reaching the blood-
stream rapidly and disseminating through the circulation to the NALT. One would suspect that a 
similar scenario would apply also to the CLN and PLN, although the proliferation rates at these sites 
remained low. Another explanation could be that the antigen-specific T cells induced in the MLN 
home to the lamina propria of the nasal cavity as effector T cells or potentially as Tregs, although this 
does not explain why increased proliferation rates were not observed in the CLN and PLN, since they 
also lie in close proximity to effector sites. Overall, despite the initially more rapid proliferation rate in 
the NALT after oral administration, with time the gastric route of administration resulted in the 
highest rates of proliferation. This could be due to a higher concentration of antigens in the gut after 
administration by gavage. With oral administration, antigens can disseminate on their way to the 
intestine and the intestine has a larger mucosal surface, which may facilitate a more efficient uptake of 
the antigen. Another interesting finding was that the NALT despite demonstrating rapid proliferation 
of the DO11.10 CD4+ T cells demonstrated a lower degree of activation of these cells as compared to 
the CLN, MLN, and PLN. This could be due to the fact that CD69 is an early activation marker and 
that it had already been down-regulated for the cells of the NALT that had proliferated. The rapid 
induction of antigen-specific T cell proliferation in the NALT might suggest that it is an optimal site 
for interactions to occur between APCs and T cells. However, support for this is lacking in the results 
presented for Study III, where the NALT was shown to display effector functions or perhaps 
tolerogenic functions rather than a strong capacity for activation. 
 
The two routes of administration were equally efficient for inducing tolerance in a model of airway 
hypersensitivity, which implies that the oral-associated lymphoid tissues do not contribute in any 
additional way to the induction of oral tolerance. This may seem contradictory, since recent research 
efforts point to important roles for other parts of the mucosal immune system. Again, this could be due 
to the fact that the intestine comprises a larger part of the mucosal immune system. Nevertheless, the 
other parts may also contribute to the induction of tolerance, albeit possibly not to the same extent as 
the intestinal mucosa. Through the experimental designs that we have applied, it has not been possible 
do elucidate merely the role of the oral mucosa, as we did not circumvent the intestinal mucosa during 
oral administration of the antigen, which could have been an option of choice. 
 
Two main questions remain unanswered: (i) Is the same step-wise model for induction of oral 
tolerance in the small intestine fully applicable or applicable to some degree to the nasal and oral 
cavities to establish tolerance in these compartments?; and (ii) Does dissemination of antigens and 
General discussion 
 80 
activated T cells from the inductive sites, i.e., the MALT structures and lymph nodes, occur to the 
circulation after the administration of an antigen nasally, orally or intra-gastrically resulting in 
systemic tolerance? As shown both in the 'Introduction' section of this thesis and here in the 
'Discussion' section, research studies have been performed and are on-going to answer these two 
questions. However, many details still remain unclear. For future reference, it is imperative to perform 
studies with a more stringent classification of the APCs and T cells. It is also necessary to include the 
B cells, since they play a significant role in mucosal immunity. More extensive studies of the 
epithelium and lamina propria of the nasal and oral cavities need to be performed to improve our 
understanding of the roles of the effector sites, and not only the inductive sites. Furthermore, it would 
be of interest to compare the oral and gastric routes of administration using three different groups of 
experimental animals, one where the antigen is administered by gavage, one where the antigen is 
administered only to the oral cavity thereby circumventing the passage to the intestine, and one where 
both the oral cavity and the intestine are exposed in the same feeding, resembling the natural route of 
an antigen. The role of the salivary glands requires additional research studies also, since they 
comprise effector sites of importance for both the nasal and oral cavities. Moreover, saliva, the 
secreted fluid from the salivary glands, plays an important role in immune defence within the oral 
cavity.  
 
 
How can studies of tolerance contribute to understanding the role of food 
components in the development of RAS? 
Ingested food antigens are exposed to the entire gastro-intestinal tract, from the oral cavity to the 
intestine. It has become clear that tolerance induction occurs also within the oral cavity and other 
mucosal sites, suggesting that abrogation of tolerance is possible also in the oropharyngeal 
compartment. The role of the oral cavity in tolerance induction is of particular interest for this thesis, 
as the abrogation of tolerance to certain food components has been proposed to underlie the 
development of RAS in a subgroup of patients suffering from this condition.  
 
Atopic diseases have been proposed to initiate with atopic dermatitis in infants and thereafter proceed 
to food allergies, allergic rhinitis, and allergic asthma (Yu et al., 2016). Loss of tolerance can lead to 
responses to innocuous food antigens (allergic sensitisation), resulting in non-atopic conditions, such 
as coeliac disease, and atopic conditions, such as IgE-mediated, non-IgE mediated, and mixed-reaction 
food allergies (Yu et al., 2016). A limited number of studies have been conducted on the prevalence of 
atopy in patients with RAS, but they all point towards a possible association between the two (Wilson, 
1980, Veller-Fornasa et al., 2003, Veller-Fornasa & Gallina, 2006). In addition, the occurrence of food 
allergies in patients with RAS has been suggested, as presented in the 'Introduction' section of this 
thesis. Furthermore, IgA deficiency, which has been reported in patients with RAS (Porter & Scully, 
1993), increases the tendency to develop allergies (Brandtzaeg, 2013). 
 
Food allergies give rise to gastro-intestinal symptoms, urticarial and airway inflammation, which 
range in severity from mild to potentially life-threatening. It is not unreasonable to assume that 
symptoms such as oral ulcerations occur in the oral cavity due to a hypersensitivity reaction or allergy 
towards a food antigen, since other oral manifestations as well as other gastro-intestinal manifestations 
have been reported for patients with RAS (Sampson, 2016). As explained previously, the number of 
different reaction patterns within the oral cavity is limited. Therefore, oral ulcerations may be 
manifested as part of the clinical picture of food allergy. However, no study has reported the 
prevalence of oral ulcerations in patients with food allergies. It would therefore be of interest to 
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conduct a study on patients with diagnosed food allergies, to estimate the occurrence of such 
symptoms, since this information is currently unavailable.  
 
How abrogation of tolerance is established in patients with food allergies is not well-understood, and 
why food tolerance is established in certain individuals and food allergy in others also remains an 
enigma. In the healthy state, tolerance is established, and during the disease state, sensitisation occurs. 
Treatment strategies for food allergies involve immunotherapy aimed at desensitisation. The 
mechanisms of desensitisation are not well-understood, and they may differ from those of immune 
tolerance in healthy individuals (Yu et al., 2016). Food allergies promote Th2-type immune responses 
(Yu et al., 2016). Damage to the epithelium occurs, which leads to an increased passage of antigens. 
This stimulates the secretion of epithelium-derived cytokines, such as IL-25, IL-33, and thymic 
stromal lymphopoietin (TSPL), allowing DCs to mature and migrate to the lymph nodes. There, naïve 
T cells differentiate into Th2 cells, which home to the lamina propria and secrete Th2 cytokines, such 
as IL-4, IL5, and IL-13. This results in the accumulation of eosinophils and basophils and allows for 
antibody class switching of B cells to IgE. Patients with food allergies are known to have an increased 
gut permeability at baseline (Ventura et al., 2006). It seems likely that increased permeability of the 
oral mucosa also occurs in allergic individuals, which increases the risk of RAS lesions.  
 
Currently, SLIT is being explored as a route for allergen-specific immunotherapy, creating an 
alternative to more conventional methods of immunisation. SLIT is becoming an alternative also for 
food allergens, for which subcutaneous immunotherapy (SCIT) was previously the only existing 
option. Compared to nasal immunisation, SLIT has the advantage that there is no risk that the antigen 
will be re-directed to the brain (Brandtzaeg, 2013). In general, this type of therapy is aimed at reducing 
or abrogating the sensitivity to a specific allergen by decreasing the levels of allergen-specific IgE and 
increasing the levels of IgG4, as well as reducing the response of effector CD4+ T cells and inducing 
Tregs (Dioszeghy et al., 2016).  
 
Until no association can be proven, food components remain as a possible aetiological factor in 
patients with RAS. The number of patients who display RAS as part of the clinical picture of a food 
allergy is probably low. However, since this condition is greatly debilitating, it is necessary to identify 
these individuals. Therefore, referral of patients with RAS and a suspected food allergy to an allergy 
specialist may be required as part of the clinical routine. However, it is a difficult task to identify these 
patients. Further research into this matter, in close collaboration with allergologists, is required to 
understand the role of food components in RAS.  
 
 
Is there any scientific basis for the hypothetical classification of foods that may cause 
RAS into foods that potentially produce an etch wound of the oral mucosa, as 
compared to foods for which a hypersensitivity or an allergic reaction has been 
proposed? 
As presented in the 'Introduction' section of this thesis, several studies on hypersensitivity and allergic 
reactions in RAS have been conducted. However, there are currently no studies that have been able to 
define exactly which foods are relevant or the exact mechanisms by which they potentially trigger 
lesion development. Anamnestic findings in patients with RAS suggest that acidic foods, such as citric 
fruits, pineapple, tomatoes, and vinegar, may cause RAS lesions (Hay & Reade, 1984). Patients with 
RAS in a Turkish population have been reported to have a higher intake of acidic foods than the 
general population (Gonul et al., 2007). In light of this, it may be necessary to distinguish between 
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foods that cause damage to the epithelium through an etch wound and foods that induce a 
hypersensitivity or allergic reaction. In 'The RAS model' (Figure 5), these foodstuffs are classified into 
type I foods and type II foods respectively. The distinction between different food components in RAS 
and the reactions that they provoke has not been clearly established. For food components that cause a 
potential etch wound, only a few early studies have been published with contradictory results. It has 
been reported that the application of citric acid and acetic acid, acids commonly found in foodstuffs, 
directly to the oral mucosa of patients with a positive history of RAS caused ulcerative lesions in a 
number of patients with a history of allergy (the type of allergy was not reported, so it is not known if 
it was specifically a food allergy or not), as compared to patients who reported no allergy and in whom 
no lesions were reported despite a positive history of RAS (Tuft & Girsh, 1958). However, it has also 
been reported that no lesions developed in a group of patients with RAS after these two acids were 
applied (Kutscher et al., 1958). From that study, it is not clear whether the patients reported any 
allergies. In our clinic, patients frequently report that various food components aggravate their 
condition of RAS. However, it is difficult to interpret whether they mean that these foods cause the 
lesions or aggravate the symptoms. Naturally acidic foods will aggravate the symptoms if in contact 
with an ulceration of the oral mucosa. However, it could also be that acidic foods assist in the 
development of lesions in allergic patients as they already are sensitised to certain food components.  
This could be the reason why the same is not observed in patients without a history of allergy. Before 
this issue can be resolved, further studies need to be conducted, as the previous studies have been too 
few and have not been able to provide clarity regarding this issue. 
 
 
What does the future hold for treatment strategies of RAS? 
Currently, there is no consensus regarding the optimal treatment regimen for RAS. Furthermore, 
conclusive evidence for different treatment strategies cannot be drawn from the available systematic 
reviews. One of many reasons for this is that the methodologies used are poor. In an attempt to solve 
this problem, Tappuni et al. introduced an ulcer severity scoring (USS) system (Tappuni et al., 2013), 
so as to standardise the assessment of the severity of oral ulcers and their responses to treatment. This 
method has now been adopted at our department and in our clinical practice, to ensure a more 
consistent evaluation of disease severity and facilitate comparisons between our own cohorts of 
patients, and hopefully in the future, comparisons with cohorts from other studies conducted nationally 
and internationally. 
 
In the management of patients with RAS, it is essential to rule out any other cause for the lesions, for 
example, hematinic deficiencies, hormonal imbalances or systemic disease, as well as any form of 
medication, local trauma or psychological factors as possible causative factors. Clinical management 
should therefore entail a systematic assessment of whether or not other factors could be associated 
with RAS, even though the putative associations with several of these factors have not yet been 
completely established. Close collaboration between the oral medicine specialists and other medical 
specialists is therefore crucial.  
 
There is a constantly growing market for non-prescription products aimed at treating aphthous lesions 
symptomatically. However, in my experience, what the patient with RAS wants is a way to avoid 
treatment if possible but still prevent the development of lesions on a long-term basis. The only 
reasonable possibility to achieve this goal is through a complete understanding of the true aetiology of 
RAS. While a cure for RAS appears elusive based on what we currently know about this disease 
effective management could be achieved using prophylactic measures that counteract disease 
progression in patients with pre-disposing factors, and in this way relieve the patients of their 
General discussion 
 
 83 
symptoms. For patients with severe forms of RAS, treatment strategies that involve prescription drugs 
will still be required. However, for many of the patients routinely treated with topical steroids (due to 
the of the lack of alternative treatments), measures that address the true aetiology in each and every 
patient could offer an alternative, more cost-effective strategy that ultimately would be beneficial for 
the patient, the clinician, and society at large. 
 
 
 
 
 
In conclusion, this thesis is one of several studies with the focus on RAS. Compared to the other 
reports that have been written on this subject, this thesis most probably has the broadest approach, in 
that several different features of the disease are taken into account. The disadvantages of this strategy 
are that a detailed analysis of one particular factor is not feasible and it is a challenge to keep up with 
the literature and different methodologies when focusing on so many different aspects. However, to 
truly understand a condition and to decide which research studies need to be carried out, it is essential 
to penetrate every aspect of the disease. The focus in this thesis has been on host genetics, the oral 
microbiota, and immunoregulatory networks and their respective contributions to the development of 
RAS. While I cannot provide definite answers regarding the precise roles of these factors, it is fair to 
say that they are all of importance in RAS and that additional studies will have to be conducted to 
elucidate unambiguously their roles. Ultimately, these factors all influence each other, so the question 
is to what extent and how this is of relevance for the disease. 
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